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Abstract  
Thermo-responsive polymers are a class of smart polymers that respond to change in 
temperature. This property makes this type of polymers useful materials in a wide range of 
applications especially, in the field of drug delivery system.  Polymers, which have primary 
amino groups, such as N-(3-aminopropyl) methacrylamide hydrochloride (APMA), have 
been used for post-polymerization modification reactions for the development of new 
materials for biomedical applications. Here I aim to fabricate an amphiphilic monomers 
composed of APMA by substituting (palmitoyl, dansyl, cholesteryl and oxadiazole) groups 
onto the primary amine in the APMA monomer.  
These monomers were then copolymerized with N-(2-hydroxypropyl)methacrylamide 
(HPMA) in six different monomer feed ratios in order to characterise the effect of 
hydrophobic pendants on the copolymer properties including lower critical solution 
temperature (LCST), solubility, drug loading and drug release.  
In this study drug loading and release properties of HPMA-co-APMA copolymers were 
studied by using four model hydrophobic drugs, propofol, griseofulvin, prednisolone and 
paclitaxel. High performance liquid chromatography (HPLC) measurements were performed 
in order to compare drug loading properties of the copolymer formulas. The most potent 
carrier candidate was loaded in order to carry out thermo-responsive release study. The 
results showed that all the copolymer formulations in this study possessed the ability to 
encapsulate practically poor-soluble drugs within their hydrophobic core. HPLC 
measurement has demonstrated that HPMA-co-(APMA-Oxadiazole 1%) (O-1) and HPMA-
co-(APMA-Dansyl 2%) (D-2) have a higher drug solubilisation capacity than other 
copolymer formulations.  
In vitro release profiles of different model drugs of the optimal formulation of copolymers 
were investigated at four different temperatures. Unfortunately, these copolymers showed 
uncontrolled release of all of the loaded drugs. To set-up thermo-responsive copolymers for 
controlled drug release, approaches based on introducing poly ethylene glycol (PEG) block as 
a part of O-1 and D-2 amphiphilic copolymers. A significant enhancement in response to the 
change in temperature as the drug release across the membrane was seen when PEG was 
present for the three hydrophobic drugs models. Then hybrid nanoparticles (HNPs) were 
prepared and attached to O-1 as localised nano-heaters to accelerate drug release in 
responded to temperature change.  
iv 
 
Finally, the optimal formulation of (O-1)-b-(PEG) and (O-1)-b-(PEG)-HNPs loaded with 
paclitaxel (PTX) were tested for their cytotoxicity in vitro on BxPC-3 cells. In-vitro MTT 
assay results established the ability of (O-1)-b-(PEG)-PTX and (O-1)-b-(PEG)-HNPs-PTX 
novel formulations to accumulate and kill pancreatic cancer cells more effectively, compared 
to the free PTX.  
Key words: Thermo-responsive drug delivery, Iron oxide-gold nanoparticles, smart 
polymers.  
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1.1- Introduction 
The search for new drugs in disease management is expensive and time consuming. 
Improvement in the safety and biological relevance of “old” drugs has been attempted using 
formulation strategies in order to exert much greater control over drug fate. These strategies 
include controlling the drug release rate as well as targeting to specific diseased tissues 
(Kshirsagar, 2000). Drug delivery systems (DDSs) have been widely applied in order to 
avoid the main limitations of traditional formulations that usually occur when a bolus 
injection is administered resulting from the high plasma drug concentration (Censi et al., 
2010). The main aim of any targeted DDS is to deliver specific amounts of the drug to the 
targeted site at an appropriate rate, in addition to minimize local and systemic toxic effects to 
healthy tissues (Balmayor et al., 2011). Moreover, DDSs can act as a protectant for drug 
molecules against physiological degradation and elimination, resulting in prolonged 
circulation times.   
The water solubility of a drug is an important factor in relation to its ability to be 
administered either intravenously or orally (Khadka et al., 2014). More than 40% of new 
drugs under investigation are poorly water-soluble (Hoskins et al., 2016).  Hence, careful 
formulation strategies are required in order to improve aqueous solubility of lipophilic drug 
candidates. Once of the major technologies arising within the past two decades for 
hydrophobic drug solubilisation is the use of polymeric micelles. 
1.2- Micelles 
Micelles are aggregates or supramolecular assemblies of amphiphilic molecules dispersed in 
aqueous solution with a size usually between 5 nm and 100 nm (Mitra et al., 2017). 
Typically, amphiphilic molecules consist of two regions; a hydrophilic (polar or charged) 
region and a hydrophobic (non-polar) region. In aqueous solution, amphiphilic molecules 
arrange themselves in a spherical form, in which the polar part (head) is outward facing 
toward the surrounding water molecules while the non-polar parts (tail) are driven to an 
interior structure away from the water (Mancin et al., 2016, Dhembre et al., 2009).  
In general, there are two types of micelle system; 1) ionic which include ionic or zwitterionic, 
and 2) neutral. Traditionally, micelles formed from surfactant molecules have been used as 
excipients for drug solubilisation and delivery. When surfactant molecules have a negative or 
positive charge on the polar head they are classified as anionic surfactants e.g. sodium decyl 
sulfate (NaDS), sodium dodecyl sulfate (SDS), cetyltrimethylammnoium chloride (CTAC) 
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and Cetyl trimethylammonium bromide (CTAB) while neutral surfactants don’t have any 
charge on their polar head groups such as poly (oxyethylene glycol tert-octylphenol) ethers 
and poly (oxyethylene glycol octylphenol) ethers. Depending on the polarity of the 
surrounding media, micelles can form into different conformations (Figure 1):  
 
(i) Direct Micelles: when formed in water or polar solvent, the polar head moieties of 
the surfactant molecules arrange themselves toward water while the hydrophobic 
groups are buried from water. 
(ii) Reverse Micelles: when the media is of low polarity this will lead to the surfactant 
to become orientated in such a way that the hydrophilic moieties are towards the 
interior of the micelle, leaving the hydrophobic part in contact with the organic 
solvent, a common example of this type is sodium bis(2-ethylhexyl) 
sulfosuccinate (AOT) (Facchin et al., 2017, Thomas et al., 2010, Fenn et al., 
2009). 
 
 
 
 
 
 
 
 
 
Figure 1- Schematic representation of direct and reverse micelle formation dependent upon 
surrounding media. 
Surfactant concentration, pH, ionic strength and temperature have an important impact on the 
size and shape of micelles. In addition to spherical shapes, micelles can be found as cylinders, 
bilayers and ellipsoids (Santos et al., 2016, Lombardo et al., 2015). Micellar formation 
occurs spontaneously at a specific concentration which is dependent on molecular make-up. 
This concentration is known as the Critical Micellar Concentration (CMC). Below the CMC, 
surfactant molecules exist as single entities, occupying the surface of the bulk liquid, at and 
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above the CMC, spontaneous aggregation occurs and micellar structures form. Further 
increase in concentration can result in an increased number of micelles, but will not impact 
the micellar size (Figure 2) (Wijaya et al., 2016, Chakraborty et al., 2011, Holmberg et al., 
2002). 
The mechanism driving spontaneous aggregation and micellar formation is due to a reduction 
in Gibbs’ free energy. It is energetically more favourable for the hydrophobic moieties to 
shield themselves from the aqueous environment and cluster together forming the 
hydrophobic core (Dhembre et al., 2009). 
 
 
 
 
 
 
 
Figure 2- Detection of critical micelle formation concentration (CMC) by measuring the 
surface tension as a function of the surfactant concentration    
Micellar technology has been widely used in technologies such as surfactants, soaps, 
lubricants and detergents, cosmetics etc. (Cornwel, 2018, Zheng et al., 2009). However, 
surfactant micelles suffer from great instability upon dilution in bloodstream following 
dosing, which hinders their usage for medical application. Additionally, a large amount of 
surfactant excipient is required in order to solubilise some of the excessively hydrophobic 
drug molecules, this result in more viscous formulations which are not very efficient or cost 
effective and may carry an increased toxicity due to the large excipient concentration. 
Advances in knowledge have led to the development of polymeric micelles. These systems 
overcome some of the challenges faced by surfactant micelles and are proving to play a key 
part in the field of cancer therapy and drug delivery, particularly in the solubilisation of 
poorly soluble anticancer agents in aqueous solution (Svenson and Prud'homme , 2012). 
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1.2.1- Polymeric micelles 
Polymer micelles are generally more stable than low molecular weight surfactants, possessing 
lower CMC values (as much as 1000 times lower), greater solubilising potential, slower 
dissociation,  prolonged retention of loaded drugs, and higher drug accumulation at the target 
site (Movassaghian et al., 2015). In order to form polymeric micelles, amphiphilic polymers 
have to be constructed, composing of hydrophilic and hydrophobic monomer units. These 
types of amphiphiles can be formed by either block copolymers or grafted comb shaped 
polymers. Poly(ethylene glycol) (PEG) also known as poly(ethylene oxide) (PEO) has been 
widely used as the hydrophilic moiety in many amphiphilic polymers because of their 
desirable properties, including high solubility in water and low toxicity (Grallert et al., 2012) 
while the hydrophobic moiety often consists of hydrocarbon chains of varied length e.g. 
alkyl, acyl or sterol-like groups (Hoskins et al., 2012a).  
Depending on the relative length of the blocks of diblock copolymers, micellar structures are 
commonly distinguished into two types: ‘star-micelles’ when the insoluble block is smaller 
than soluble one, in this case, the micelle core will be small and the corona very large; and 
‘crew-cut micelles’ when the micelles have a short soluble corona and large insoluble 
moieties (Rodrı´ et al., 2005, Karayianni and Pispas, 2016) (See Figure 3). 
Polymeric micelles have been reported to have several features including: very small size 10-
100 nm, high structural stability (static and dynamic) which plays an essential role in their in 
vivo application, ability to encapsulate a high amount of hydrophobic drug, maintaining their 
aqueous dissolution, bioavailability enhancement and reduction in the toxicity of poorly 
soluble drugs in water (Movassaghian et al., 2015). 
 
 
 
 
 
 
 
 
 
Figure 3-Schematic representation of (a) star micelle (b) crew-cut micelle. 
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Japanese researchers have had precedence to use polymeric micelle carriers in drug tumour 
targeting and clinical trials as well. Yokoyama and colleagues identified that polymeric 
micelles forming from poly(ethylene glycol)-b-poly(aspartic acid) PEG-b-poly(ASP) could 
be used as successful polymeric micelle carriers for platinum chelate cisplatin via a reaction 
between a carboxylic acid ligand exchange reaction between a chloride ion of cisplatin and a 
carboxylic acid residue of the poly(ASP) chain (Yokoyama., 2011, Yokoyama et al., 1996).  
The poor-soluble anticancer drug can be also incorporated physically into polymeric micelles. 
Li and colleagues reported using a dialysis method to encapsulate ethaselen anticancer drug 
into polymeric micelles fabricated from monomethoxy poly(ethylene glycol)-poly(lactide) 
(mPEG-PLA) diblock copolymers. They mention a remarkable increase in ethaselen 
solubility in water up to 82 µg/mL before freeze-drying (Li et al., 2009). More examples are 
shown in Table 1. 
Table 1- Tumour-targeting selectivity of anticancer-incorporated polymeric micelle. 
Polymeric 
micelle 
Block Copolymer Drug 
Micelle 
Size 
(diameter) 
Indication Reference 
Genexol 
PM 
PEG-P(D,L-
lactide) 
Paclitaxel 20-50 nm 
Breast cancer, 
Pancreatic cancer, 
Small cell lung 
cancer 
Kim et al., 
2004 
Wilson et al., 
2008 
NK012 PEG-PGL(SN-38) SN-38 20 nm Breast cancer 
Matsumura et 
al., 2009 
NC-6004 
PEGPGL 
(Cisplatin) 
Cisplatin 30 nm Solid tumours 
Matsumura, 
2008 
Wilson et al., 
2008  
SP1049C 
Pluronic L61and 
F127 
Doxorubicin 22-27 nm 
Adenocarcinoma 
of oesophagus 
Sutton et al., 
2007 
NK105 PEG-(aspartate) Paclitaxel 85 nm 
Advanced 
stomach cancer 
Matsumura, 
2008 
Hamaguchi et 
al., 2007 
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Various types of amphiphilic copolymers have been designed for this matter included grafted 
and block copolymers, dendrimers, comb and star shaped polymers. 
1.3- Copolymers 
Polymer alteration with the goal of getting specific properties to the final product has given a 
considerable push to macromolecular science. Copolymerization reactions are used to 
enhance the desirable and targeted properties of some polymers to meet the requirements of 
the special application. A copolymer is a macromolecule composed of two or more 
monomeric repeating subunits linked together to control the resulting material properties. A 
copolymerization reaction of a mixture of vinyl esters was first revealed in 1914 by Klatte F. 
The intensive applied research in the subsequent period showed that the copolymers have 
desirable physical properties as compared to polymers of single monomers (Mayo and 
Walling, 1950). 
 
Copolymers can be sorted into four general classes (see Figure 4) 
1- Alternating copolymers. 
2- Random copolymers.  
3- Block copolymers. 
4- Graft copolymer. 
 
The majority of the commercial polymer blends consist of 2-3 polymers as a block or graft 
copolymer. This technology is widely used because it’s cheap and reduces the time that is 
consumed to develop new monomers and new polymerization methods to create new 
polymeric materials (Cor et al., 1998).  One of the most commonly used copolymer is 
Acrylonitrile-Butadiene-Styrene (ABS). Copolymerization of these three polymers together 
shows an enhancement in chemical and thermal resistance; good dimensional stability; and 
increased toughness and impact strength to the copolymer (Figure 5) (Kulich et al., 2001). 
Many commercial copolymers are used in medical and pharmaceutical sectors including burn 
wound care such as polyvinyl alcohol-polyethylene glycol (PVA-co-PEG), sutures such as 
Polyglactin 910, artificial hip joints made by grafting poly(2-methacryloyloxyethyl 
phosphorylcholine) (MPC) onto a highly cross-linked UHMWPE (X-UHMWPE)…etc. 
(Madaghiele et al., 2014, Sharp et al., 1989, Kazuhiko, 2015). 
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Amphiphilic graft copolymers have gained much attention because of their sensitivity to the 
outer chemical and physical stimuli include pH, temperature, light and electric field (Zhang et 
al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-Schematic representation of copolymer types. 
 
 
 
 
 
 
 
 
Figure 5-Chemical structure of ABS copolymer. 
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1.3.1- Block copolymers 
Block copolymers are one of most widely used materials for self-assembly studies in 
nanomedicine (Cabral and Kataoka, 2010). Block copolymers are macromolecules that 
consist of different monomer clusters formed together in continuous blocks. In general, block 
copolymers are sorted into three categories depending on the types and numbers of polymer 
blocks AB, ABA or BAB and ABC (Tharmavaram et al., 2017). Typically, amphiphilic block 
copolymers are made-up from the polymerization of one hydrophobic segment and one 
hydrophilic segment. The most popular application of amphiphilic diblock copolymers in the 
pharmaceutical and biomedical sector is their use as drug and gene delivery vehicles.  
Polymers such as poly (ethylene oxide) (PEO), poly (acrylic acid) (PAA), poly (2-
hydroxyethyl methacrylate) (pHEMA) and poly (2-methyl-2-oxazoline) (PMOXA) are 
examples of the hydrophilic polymer. Among the many hydrophilic polymers, poly (ethylene 
oxide) (PEO) is still particularly interesting compared to fabricated amphiphilic block 
copolymers due to its high solubility in water and its biocompatibility. Moreover, PEG blocks 
protein and cell surface interactions which lead to reduce nanoparticle uptake (Yue and Ian, 
2016, Ulbrich et al., 2016, Dehbari et al., 2017, Achilias and Siafaka, 2017, Zhang and 
Zhang, 2017) 
 
 
 
 
 
 
 
Figure 6- Chemical structure of hydrophilic polymers commonly used in block copolymers 
A) poly (ethylene oxide), B) poly (acrylic acid), C) poly (2-hydroxyethyl methacrylate) and 
D) poly (2-methyl-2-oxazoline). 
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There is a plethora of hydrophobic polymer moieties that have been described in the literature 
such as poly(propyleneoxide) (PPO), polystyrene (PS), poly (L-lactic acid) (PLLA) and poly 
(diethylaminoethyl methacrylate) (PDEA) (Figure 7).   
 
 
 
 
 
 
 
Figure 7- Chemical structure of hydrophobic polymers commonly used in block copolymers 
A) poly (propyleneoxide), B) polystyrene, C) poly (L-lactic acid) and D) poly 
(diethylaminoethyl methacrylate). 
Polymers for the preparation of self-assembled polymer micelles for drug delivery can either 
be di-block (hydrophilic-hydrophobic) or tri-block (hydrophilic-hydrophobic-hydrophilic) in 
common (Torchilin, 2006). 
One of the common tri-block (ABA) systems is Poloxamers also known by the trade name 
Pluronics® which consists of poly (ethylene oxide)-block-poly (propylene oxide)-block-poly 
(ethylene oxide) PEO-PPO-PEO.  It is highly biocompatible and resistant to protein 
adsorption and cellular adhesion due to its amphiphilic nature (Yue and Ian, 2016, Elena and 
Alexander, 2008). 
Most other amphiphilic block copolymers have been formulated from, poly(N-
isopropylacrylamide), Poly(E-caprolactone), poly(methyl methacrylate), and  poly(l-lactide) 
as a hydrophobic polymer segment and Poly(ethylene glycol) (PEG) as a hydrophilic polymer 
segment which is considered as a gold standard in the field of drug delivery among other 
hydrophilic polymers (Xinru et al., 2009, Grossen et al., 2017, Shalgunov et al., 2017, Jiang 
et al., 2017) 
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1.3.2- Graft copolymers 
Generally, graft copolymers are easier to synthesize than block copolymers and offer all its 
properties. Graft copolymers can be made by attaching polymeric side groups onto the liner 
polymer backbone, where the grafted side groups have different properties than the backbone 
and depending on the nature of these two parts, graft copolymers have found a wide range of 
applications (Sebastian and Axel, 1999). In this respect, Rieger and colleges reported the use 
of ring-opening copolymerization to prepare novel biodegradable and biocompatible poly (ε-
caprolactone)-graft-poly(ethylene oxide), PCL-g-PEO. These amphiphilic graft copolymers 
have similar surfactant properties of PEO-b-PCL diblock copolymers (Rieger et al., 2006).  
Graft copolymers have shown promising potential in drug, proteins and gene delivery 
application. Several monomers have been used for this purpose such as methyl methacrylate 
(MMA), N-dimethylaminoethyl methacrylate hydrochloride (DMAEMC), methacrylic acid 
(MAA) and N-trimethylaminoethyl methacrylate chloride (TMAEMC) (Sadeghi and Heidari, 
2011, Qian et al., 2006). In the aqueous medium, the hydrophobic moieties form the inner 
core of the structure, and the bioactive material molecules are incorporated into the 
hydrophobic inner core, particularly for hydrophobic drugs (Figure 8).  
 
 
 
 
 
 
 
Figure 8- Schematic illustration of drug incorporation into amphiphilic copolymer in 
aqueous medium. 
Grafting copolymerization has also been used to graft synthetic polymers onto natural 
polymers to add some new properties, in the meanwhile reduce the initial properties loss due 
to change in the original structure. Natural polymers such as chitosan, alginate, starch, 
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gelatine and cellulose seem attractive raw materials in this respect due to their structural 
variety and water solubility. Mochalova and his co-workers performed graft 
copolymerization of acrylamide in water-acetic acid solutions of chitosan. The graft 
copolymerization of acrylamide with chitosan using ammonium persulfate as an initiator has 
also been reported. The studies showed that the copolymer films show better mechanical 
properties as compared with those of polysaccharide (Mochalova et al., 2006). In another 
study by Sadeghi and Heidari, a pH-sensitive gelatine-based hydrogel was synthesized 
through cross-linking graft copolymerization of methacrylic acid (MAA) onto gelatine. They 
concluded that the gelatine-g-PMAA hydrogel demonstrated a pH-responsiveness character 
at pH between 2 to 8; give the synthesized hydrogels great potential as a good candidate for 
controlled delivery of bioactive agents (Sadeghi and Heidari, 2011). 
Smart polymers or stimuli-responsive polymers have been extensively used for 
responsive drug delivery. The following outline is provided as an overview of smart polymers 
with some examples. 
1.4- Smart polymers 
Smart polymers or so-called “Stimuli-responsive polymers” are an exciting and emerging 
class of macromolecule materials which respond to an internal or external stimulus by 
changing their dimension, structure, or aggregation state (Menglian et al., 2017, Qi et al., 
2017). Many Stimuli-responsive polymers are found in nature, including proteins, 
polysaccharides and nucleic acids (Pasparakisa and Vamvakaki, 2011).  
In general, the stimuli can be either physical, chemical or biochemical. Typical physical 
stimuli are temperature, ultrasound, light, and magnetic and electrical fields whereas 
chemical stimuli comprise the solution pH and the addition of salt or metals, while 
biochemical stimuli include the occurrence of biomolecules and bioactive molecules such as 
proteins, polysaccharides, amino acids and glucose (Manourasa and Vamvakaki, 2017). 
Table 2 below provides examples of various stimuli and responsive materials. Sophisticated 
polymeric systems, that respond to combinations of two or more of the various stimuli, which 
are known as dual or multi-stimuli-responsive polymers, can be even smarter than their 
mono-responsive counterparts and further enhance the loading efficiency and prolonged 
sustained release times (Karimi et al., 2015). 
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Table 2- Various stimuli and responsive materials. 
Environmental 
stimulus 
Responsive material Reference 
Temperature 
N-(2-hydroxypropyl)methacrylamide) 
(HPMA), Poly (N-isopropylacrylamide) 
(PNIPAAm), Poly(2-isopropyl-2-oxazoline) 
(PiPOx) 
Tang et al., 2017 
Škvarla et al., 2017 
Kim et al., 2016 
Alfurhood et al., 2016  
pH 
Poly (acrylic acid), poly (methacrylic acid) 
(PMAA), poly (ethylene imine), poly(L-
lysine), and poly(N,N-dimethyl aminoethyl 
methacrylamide)  
Karolewicz et al., 2016 
Temperature 
and Light 
Modified poly(acrylamide)s Kawatani et al., 2017 
Electric field 
poly(vinyl alcohol) and poly(acrylic acid-co-
2-acrylamido-2-methyl propyl sulfonic acid)  
Song-Bai et al., 2008 
Ultrasound poly(lactic acid-co-glycolic acid) Zhang et al., 2014 
Temperature 
and electric field 
Poly(pyrrole) Jun Ge et al., 2012 
Temperature 
and pH 
poly(β-amino ester) Lu et al., 2017 
 
Researchers have used these stimuli-responsive polymeric systems to endorse the drug 
loading and to modulate the rate and site of drug release. The use of these polymers has 
shown enhanced drug release behaviour depending on the type of stimulus and rate of 
response (Figure 9). In this section, some specific stimuli-responsive polymer systems will be 
discussed. Special emphasis is placed on thermo-responsive polymers. 
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Figure 9- Different types of smart polymeric drug delivery systems for controlling drug 
release. 
1.4.1- pH-Responsive polymers 
pH-responsive polymers are polyelectrolytes that endure in their structure ionisable groups 
(weak acidic or basic groups) with pKa values 3 to 10. These groups either accept or donate 
protons in response to changes in environmental pH. The pendant acidic or basic groups such 
as carboxylic, sulfonate and primary or tertiary amino groups on polyelectrolytes demonstrate 
a change in ionization state as a function of pH. The alterations in structural and properties 
such as solubility, surface activity, and chain conformation have been explained by changes 
in the ionization, where specific polymer groups switch between a neutral and charged state 
(Figure 10) (Mihai et al., 2011). These unique properties of pH-responsive polymers have 
sparked particular interest in their use in drug delivery applications based on the fact that the 
human body presents a range of pH along the gastrointestinal tract and also in some specific 
segments of tumours, which provide environmental stimuli for responsive drug release.  
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Figure 10- Representation of the switch between a neutral and charged state of pH-
responsive polymer particles. 
There are a number of different mechanisms which control the release of 
entrapped/encapsulated drug from a pH-responsive polymer including diffusion controlled, 
swelling controlled, and chemically controlled mechanisms (Muhammad et al., 2017). 
Recently, pH-responsive crosslinked natural rubber (NR) and poly (4-vinylpyridine) (P4VP) 
via free radical crosslinking reaction have been synthesised (Chanon et al., 2017). It was 
reported that the P4VP-crosslinked NR was found to be pH-responsive in acidic solution. The 
release of dye from the P4VP-crosslinked NR could happen upon increasing the pH of 
solution above 4 (Chanon et al., 2017).  
Mitra and Kamyar fabricated magnetic nanoparticles grafted pH-responsive poly 
(methacrylic acid-co-acrylic acid)-grafted poly(vinylpyrrolidone). They found that at pH 1.2 
the cumulative release of the drug from nano-carrier was 78% compared with 5 and 31% at 
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pH 5.5 and 7.2 respectively. They concluded that the drug release kinetics and mechanism 
follows a Fickian diffusion controlled and Fickian pattern (Mitra and Kamyar, 2017). 
An acidic tumour pH-responsive nanophotomedicine (pH-NanoPM) was synthesised by Park 
and colleagues for targeted photodynamic therapy (PDT). It was reported that the pH-
NanoPM was fabricated by self-assembly of a pH-responsive polymeric photosensitizer (pH-
PPS) containing pH-cleavable methoxypolyethylene glycol (pH-C-mPEG) with a size of 
~110 nm. They also reported that pH-NanoPM showed improved cellular internalisation at 
acidic tumour pH compared to normal pH when exposing HeLa human cervical cancer cells, 
which led to a remarkable cancer cell killing effect (Park et al., 2016).  
1.4.2- Bio-responsive polymers 
Bio-responsive polymers present an interesting option for the delivery of some hormones and 
drugs. Glucose-responsive hydrogels, one of the bio-responsive polymers, are a powerful 
approach for the treatment of diabetes (Dong et al., 2016, Matsumoto et al., 2017). The 
approach is based on delivering appropriate amounts of insulin in response to changing 
glucose levels. As glucose diffuses within the hydrogel, it converts to gluconic acid by 
glucose oxidase (GOD) catalyses leading to decrease in the pH of the environment resulting 
in swelling or collapsing the gel depending on its characteristics and the subsequent release of 
insulin (Nicholas and Christie, 2006) (Figure 11).  
Kataoka and colleagues have previously reported that a gel composed of N-
isopropylacrylamide (NIPAAm) and 3-acrylamidophenylboronic acid (AAPBA), 
demonstrates a reversible volume change in response to glucose concentration. Kataoka 
found that adequately controlled and pulse-shaped release of insulin can be achieved at pH 9 
and 28 °C (Kataoka et al., 1998). 
In another interesting piece of research, the self-assembly of two types of diblock 
copolymers, poly(ethylene glycol)-b-poly(aspartic acid-co-aspartamidophenylboronic acid) 
(PEG-b-Poly(Asp-co-AspPBA)) and poly(N-isopropylacrylamide)-b-poly(aspartic acid-co-
aspartamidophenylboronic acid) (PNIPAM-b-Poly(Asp-co-AspPBA)) have been used to 
develop a glucose-responsive complex polymeric micelle (CPM). The block copolymers 
form complex micelles with a novel core-shell-corona structure by controlling the weight 
ratio between PNIPAM and the PEG (WPNIPAM/WPEG = 6/4). The CPM shows reversible 
glucose-induced swelling changes in response to a stepwise change in the glucose 
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concentration, facilitating the repeated on-off release of insulin controlled by glucose level. It 
was also reported that the CPM provides effective protection for the encapsulated insulin 
against protease degradation (Liu et al., 2013). 
 
 
 
 
 
 
 
 
 
 
Figure 11- Representation of the glucose-responsive controlled release of insulin. 
1.4.3- Light Responsive polymers 
Inexpensive and easily controlled are the main advantages that make light (ultraviolet or 
visible) represent as one of the most important external stimuli for drug delivery systems 
(Thakur and Thakur, 2016). When a light source with appropriate wavelength is applied to 
the hydrogels, which employs photosensitizers such as azobenzene, stilbene, and 
triphenylmethane, the chromophore absorbs the light, resulting in an increase in local 
temperature of the hydrogel. As a result, the hydrogel changes its degree 
of swelling behaviour in response to temperature change (Jin et al., 2010). 
One of the major limitations in the use of light stimuli-responsive polymers in drug delivery 
systems is leakage of non-covalently-bound chromophores during swelling or shrinking of 
the system which leads to an inconsistent and slow response of the hydrogel towards the 
stimulus. A second drawback from the point of view of the researchers is dark toxicity 
(Honey et al., 2014). 
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Jiang and co-workers described the synthesis of diblock copolymers containing hydrophilic 
poly (ethylene oxide) (PEO) and a hydrophobic poly(methacrylate) bearing pyrene pendant 
groups (PPy). The self-assembly of amphiphilic block copolymers bearing these groups in 
water led to the formation of micelles, which can be can be dissociated by light. UV light 
irradiation of the micellar solution triggers the cleavage of the photo-responsive pyrene 
moieties, generating a hydrophilic poly (methacrylic acid). As a result of the cleavage, the 
polymer micelles will be complete dissociated (Jiang et al., 2005).  
Recently, a photo-responsive lipid-polymer hybrid nanoparticle system consisting of three 
distinct functional components has been reported. This comprised of (i) a poly (D,L-lactide-
co-glycolide) (PLGA); (ii) a soybean lecithin monolayer and (iii) a photo-responsive 
polymeric shell with anti-biofouling properties have been synthesised. It was reported that the 
poly (D,L-lactide-co-glycolide) (PLGA) used to encapsulate doxorubicin while soybean 
lecithin monolayer acts as an active barrier to prevent drug leakage. Furthermore, the 
nanoparticle stability under light irradiation was enhanced by the photo-responsive polymeric 
shell with anti-biofouling properties. The in vitro result indicated that 76 % of the 
encapsulating drug was released upon light irradiation against 10% release without light 
irradiation. The results obtained from the confocal microscopy and flow cytometry 
support the light-controlled drug release behaviour inside the cancer cells (Yao et al., 2017).  
1.4.4- Thermo-responsive polymers 
Generally, the solubility of most substance will increase with increased temperature. 
However, smart polymers have been developed which exhibit   thermo-responsive solubility 
changes (increase or decrease) in response to a change in temperature. This unique property 
has resulted in a great focus on thermo-responsive polymers as modern, highly controllable 
drug delivery systems.  
In general, thermo-responsive polymers can be categorised into two groups according to 
either their lower critical solution temperature (LCST) or their upper critical solution 
temperature (UCST) properties.  Some of the thermo-responsive polymers have been 
recorded in Table 3. 
Almost all applications of these polymers rely on sudden solubility changes in aqueous 
environments at the lower critical solution temperature (LCST). The rapid change in 
solubility of thermo-responsive polymers around LCST can be attributed to the considerable 
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hydrogen bonding interactions with neighbouring water molecules, and limited intra/inter-
molecular hydrogen bonding between polymer molecules (Figure 12). At increased 
temperatures, hydrogen bonding between the polymer and water breaks down and intra-and 
intermolecular hydrogen bonding / hydrophobic interactions dominate above the LCST, 
which results in a transition in solubility (Roy et al., 2013).  
 
 
 
 
 
 
 
 
 
 
 
Figure 12- Schematic illustration of the LCST-type phase transition. 
 
There are two important characteristics of thermo-responsive polymers: 1) tunability of their 
LCST and 2) sharp phase transitions in both heating and cooling processes. Dehydration and 
rehydration of the polymer chains are effected by the sharpness in phase transitions, which 
rely on the interaction balance among polymer chains and between polymer chains and the 
solvent water as well (Yan et al., (2012).  
 
One of the most successful polymeric systems which have been used for passive drug 
targeting purposes, is N-(2-hydroxypropyl) methacrylamide (HPMA) based copolymers 
(Kadajji and Betageri, 2011). Poly(N-(2-hydroxypropyl) methacrylamide) (pHPMA) 
possesses desirable properties as drug carriers such as non-immunogenicity, biocompatibility, 
and the possibility for functionalisation. These properties have resulted in a wide range of 
pharmaceutical and biomedical applications as well as in the micelle technology research 
(Talelli et al., 2010). pHPMA self-assemblies have also been used in the design of hybrid 
block and grafted HPMA copolymers that self-assemble into smart hydrogels 
(Kopeček and Kopečková, 2010). 
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Table 3- Examples of thermo-responsive polymers. 
Polymer Type CST Reference 
Poly(N-n-propylacrylamide) (PNNPAM) 
 
 
LCST 10 
 
Ito and Kubota, 
1997 
 
Poly(ethylene oxide) ( PEO) 
 
UCST 296 Bae et al, 1991 
Poly(N-isopropylacrylamide) (PNIPAM) 
 
 
LCST 32 Klaus et al., 2009 
Poly (vinyl methyl ether) (PVME) 
LCST -15, -25 
 
Van et al., 2007 
Assche et al., 2011 
Poly(2-isopropyl-2-oxazoline) (PiPOx) 
 
 
LCST 36 
Uyama and 
Kobayashi, 1992 
Poly(methyl methacrylate) (PMMA) 
 
 
UCST 
87 or 
above 
Cowie et al., 1986 
N
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(              ) n
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(              ) n
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Poly(2-hydroxypropylacrylate) (PHPA) 
 
 
 
LCST 30-60 Vo et al., 2010 
 Poly(styrene)/poly(styrene-co-acrylonitrile) 
(PS/SAN) 
 
 
UCST 171 Qi et al., 2004 
 
There are many examples of HPMA based copolymers being used for drug and gene delivery 
applications (Burke and Pun, 2010, Tang et al., 2017, Abd Ellah et al., 2015, Johnson et al., 
2011). Qin et al, prepared and evaluated co-polymers consisting of N-3-aminopropyl 
methacrylamide (APMA) and N-2-hydroxypropyl methacrylamide (HPMA) to develop novel 
non-viral gene transfection carriers. They used free radical synthesis in order to fabricate the 
copolymers followed by total guanidination of amino groups. They found that parent 
cytotoxicity and efficient transfection decreased significantly at relative low charge ratios 
(Qin et al., 2012). 
Recently, Chu et al, reported the use of HPMA-co-APMA polymer backbone grafted by 
BM9 peptide, which included bivalirudin fused to a protease substrate sequence. This 
copolymer formula was used for localized and prolonged bivalirudin delivery following 
spinal cord injuries. The results show decreased proliferation and reduced gliosis in rats 
treated with these bivalirudin-release depots (Chu et al., 2015). 
Another example of the most widely thermo-responsive polymer (amide type) is poly (N-
isopropyl acrylamide) (PNIPAM). It has a sharp and reversible phase transition at a 
temperature near to body temperature because of the secondary amide group and a 
hydrophobic isopropyl group, this behaviour can reveal that some hydrogen bonds between 
C=O and H2O decreased, while another type of hydrogen bonding formed between C=O and 
NH groups throughout the coil-globule transition (Lai et al., 2012). 
N
O O
OH
(              ) n
(         )n (          )m
CN
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Contreras-García et al, grafted polypropylene (pp) by N-isopropylacrylamide (NIPAAm) and 
N-(3-aminopropyl) methacrylamide hydrochloride (APMA) by using γ-irradiation to obtain 
interfaces polymers that are stimuli-responsive under physiological conditions. The scientific 
team reported that when they used 1 M NIPAAm/0.5 M APMA the copolymer around the 
physiological temperature showed rapid and reversible transitions showing a LCST, while 
with higher content of APMA the hydrophilicity of PP-g-(1NIPAAm-r-1APMA) becomes 
higher and that prevented the grafted polymer from shrinking (Contreras-García et al., 2010).  
Another report done by Yuting et al, refer to using reversible addition fragmentation chain-
transfer polymerization to prepare hydrophilic block copolymers, poly(N-(3-
aminopropyl)methacrylamide hydrochloride)-block-(N-isopropylacrylamide) (PAMPA-b-
PNIPAM). The researcher found when the solution temperature is increased that these block 
copolymers will self-assemble into vesicles, with the size and size distribution of the vesicles 
influence by the heating rate and the solution concentration (Yuting et al., 2006). 
Thermo-responsive polymeric materials can elicit potentially a therapeutically effective dose 
without unacceptable adverse effects. More recently, a number of studies have confirmed the 
ability of the thermo-responsive polymeric micelle to release its payload into the surrounding 
environment by relatively small differences in temperature.  
In one of these studies (Sun et al., 2014) they used methotrexate as an anticancer model. 
Methotrexate is a poorly soluble anticancer drug that introduces severe side effects, and thus 
imposes major restrictions on both clinical efficacy and therapeutic safety. To address these 
problems, Sun and colleagues loaded the methotrexate drug into poly(N-
isopropylacrylamide-co-acrylamide)-b-poly(n-butyl methacrylate) block copolymer micelles. 
The ultimate goal was to produce a polymer formulation which could be stimuli-responsive 
on/off release and spatial specificity. Sun`s group reported that the thermally triggered release 
of methotrexate was observed in vitro. Also, this work showed that the cytotoxicity activity 
of methotrexate-loaded micelles, on Lewis lung carcinoma cells, was considerably increased 
in combination with hyperthermia (Sun et al., 2014). 
In another study, doxorubicin (DOX) and camptothecin (CPT) were loaded into shape 
transformable amphiphilic scaffolds by Kashyap and Jayakannan. The in vitro drug release 
studies revealed that the DOX loaded scaffolds showed a selective release to deliver 90% of 
loaded drug at the cancer tissue temperature (40-43 °C) as compared to that of normal body 
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temperature (37 °C, <10%). The kinetics of DOX release at the cancer tissue temperature 
indicated that the formulation followed non-Fickian diffusion kinetics (Kashyap and 
Jayakannan, 2014).  
1.4.5- Multi-responsive polymer  
Some smart polymer systems have been devised to respond to more than one stimulus. These 
polymer systems could present a unique opportunity to fine tune their response to each 
incentive individually.  
Ryskulova et al, investigated the pH and temperature dual responsive system comprised of 
poly(phenylene vinylene)s (PPVs) having both carboxylic acid and methoxyoligoethylene 
glycol pendant groups. The fluorescence intensity is affected by pH change in a range from 3 
to 10 and temperatures from 10 °C to 85 °C (Ryskulova et al., 2016). In another interesting 
piece of research, an amphiphilic copolymer containing PEO and poly N-3-acrylamido 
phenylboronic acid (PAPBA) linked by a disulfide bond (PEO-SS-PAPBA) was fabricated 
by Yuan and co-workers. This copolymer showed glucose, pH and redox triple responses. 
They also reported that the controlled release of insulin could be achieved via adding glucose 
or glutathione (GSH) (Yuan et al., 2014). 
Zhou and colleagues reported that selenium-containing polymer with the drug could be used 
as successful multi-responsive drug release. They prepared micelles of the selenium-
containing PEG with redox-triggered property and the metal-organic frameworks (MOFs) 
with pH-triggered property in drug delivery systems. They concluded that the cores easily 
collapsed in the presence of redox agents and that the shell can breakdown only under low pH 
conditions (Zhou et al., 2017). 
1.5- Combination of stimuli-responsive polymers and magnetic nanoparticles 
properties. 
In recent years, the combination of stimuli-responsive polymers and magnetic nanoparticles 
into a single platform has attracted much consideration due to their unique properties. 
Magnetic nanoparticles (MNPs) can be triggered by internal or external stimulus which leads 
to internally stimulate changes to the polymeric network, allowing for a versatile stimuli-
responsive system. Many of the MNPs types have been used for this purpose including 
hybrid nanoparticles (Jalili et al., 2016, Song et al., 2015).  
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Hybrid nanoparticles (HNPs) that are composed of iron oxide cores coated with gold have 
received increased interest in terms of using these nanostructures for image-guided drug 
delivery (Barnett et al., 2013). Moreover, the introduction of HNPs between the polymer 
structures provide localized trigger of heating, when irradiated with a short laser burst, they 
lead to remote control of bulk polymer shrinkage (Roach et al., 2013).  
Using laser irradiation for medical applications has helped researchers to achieve specific 
targeting, in addition to, reduce the energy level to be compatible with medical safety 
standards. This phenomenon has been confirmed by using the targeting agents to diminish the 
laser power needed to reach therapeutic effects in cancers (Kirui et al., 2010). Additionally, 
the magnetic properties of the iron oxide core confer imaging capability using magnetic 
resonance imaging (MRI) and hence real time tracking in vivo is possible. 
Recently Hoskins et al, reported the fabrication of Fe3O4-PEI-Au-PEG (HNPs) using 
poly(ethylenimine) as an intermediate separating the core and shell. The gold surface was 
functionalized via coating by poly(ethylene glycol) (PEG) which consist of the thiol group (-
SH). The HNPs seemed to reduce T2 values in line with previously clinically utilized MRI 
contrast agent Feridex
® 
(Hoskins et al., 2012b). Roach and co-workers reported the in vitro 
release of methylene blue (as a model drug) from smart scaffolds based on thermo-responsive 
poly(N-isopropylacrylamide) (pNiPAM). They reported that the incorporation of HNPs 
resulted in scaffold deformation after very short times (seconds) of laser irradiation which 
lead the model drug to be released during a remote structural change of the scaffold (Roach et 
al., 2013).  
Conjugation of HNPs and polymers to the thiol-containing oxadiazole (Ox) groups is an 
attractive method to fabricate bi-functional imaging and as a drug delivery platform. In this 
respect, a new class of poly (allylamine) (PAA) polymer containing rigid oxadiazole (Ox) 
groups has been prepared by Barnett and colleagues. In vitro results showed that polymer-
drug conjugates had significantly higher drug uptake in BxPC-3 cells with decreased IC50 
compared with free drug (Barnett et al., 2013). On the other hand, the nano size and negative 
charge of the gold nanoparticles (AuNPs) could help to penetrate deeply inside the cells 
(Sonavane et al., 2008). This finding helped considerably in delivering different biomaterials 
to target cells via conjugation with AuNPs. Moreover, AuNPs are now being developed to 
improve imaging with MRI and CT due to their ability to be conjugated to molecular proteins 
on the contrary of the iodine. In this respect, Popovtzer and co-workers reported the ability to 
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detect head and neck cancer at the cellular and molecular level with standard clinical CT by 
conjugated UM-A9 antibodies to HNPs (Popovtzer et al., 2008). 
 
1.6- Aims and Objectives 
The inclusion of hybrid iron oxide-gold nanoparticles (HNPs) into thermo-responsive 
copolymer micelles was studied here towards the development of a targeted, thermally-
triggered drug delivery system for cancer therapy. Herein, we aim to synthesis of HNPs and 
an amphiphilic graft polymer composed of a poly(N-(2-hydroxypropyl) methacrylamide) 
pHPMA backbone, and experimental verification of laser heating of the HNPs, self-assembly 
of the copolymers to form magnetic micelles, and thermally-enhanced drug release at target 
cells, in the meantime; enhance solubility of hydrophobic drugs, reduce side effects/toxicities 
of loaded drugs, which are key factors affecting anticancer drug developments. 
Hydrophobic groups of palmitoyl, dansyl, cholesteryl and 5-(4-chlorophenyl)-1,3,4- 
oxadiazole were grafted onto the primary amine group of APMA monomers. These 
monomers were polymerised with water-soluble thermo-responsive HPMA. Optimal 
substitution onto the backbone of both hydrophobic and hydrophilic groups onto the primary 
amines of the polymer was determined. HNPs were synthesized and incorporated into the 
intrinsic amphiphiles structure in the oxadiazole modified polymers.  
Characterisation of the novel amphiphiles was carried out using various techniques to 
determine the success of synthesis and physical properties of the system including aggregate 
formation, the magnetic potential for imaging and potential for heating via laser irradiation. 
Drug loading studies were carried out in order to determine optimal loading parameters such 
as initial drug:polymer feed, polymer concentration etc. Drug release studies were performed 
highlighting the capability of the system to act in a thermo-responsive manner. The structure 
of the oxadiazole pendant allows for further conjugation of hybrid iron oxide-gold 
nanoparticles (HNPs) via dative covalent linkage between the thiol (-SH) group in the 
oxadiazole structure and the gold surface of the HNP. This was realised by using heating 
plates. Biological investigations into drug uptake, cytotoxicity and cellular localisation were 
realised in vitro using simple assays. 
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Chapter Two 
 
 
Synthesis and Characterisation of modified 
monomers and copolymers 
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2.1- Introduction 
Intelligent polymer systems have been attracting wide interest in recent years from the 
scientific community. Thermo-responsive polymers are a class of smart polymers that 
respond to change in temperature. The characteristic feature to respond to very slight changes 
in the environmental conditions has actually made this class of polymers very promising for 
many applications especially in the field of nanomedicine (Jochum and Theato, 2013). 
Here a thermo-responsive polymer was synthesised by introducing hydrophobic groups onto 
the primary amine group N-(3-aminopropyl) methacrylamide hydrochloride (APMA) then 
polymerizing with a water soluble N-(2-hydroxypropyl) methacrylamide (HPMA) monomer 
followed by block copolymerization with poly(ethylene glycol) (PEG). 
p(HPMA) (Figure 13) is a thermo-responsive polymer which undergoes a conformational 
change at its lower critical solution temperature (LCST); this change results in the shrinkage 
of the polymer structure and disruption of the aggregates leading to drug release 
(Cunningham et al., 2014). 
 
 
 
 
 
 
 
 
Figure 13- Chemical Structure of pHPMA. 
 
Polymers, which have primary amino groups, such as N-(3-aminopropyl) methacrylamide 
hydrochloride (APMA) (Figure 14), have been used for post-polymerization modification 
reactions for the development of new materials for biomedical applications.  
 
N-(3-aminopropyl)methacrylamide, a monomer that contains primary amine, has been used 
to prepare copolymers and cross-linked micelles for drug and gene delivery (Mendonça et al., 
2014). APMA can be modified via its primary amine functional group allowing attachment of 
various hydrophobic groups by a simple nucleophilic substitution reaction.  
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Figure 14- Chemical Structure of APMA. 
 
In this study we grafted hydrophobic groups onto the primary amine group of APMA using 
palmitoyl, dansyl, cholesteryl and 5-(4-aminophenyl)-1,3,4- oxadiazole (Figure 15). These 
monomers will ultimately be polymerised with water-soluble thermo-responsive HPMA to 
form an amphiphilic polymer system to be exploited for drug solubilisation and heat activated 
release. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15- Chemical Structure of (A) palmitoyl chloride (B) 5-(4-aminophenyl)-1 3 4-
oxadiazole-2-thiol (c) dansyl chloride (D) cholesteryl chloroformate. 
The main purposes of using these hydrophobic moieties are: to develop the self- assembly of 
amphiphilic block copolymers, improve drug loading, enhance solubility and bioavailability 
of poorly soluble drugs (Trivedi and Kompella, 2010, Mourya et al., 2011).  
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Grafted polymers based on poly(allylamine) with 5% and 10% molar substitution of 
cholesterol and dansyl have been previously reported. These systems have been shown to 
successfully formed self-assemblies by probe sonication in water, demonstrated universal 
drug solubiliser property and had significantly enhanced propofol, griseofulvin, prednisolone, 
and Bisnaphthalimidopropyldiaaminooctane (BNIPDaoct) solubility (Hoskins et al., 2012, 
Hoskins et al., 2012a, Hoskins et al., 2010)   .  
Furthermore, cholesterol is able to regulate the membrane permeability during uptake and 
intracellular trafficking (Wanga et al., 2015). Zheng et al, showed that cholesterol derivatives 
like cholesteryl chloroformate can enhance the grafting ratio and drug loading of alginates 
(Zheng et al., 2014). 
Additionally, the use of oxadiazole as a hydrophobic pendant group has also been reported by 
Barnett et al. Barnett exploited the strong dative covalent binding between the thiol in the 
oxadiazole pendant and the colloidal gold surface of hybrid nanoparticles HNPs (Barnett et 
al., 2013). They reported that the system was capable of image guided drug delivery for the 
solubilisation of hydrophobic compounds. 
In this work we will employ oxadiazole pendants to confer amphiphilic properties into our 
polymeric system, subsequently incorporate HNPs into the structure and utilise these HNPs 
as localised triggers for heat initiated polymer shrinkage and ultimately drug release. In order 
to develop such  a system, a wide range of techniques are required in order to fully 
characterise the system before drug loading and release studies can be performed. The main 
methods of characterisation are described below. 
2.1.1- Thin Layer Chromatography (TLC) 
Chromatography in general is a technique used to separate several different kinds of chemical 
mixtures. Chromatographic methods included many of the processes that rely on different 
distributions of the components of the substance to be separated between two phases: one 
remains constant and called the stationary phase which can be either solid or liquid, and the 
second phase is called the mobile phase which can be either liquid or a gas (Coskun, 2016). 
There are many types of the chromatography such as: Thin layer chromatography (TLC), Gas 
chromatography (GC), Column liquid chromatography (CLC) and high performance liquid 
chromatography (HPLC) (Thammana, 2016).  
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TLC is a simple method that can be used in the laboratory to: monitor reactions by checking 
whether the reaction is complete or not, determine the number of components in a mixture, 
identify compounds and purity, in addition to quantification, an ability especially used in 
pharmaceutical industry etc. (Coskun, 2016, Yua et al., 2016). 
 
 
 
 
 
 
 
Figure 16- Schematic design of a basic TLC plate for monitoring reaction progress. 
In this technique, a sample mixture is introduced in a certain amount about 1 cm from the 
bottom of the TLC plate and then the plate is placed in a container of solvent (Figure 16). The 
solvent front travels up the plate by capillary action and draws the compounds up at different 
speeds, thus separating the components of a mixture. Each component has a retention factor 
(Rf) which can be calculated by dividing the distance travelled by the sample over the 
distance travelled by the mobile phase. The Rf value is unique for each compound and it can 
be used in the qualitative analysis (Yua et al., 2016). 
2.1.2- Fourier Transform Infrared Spectroscopy (FTIR) 
Fourier Transform Infrared Spectroscopy (FTIR) is a well-known system which has been 
widely used by chemists to identify the presence of certain functional groups in a sample that 
can be in the solid, liquid or gaseous state. FTIR spectroscopy offers qualitative and 
quantitative analysis for organic and inorganic compounds, polymers and polymer blends 
(Shaikh and Agrawal, 2014). 
Infrared spectroscopy is a technique that involves the interaction of infrared radiation with 
sample molecules. It is based on the fact that most chemical functional groups are absorbing 
in the infra-red light in a region between 4000-600 cm
-1
 which led to the change of dipole 
moment of sample molecule bonds. These regions involve a biochemical fingerprint of the 
structure and functional groups of each sample (Matthew et al., 2014). FTIR represents the 
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third generation of infrared spectroscopy. The main idea is based on using an interferometry 
technique to collect the interferogram of the sample signal followed by performing a Fourier 
Transform (FT) on the interferogram to get the spectrum. 
FTIR spectroscopy has several advantages over the old version IR such as: very fast scan, 
high resolution, very useful for examining small samples and the digital form in which the 
data are handled in the computer allows for adjustment and refinement (Williams and 
Fleming, 2008). 
 
 
 
 
 
 
 
 
 
 
Figure 17- Schematic diagram illustrate the essential features of FTIR spectrometer. 
 
2.1.3- Nuclear Magnetic Resonance Spectroscopy (NMR) 
NMR spectroscopy is one of the most important techniques used in chemistry to investigate 
the structure and chemical environment of unknown compounds (Equbal et al., 2015).  In fact 
there are two common types of NMR spectroscopy are used to characterise organic 
structures: 
1
H NMR and 
13
C NMR. 
Principles of these techniques are based on the fact that nuclei of atoms have magnetic 
properties that can be used to get chemical information. When these atoms are placed inside a 
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strong magnetic field there will be splitting of the energies one with the external field, while 
the other against the field (Gerothanassis et al., 2012). 
When an external radio-frequency signal is applied, nuclei at the lower energy level will 
excite into the higher energy level, when the nuclei returns to its lower level again, energy is 
released at the same frequency. This phenomenon is called the nuclear magnetic resonance. 
The absorption of energy can be detected and enlarged as a liner spectrum called the 
magnetic resonance signal. The applied field can be shield by the electron(s) surrounding the 
proton leading to a slight different between the externally applied magnetic field and the field 
at the nucleus. The level of shielding is influenced by several structural properties within the 
molecule, leading to diverse chemical shift in the NMR spectrum. The common unit to 
express the chemical shift is part per million (ppm) (Shoolery, 2008, Ashbrook and McKay, 
2016). 
 
 
 
 
 
 
 
 
Figure 18- Schematic diagram illustrate the essential features of NMR spectrometer. 
 
2.1.4- Aims and Objectives 
The aim of this chapter is to fabricate an amphiphilic monomer composed of N-(3-
aminopropyl) methacrylamide (APMA) by substituting (palmitoyl, dansyl, cholesteryl and 
oxadiazole) groups onto the primary amine in the APMA monomer and then polymerizing 
with HPMA monomer. All the products were characterized by thin layer chromatography 
(TLC), melting point (MP), Fourier transform infrared spectroscopy (FTIR) and nuclear 
magnetic resonance (NMR). 
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2.2- Materials and Methods 
2.2.1- Materials 
Item 
No 
Material Supplier 
1 N-(3-aminopropyl) methacrylamide hydrochloride, ≥ 98% Polysciences, Inc. 
2 Palmitoyl chloride, 98% Alfa Aesar 
3 Dansyl chloride,  97+% Alfa Aesar 
4 5-(4-chlorophenyl)-1,3,4-oxadiazole-2-thiol, 96% Alfa Aesar 
5 Cholesterol Chloroformate, 95% Sigma-Aldrich Co. 
6 Triethylamine, 99% Acros organics 
7 4-Aminobenzhydrazide, 98% Alfa Aesar 
8 Carbon disulphide, ≥ 99% Sigma-Aldrich Co. 
9 Sodium hydroxide, 98% Fisher Scientific, UK 
10 Hydrochloric acid, 37% Fisher Scientific, UK 
11 Succinic anhydride, ≥ 99% Sigma-Aldrich Co. 
12 4-dimethyl amino pyridine, ≥ 99% Fluka 
13 N-Hydroxysuccinimide, ≥ 98% Alfa Aesar 
14 N,N'-Dicyclohexylcarbodiimide, 99% Acros organics 
15 N-(2-hydroxypropyl) methacrylamide Polysciences, Inc. 
16 Azobisisobutyronitrile, 98% Sigma-Aldrich Co. 
17 Dichloromethane, 99% Fisher Scientific, UK 
18 Anhydrous dimethylformamide, 99.8% Alfa Aesar 
19 Anhydrous diethyl ether, ≥ 99% Fisher Scientific, UK 
20 Methanol, reagent grade Fisher Scientific, UK 
21 Acetone, ≥ 99% VWR chemicals 
22 Deuterated chloroform-D (D, 9.98%) 
Cambridge isotope 
laboratories, Inc. 
23 Deuterated dimethyl sulfoxide-D6 (D, min.99.8%) Apollo scientific limited 
24 Deuterated methanol-D4 (D, 9.98%) 
Cambridge isotope 
laboratories, Inc. 
25 Ethanol, absolute ≥ 99.8% VWR chemicals  
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26 Potassium hydroxide, ≥ 99.97 Sigma-Aldrich Co. 
27 Poly(ethylene glycol) average mol wt 200 Sigma-Aldrich Co. 
 
2.2.2- Methods 
2.2.2.1- Chemical modification reactions 
2.2.2.1.1- Substitution of palmitoyl chloride onto the n-(3-aminopropyl) 
methacrylamide hydrochloride monomer (P-APMA) 
P-APMA was synthesized as follows: in a 100 cm
3
 round bottom flask (RBF), N-(3-
aminopropyl) methacrylamide hydrochloride (1.79 g, 10 mmol) and (2.12 g, 10 mmol) 
palmitoyl chloride were dissolved in 50 mL of anhydrous dimethylformamide (DMF). The 
reaction was stirred at 0°C under argon atmosphere. After that, (2.92 mL, 21 mmol) of 
triethylamine was added to the mixture drop wise. The reaction was monitored by TLC plate 
and the reaction was carried out under stirring at 0°C for 3 h (Figure 19).  
The reaction mixture was colourless until the triethylamine was added. A white precipitate 
was produced as soon as the triethylamine was added. 
After evaporation of DMF, the residue was dissolved in DCM and extracted with water to 
remove all the triethylamine hydrochloride. The organic phase was evaporated to yield a 
white solid with a yield of 79%. 
 
 
 
 
 
Figure 19- Chemical synthesis of P-APMA. 
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2.2.2.1.2- Substitution of dansyl chloride onto the n-(3-aminopropyl) 
methacrylamide hydrochloride monomer (D-APMA) 
D-APMA was prepared from a mixture of (1.79 g, 10 mmol) of n-(3-aminopropyl) 
methacrylamide hydrochloride and (2.69 g, 10 mmol) of dansyl chloride were dissolved in 
(50 mL) anhydrous dimethylformamide. To this mixture (2.92 mL, 21 mmol) of 
triethylamine drop wise was added. The reaction has kept on a stirrer for 24 h at 0°C under an 
argon environment (Figure 20). 
The reaction mixture was orange until the triethylamine was added. A white precipitate was 
produced as soon as the triethylamine was added and the solution colour became yellow.  
The reaction solvent (DMF) was evaporated by rotary evaporation, the crude product was re-
dissolved in DCM and washed by water to remove the triethylamine hydrochloride and the 
organic phase was dried under reduced pressure to obtain D-APMA as a dark yellow thick 
liquid. The yield was 65 %. 
 
 
 
 
 
Figure 20- Chemical synthesis of D-APMA. 
2.2.2.1.3- Substitution of cholesteryl chloroformate onto the n-(3-
aminopropyl) methacrylamide hydrochloride monomer (C-APMA) 
C-APMA was synthesized via the reaction of N-(3-aminopropyl) methacrylamide 
hydrochloride (1.79 g, 10 mmol) and (4.41 g, 10 mmol) of cholesteryl chloroformate in (50 
ml) of anhydrous DMF at 0 °C. After that, (2.92 mL, 21 mmol) of triethylamine was added 
drop wise.  A magnetic stirrer and bar was used to stir the suspension. After 24 h stirring at 
0°C under argon, the mixture was evaporated to remove the DMF.  Then the residue was 
dissolved in DCM and washed with water. The DCM layer then evaporated by rotary 
evaporation, C-APMA (75% yield) was obtained as a white solid after dried. 
36 
 
 
 
 
 
 
 
 
 
 
Figure 21- Chemical synthesis of D-APMA. 
2.2.2.1.4- Synthesis of 5-(4-Aminophenyl)-1,3,4-oxadiazole-2-thiol (D1) 
In 20 mL of 95% ethanol, potassium hydroxide (0.28 g, 5 mmol) and 4-aminobenzhydrazide 
(0.75 g, 5 mmol) were dissolved. The mixture was stirred at room temperature for several 
minutes, followed by adding carbon disulphide (0.38 g, 0.3 mL, 7.5 mmol) dropwise to the 
reaction mixture. The reaction was carried out under reflux for 24 h. After evaporation of the 
solvent, the residue was dissolved in 50 mL water; the aqueous solution was acidified with 
diluted hydrochloric acid to pH 6.0. Subsequently, then the precipitate was separated by 
filtration and washed with water for several times (Figure 22). The yield was 81.9 %. 
 
 
 
 
 
 
 
 
Figure 22- Chemical synthesis of D1. 
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2.2.2.1.5- Synthesis of 4-oxo-4-{[4-(5-sulfanyl-1,3,4-oxadiazol-2 yl) phenyl] 
amino}butanoic acid (D2) 
Under inert atmosphere 5-(4-Aminophenyl)-1,3,4-oxadiazole-2-thiol (D1) (1.93 g, 10 mmol) 
and succinic anhydride ( 2 g, 20 mmol) were dissolved in 50 mL dichloromethane, stirring 
the mixture at room temperature. 4-dimethyl amino pyridine (1.2 g, 10 mmol) was dissolved 
in 5 mL DMF and added dropwise. After 2 h reaction at room temperature, the solution was 
poured into cooled anhydrous diethyl ether to isolate the product as pile yellow powder after 
washing it with diethyl ether (Figure 23). The yield was 70.54 %. 
 
 
 
 
 
 
 
Figure 23- Chemical synthesis of D2. 
 
2.2.2.1.6- Synthesis of 4-[(2,5-dioxopyrrolidin-1-yl)oxy]-4-oxo-N-[4-(5-
sulfanyl-1,3,4-oxadiazol-2-yl)phenyl]butanamide (D3) 
In a dry RBF, 4-oxo-4-{[4-(5-sulfanyl-1,3,4-oxadiazol-2-yl) phenyl] amino}butanoic acid 
(1.46 g, 5 mmol), N-Hydroxysuccinimide (0.57 g, 5 mmol) and N,N'-
Dicyclohexylcarbodiimide (1.03 g, 5 mmol) were dissolved in 50 mL dichloromethane. After 
reaction at room temperature for 24 h, the mixture was filtered to remove the reaction side 
product and the active product was obtained as powder by precipitating in cold anhydrous 
diethyl ether and then washed several times with anhydrous diethyl ether (Figure 24). The 
yield was 71.4 %. 
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Figure 24- Chemical synthesis of D3. 
 
2.2.2.1.7- Substitution of 4-oxo-4-{[4-(5-sulfanyl-1,3,4-oxadiazol-2 yl) 
phenyl] amino}butanoic acid onto the n-(3-aminopropyl) methacrylamide 
hydrochloride monomer (O-APMA( 
Under inert atmosphere, 4-[(2,5-dioxopyrrolidin-1-yl)oxy]-4-oxo-N-[4-(5-sulfanyl-1,3,4-
oxadiazol-2-yl)phenyl]butanamide ( 1.17 g, 3 mmol) and N-(3-aminopropyl) methacrylamide 
hydrochloride (0.53 g, 3 mmol) were dissolved in 30 mL DMF in a100 mL RBF. The 
reaction mixture was stirred at room temperature followed by adding 1.6 mL of triethylamine 
drop wise and the reaction stirred overnight. After removal of DMF with the rotatory 
evaporator, the crude was washed by anhydrous diethyl ether (Figure 25). The yield was 
78%. 
 
 
 
 
 
 
Figure 25- Chemical synthesis of O-APMA. 
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2.2.2.2- RAFT polymerization of HPMA with modified APMA 
HPMA- modified APMA copolymerization (Figure 26) was performed in methanol at 60 °C 
by using azobisisobutyronitrile (AIBN) as the initiator as follows: An ampoule containing 
HPMA and modified APMA was attached to the Schlenk-line. After three vacuum-nitrogen 
cycles to remove oxygen in the ampoule, 5 mL degassed methanol was added, followed by 
addition of AIBN solution in methanol (0.55 mg in 1 mL) via syringe (Table 4). 
The ampoule was sealed and polymerization was performed at 60 °C for 24 h. The polymer 
was obtained by precipitation into acetone and purified by re-dissolving in methanol and 
precipitation in acetone two more times.  
 
Table 4- Monomer feeding Ratio. 
C
o
p
o
ly
m
er
is
a
ti
o
n
 r
a
ti
o
  
Mole 
fraction 
of  
HPMA, 
M1 
Mole 
fraction 
of  
APMA-R, 
M2 
Monomer feeding ratio (APMA-R / HPMA) per gram 
AIBN 
per gram 
APMA-P APMA-D APMA-C APMA-O 
0.25 % 99.75 0.25 0.0035/0.5000 0.0033/0.5000 0.0049/0.5000 0.0037/0.5000 0.0055 
1 % 99 1 0.0236/0.8448 0.0224/0.8448 0.0340/0.8448 0.0249/0.8448 0.0055 
2 % 98 2 0.0476/0.8448 0.0453/0.8448 0.0669/0.8448 0.0503/0.8448 0.0055 
5 % 95 5 0.1202/0.8202 0.1144/0.8202 0.1690/0.8202 0.1271/0.8202 0.0055 
10 % 90 10 0.2380/0.7770 0.2264/0.7770 0.3346/0.7770 0.2518/0.7770 0.0055 
 
 
 
Figure 26- Synthesis of poly (HPMA-co-APMA-R). 
40 
 
2.2.2.3- Synthesis of block copolymer 
 (HPMA-co-APMA-R)-b-PEG diblock copolymer (Figure 27) was synthesized in the 
presence of a free radical source in methanol. A tube was charged with 10% : 90% or 20% : 
80% PEG : HPMA-co-APMA-R molar ratios respectively, and AIBN under nitrogen 
atmosphere. Reaction was carried out at 60 °C for 24 h with continuous stirring. After the 
polymerizations were completed, block copolymers were precipitated in methanol. 
 
 
 
Figure 27- Synthetic scheme for (HPMA-co-APMA-R)-b-PEG diblock copolymers. 
 
2.3- Characterisation of modified monomer 
2.3.1- Melting point 
The melting point for all modified monomers was measured by using Advanced, Digital, 
Melting Point / SMP3 (Bibby sterilin LTD, UK). Determination of the melting point of each 
compound consisted of using pre-sealed (one end) capillary tubes to hold samples, filled with 
0.1-0.2 g of dry compound. The sample tubes were then placed in the melting point 
apparatus. Hence, slowly increasing the temperature of the heating block, the melting process 
was observed through the magnifying lens. 
 
2.3.2- Thin layer chromatography 
Thin-layer chromatography (TLC) analyses were carried out using Merck KGaA silica gel 60 
F254 using UV detection and ethyl acetate, petroleum ether, dichloromethane and methanol 
as eluent solvents. A tiny amount of diluted sample was applied to TLC plate (3× 8 cm) using 
a clean capillary. The TLC plate then placed inside a sealed developing chamber containing 
the mobile phase (eluent solvents) until the solvent front is close to the top of the plate. 
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Hence, the RF of products being compared to starting materials in order to ensure reactions 
had gone to completion.  
2.3.3- Fourier transform infrared spectroscopy (FTIR) 
Infrared spectra of all samples were determined on a Nicolet iS 10 FT-IR (Thermo scientific 
LTD, USA, at room temperature over the range 400 to 4000 cm
 − 1 
using a BOMEM DA-8 
Fourier Transform Spectrometer (FTS) in 16 scan mode (background noise reduction) with a 
resolution of 4 cm
-1
. 
2.3.4- Nuclear magnetic resonance spectroscopy (NMR) 
NMR 
1
H and 
13
C spectra were recorded on a 300 MHz Bruker spectrometer-Avance 300 by 
using deuterated chloroform (CDCl3) and deuterated dimethyl sulfoxide (DMSO) as a 
solvent. The temperature of the measurements was 25 °C.  
2.4- Results  
2.4.1- Physical properties 
Modified monomers synthesis was performed in accordance to Table 5. The table shows the 
physical properties of each modified monomer.  
The yield of all reactions was calculated using the following formula: 
 
          Moles of products obtained 
Yield =    ---------------------------------------      * 100%  
                  Moles of limiting reagent used   
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Table 5- Physical properties of the modified monomers. 
Compound code 
Molecular 
formula 
Molecular 
mass 
Colour 
Physical 
state 
MP Rf 
Yield 
% 
P-APMA C16H44N2O2 394.63 White Powder 91.5 0.39 79 % 
D-APMA C19H25N3O3S 375.48 Yellow 
Thick 
liquid 
----- 0.66 65% 
C-APMA C35H58N2O3 554.84 White Powder 154.5 0.74 75 % 
D1 C8H7N3OS 193.22 Yellow Powder 235 0.92 81.9 % 
D2 C12H11N3O4S 293.29 Yellow Powder 171 0.43 70.54% 
D3 C16H14N4O6S 390.37 Yellow Powder 195 0.89 71.4% 
O-APMA C20H24N4O4S 417.48 Yellow 
Thick 
liquid 
------ 0.8 78% 
 
2.4.2 - Characterization of Modified Monomers  
2.4.2.1 - Characterization of (P-APMA)  
TLC analysis (Figure 28) revealed a new product single spot with Rf = 0.39. The purity of      
P-APMA is about 100% as established by analytical TLC. 
 
 
 
 
 
 
 
 
 
Figure 28- Chromatogram of TLC plate (P-APMA). 
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The FTIR spectra of P-APMA are shown in (Figure 29). The sharp intense peak at 3294 cm
−1
 
was attributed to the -NH stretching vibration of APMA while the sharp band at 2916 cm
−1
 
was assigned to the C-H Stretch. The peak at 1637 cm
−1
 is due to carbonyl groups. Other 
peaks bandwidth of the principle bands are shown in Table 6. 
 
 
 
 
 
 
 
 
Figure 29- FTIR spectra of P-APMA. 
Table 6- Summary of functional P-APMA. 
Compound code Frequency, cm
–1
 Bond Functional group 
P
-A
P
M
A
 
3294 N-H Stretch Secondary amines 
2916, 2848 C-H Stretch Alkane 
1637 C=O Stretch Carbonyls (general) 
1607 –C=C– stretch Alkene 
1548 N–H bend Secondary amines 
1127 C–N stretch Aliphatic amines 
729, 720, 685 =C–H bend Alkene 
  
The 
1
H NMR spectrum (Figure 30) of compound P-APMA shows the palmitoyl group at the 
following position: 0.75 ppm (t, CH2-CH2-CH3, 3H), 1.27 ppm (m, CH3(CH2)12, 24H), 1.65 
ppm (m, CO-CH2-CH2-CH2, 2H), 2.2 ppm (t, CO-CH2-CH2, 2H) and APMA at: 1.65 ppm (m, 
NH-CH2-CH2-CH2-NH, 2H), 2 ppm (s, CH3-C(CH2)-CO, 3H), 3.1 ppm (t, NH-CH2-CH2-
CH2-NH, 2H), 5.36 ppm, 5.8 ppm (s, CO -C(CH3) -CH2, 2H), 6.12 ppm (s, C-CO-NH-CH2, 
1H), 6.75 ppm (s, CH2-CO-NH-CH2, 1H). 
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Figure 30- 
1
H NMR spectra of P-APMA in CDCl3 carried out using 300MHz NMR at 25 °C. 
 
The 
13
C-NMR spectrum (Figure 31) show peaks at 174 ppm and 168 ppm due to the C=O 
bonds of palmitoyl and APMA respectively, the peaks at 139.7 ppm and 119.9 ppm due to 
the vinyl group and the peaks of methyl groups of palmitoyl and APMA at 14.15 ppm for the 
former and 18.67 ppm for the latter, the rest of band are related to CH2 groups in palmitoyl. 
 
 
 
 
 
 
 
 
 
Figure 31- 
13
C NMR spectra of P-APMA in CDCl3 carried out using 300MHz NMR at 25 
°C. 
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2.4.2.2- Characterization of (D-APMA) 
TLC analysis (Figure 32) indicated the formation of D-APMA (Rf  = 0.66) with around 100% 
purity.  
 
 
 
 
 
 
 
 
Figure 32- Chromatogram of TLC plate (D-APMA). 
The FT-IR spectra of the D-APMA are shown in (Figure 33) and the main functional groups 
bands of the spectra are listed in table 7. 
 
 
 
 
 
 
 
 
Figure 33- FTIR spectrum of D-APMA. 
The FT-IR spectrum (Figure 33) indicate the presence of a broad band of N-H at 3289 cm
-1
, 
sulphonyl group 1712 cm
-1
, C=O group at 1655 cm
-1
and C-C aromatic 1530 cm
-1
  -1406 cm
-1
  
peaks confirming the combination of the APMA with dansyl group.  
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Table 7- Summary of functional D-APMA. 
Compound code Frequency, cm
–1
 Bond Functional group 
D
-A
P
M
A
 
3289 N-H Stretch Secondary amines 
2939, 2869 C-H Stretch Alkane 
1712 S=O Stretch Sulphonyl 
1655 C=O Stretch Carbonyl 
1611 –C=C– stretch Alkene 
1574, 1588 N–H bend Secondary amines 
1530, 1453, 1406 C–C stretch (in–ring)  Aromatic 
1354 =C–H bend Alkenes 
1308 S=O  Sulphonyl 
1230 C–N stretch Aromatic amines 
1201 C–H bend Alkanes 
1140, 1091, 1073 C–N stretch Aliphatic amine 
943, 788, 738, 683, 
622 
=C–H bend Alkene 
 
The 
1
H NMR spectrum (Figure 34) of compound P-APMA (CDCl3) shows the dansyl group 
at the following position: 2.88 ppm (s, N-CH3, 6H), 7.2 ppm (d, naphthalene proton in 
position 6, 1H), 7.57 ppm (q, naphthalene protons in position 3 and 8, 2H), 8.13 ppm (d, 
naphthalene protons in position 4, 1H), 8.3 ppm (d, naphthalene protons in position 7, 1H),  
8.32 ppm (d, naphthalene proton in position 2, 1H) and APMA at: 1.6 ppm (m, NH-CH2-
CH2-CH2-NH, 2H), 1.9 ppm (s, CH3-C(CH2)-CO, 3H), 3.38 ppm (t, NH-CH2-CH2-CH2-NH, 
2H), 5.33 ppm, 5.67 ppm (s, CO -C(CH3) –CH2, 2H), 6.14 ppm (s, C-CO-NH-CH2, 1H), 7.27 
ppm (s, CH2-CO-NH-CH2, 1H) . 
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Figure 34- 
1
H NMR spectra of D-APMA in CDCl3 carried out using 300MHz NMR at 25 
°C. 
The 
13
C-NMR spectrum (Figure 35) shows the peaks of vinyl group at 123.19 ppm and 
139.42 ppm, peaks at 45.44 ppm and 18.62 ppm, which are characteristics of the methyl 
groups in dansyl and APMA respectively. The spectrum displays the peak at 169 ppm, 
corresponding to carbonyl groups in APMA. The spectrum also indicates signals at 115.24 
ppm, 118.88 ppm, 120.16 ppm, 128.45 ppm, 129.18 ppm, 129.52 ppm, 129.85 ppm, 130.34 
ppm, 135.07 ppm and 151.9 ppm, which belong to dansyl aromatic carbons. 
 
 
 
 
 
 
 
 
 
Figure 35- 
13
C NMR spectra of D-APMA in CDCl3 carried out using 300MHz NMR at 25 
°C. 
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2.4.2.3- Characterization of (C-APMA) 
TLC analysis (Figure 36) shows a new product single spot with Rf  = 0.74. C-APMA is high-
purity as established by analytical TLC.  
 
 
 
 
 
 
 
 
 
 
Figure 36- Chromatogram of TLC plate (C-APMA). 
The FTIR spectrum of C-APMA is shown in Figure 37.  
 
 
 
 
 
 
 
Figure 37- FTIR spectrum of C-APMA. 
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The FTIR spectrum indicates two peaks appeared at 3386 cm
-1
 and 3272 cm
-1
 due to the 
presence of NH group. The peak at 1659 cm
-1
 is assigned to C=C stretching while the peak at 
1702 cm
-1
 due to C=O stretching. Other peaks bandwidth of the principle bands are shown in 
Table 8. 
Table 8- Summary of functional C-APMA. 
Compound code Frequency, cm
–1
 Bond Functional group 
C
-A
P
M
A
 
 
3386, 3272 N-H Stretch Secondary amines 
2929, 2865 C-H Stretch Alkane 
1702 C=O Stretch Carbonyls (general) 
1659 –C=C– stretch Alkenes 
1614, 1538 N–H bend Secondary amines 
1451, 1437, 1382, 
1366 
C–C bend Alkane 
1314 C–O stretch Esters 
1290, 1247 C–N stretch Aliphatic amines 
1148, 1135 C-O Bend Carbonyl 
1091, 1041 C–O stretch Esters 
1015 C–N stretch Aliphatic amines 
936 C-O Bend Carbonyl 
809, 781, 718, 637 =C–H bend Alkenes 
 
 
The 
1
H NMR spectrum (Figure 38) of compound C-APMA shows the cholesteryl group at 
the following position: 0.87 ppm ((CH3)2-CH-CH2, 6H), 0.67ppm -2 ppm (m, cholesteryl 
protons, 38H), 2.37 ppm (m, CH2, 2H), 4.5 ppm (b, oxycyclohexyl, 1H), 5.35 ppm (b, 
alkenyl, 1H), and APMA at: 1.68 ppm (m, NH-CH2-CH2-CH2-NH, 2H), 1.98 ppm (s, CH3-
C(CH2)-CO, 3H), 3.24 ppm (t, NH-CH2-CH2-CH2-NH, 2H), 5.3 ppm, 5.76 ppm (s, CO -
C(CH3) -CH2, 2H), 6.67 ppm (s, C-CO-NH-CH2, 1H), 7.26 ppm (s, CH2-CO-NH-CH2, 1H). 
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Figure 38- 
1
H NMR spectra of C-APMA in CDCl3 carried out using 300MHz NMR at 25 °C. 
 
The 
13
C-NMR spectrum (Figure 39) show the peak of carbonyl group (cholesteryl) at 157 
ppm while APMA carbonyl group at 168 ppm, peaks at 11.86 ppm, 18.70 ppm and 22.85 
ppm due to the methyl groups in the cholesteryl and APMA, and the peaks at 22.54 ppm and 
139.85 ppm corresponding to vinyl groups in the cholesteryl and APMA.  
 
 
 
 
 
 
 
 
 
 
 
Figure 39- 
13
C NMR spectra of C-APMA in CDCl3 carried out using 300MHz NMR at 25 
°C. 
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2.4.2.4- Characterization of 5-(4-Aminophenyl)-1,3,4-oxadiazole-2-thiol (D1) 
TLC analysis (Figure 40) (ethyl acetate: petroleum ether 1:1) indicated formation of D1 (Rf = 
0.92). The purity of D1is about 100% as established by analytical TLC. 
 
 
 
 
 
 
 
 
 
 
Figure 40- Chromatogram of TLC plate D1. 
The FTIR spectrum of D1 is shown in Figure 41.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41- FTIR spectrum of D1. 
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The compound show characteristic band for primary amine group at 3446 cm
−1
 and 3349 
cm
−1
. The band observed at 1440 cm
−1 
to 1514 cm
−1
 is due to –C=C- starch (aromatic). 
  
Table 9- Summary of functional D1. 
Compound code Frequency, cm
–1
 Bond Functional group 
D
1
 
3446, 3349 N-H Stretch Primary amines 
3082  C=C  Aromatics 
2947, 2769 C-H Stretch Alkane 
2359 S-H Thiol 
1629 C=N Imines 
1603 N–H bend Primary amines 
1514 =C–H bend Alkenes 
1440 -C-O-C- Ether  
1353 –C=C–   Aromatics 
1201 -C-H bend Alkanes 
1077 C–N stretch Aromatic amines 
 
The 
1
H-NMR spectrum of compound D1 is shown in Figure 42. The following peaks appear 
in the compound spectrum: at 6.65 ppm (d, aromatic protons in position 2 and 6, 2H) and 7.5 
ppm (d, aromatic protons in position 3 and 5, 2H).  
 
 
 
 
 
 
 
 
 
Figure 42- 
1
H-NMR spectra of D1 in DMSO carried out using 300MHz NMR at 25 °C. 
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The peak assignments for D1 were as follows (Figure 43): the peaks of aromatic group at 
positions meta and ortho 113.5 ppm, 127.4 ppm respectively, while para at 108.2 ppm and 
152.5 ppm. The spectrum also indicates signals at 161.5 ppm and 176.4 ppm which belong to 
oxadiazole carbons ring. 
 
 
 
 
 
 
 
 
Figure 43- 
13
C NMR spectra of D1 in DMSO carried out using 300MHz NMR at 25 °C. 
2.4.2.5- Characterization of 4-oxo-4-{[4-(5-sulfanyl-1,3,4-oxadiazol-2 yl) 
phenyl] amino}butanoic acid (D2) 
TLC analysis (Figure 44) (ethyl acetate: petroleum ether 1:1) indicated formation of D2 (Rf = 
0.43). D2 is high-purity as established by analytical TLC.  
 
 
 
 
 
 
 
 
 
Figure 44- Chromatogram of TLC plate D2. 
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The FTIR spectrum of D2 is shown in Figure 45.  
 
 
 
 
 
 
 
 
 
Figure 45- FTIR spectrum of D2. 
The FTIR spectrum of D2  (Figure 45) shows broad band at 3330 cm
-1
 was assigned to the O-
H Stretch this absorption overlaps the N-H stretching peaks, in addition of two strong 
absorption of carbonyl band at 1707cm
-1 
and 1645 cm
-1
 were observed, which confirmed the 
creation of D2. 
 
Table 10- Summary of functional D2. 
Compound code Frequency, cm
–1
 Bond Functional group 
D
2
 
3330 
O-H  Carboxylic acid 
N-H Stretch Secondary amines 
2931 C-H Stretch Alkane 
2359 S-H Thiol 
1707 
C=O Stretch 
Carboxylic acid 
carbonyl 
1645 Amide carbonyl 
1608 N–H bend Secondary amines 
1532 C=N Imines 
1437 -C-O-C- Ether  
1306 =C–H bend Alkenes 
1213 C–N stretch Aromatic amines 
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1162 C–H bend Alkanes 
933 O-H bend  Carboxylic acid 
 
The 
1
 H chemical shift data (Figure 46) for D2 compound are presented a peak at 2.5 ppm (t, 
the aliphatic protons, 4H), and 6.6 ppm, 6.8 ppm, 7.45 ppm and 8.18 ppm (d, the aromatic 
protons, 4H). 
 
 
 
 
 
 
 
 
 
Figure 46- 
1
H NMR spectra of D2 in DMSO carried out using 300MHz NMR at 25 °C. 
 
The results obtained from 
13
C NMR spectrum (Figure 47) show the peaks of carbonyl group 
at 161.5 ppm and 177.3 ppm, peaks at 28.99 ppm and 111.3 ppm, which are characteristics of 
the oxadiazole ring. The spectrum displays two peaks at 106.8 ppm and 113.4 ppm, 
corresponding to aliphatic carbons. The spectrum also indicates signals at 126.7 ppm, 143.2 
ppm, 155.6 ppm and 151 ppm which belong to aromatic carbons. 
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Figure 47- 
13
C NMR spectra of D2 in DMSO carried out using 300MHz NMR at 25 °C. 
 
2.4.2.6- Characterization of 4-[(2,5-dioxopyrrolidin-1-yl)oxy]-4-oxo-N-[4-(5-
sulfanyl-1,3,4-oxadiazol-2-yl)phenyl]butanamide (D3) 
TLC analysis (Figure 48) indicated the formation of D3 (Rf  = 0.89) with around 100% purity.  
 
 
 
 
 
 
 
 
 
Figure 48- Chromatogram of TLC plate D3. 
 
57 
 
The FTIR spectrum of D3 is shown in Figure 49. 
 
 
 
 
 
 
 
 
 
Figure 49- FTIR spectrum of D3. 
The disappearance of hydroxyl groups peaks at around 3300 cm
-1
 suggest the substitution 
reaction between D2 and NHS occurred.  
Table 11- Summary of functional D3. 
Compound code Frequency, cm
–1
 Bond Functional group 
D
3
 
3322 N-H Stretch Secondary amines 
2929  
C-H Stretch Alkane 
2849 
2160 S-H Thiol 
1622 
C=O Stretch 
Succinimide and 
amide Carbonyl  1573 
1611 N–H bend Secondary amines 
1533 C=N Imines 
1448, 1434 C–C stretch (in–ring)  Aromatics 
1312 =C–H bend Alkenes 
1240 -C-O-C- Ether  
1242 C–N stretch Aromatic amines 
1201 C–H bend Alkanes 
1087 C–N stretch Aliphatic amines 
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Figure 50 illustrates 
1
H NMR spectrum for D3. In 1H NMR signals at: 2.47 ppm and 2.76 
ppm (t, succinimide protons, 4H), 2.8 ppm and 3.07 ppm (t, CO-CH2-CH2-CO, 4H), 6.9, 7.4, 
7.9 and 8.2 ppm (d, aromatic protons, 4H). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50- 
1
H NMR spectra of D3 in DMSO carried out using 300MHz NMR at 25 °C. 
The peak assignments for D3 were as follows (Figure 51): the peaks of carbonyl group at 
172.8 ppm, 170.89 ppm, 161.57 ppm and 155.99 ppm, while the aromatic carbons 126.8 
ppm, 125.8 ppm, 113 ppm, 111 ppm and 106.8 ppm. The spectrum also indicates signals at 
151.2 ppm, 142 ppm which belong to oxadiazole carbons ring. The rest of peaks are 
corresponding to aliphatic carbons along the compound skeleton.  
 
 
 
 
 
 
 
 
 
Figure 51- 
13
C NMR spectra of D3 in DMSO carried out using 300MHz NMR at 25 °C. 
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2.4.2.7- Characterization of (O-APMA) 
TLC analysis (Figure 52) indicated the formation of O-APMA (Rf = 0.8) with around 100% 
purity.  
 
 
 
 
 
 
 
 
Figure 52- Chromatogram of TLC plate (O-APMA). 
The FTIR spectrum of O-APMA is shown in Figure 53. 
 
 
 
 
 
 
 
Figure 53- FTIR spectrum of O-APMA. 
The FTIR spectrum of O-APMA (Figure 53) showed the presence of N-H, S-H and C=O 
peaks due to absorbance at 3303 cm
-1
 , 2033 cm
-1
 and 1661 cm
-1
 respectively indicating the 
presence of the main groups of the backbone and the oxadiazole moiety. 
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Table 12- Summary of functional O-APMA. 
 
Compound code Frequency, cm
–1
 Bond Functional group 
O
-A
P
M
A
 
3303 N-H Stretch Secondary amines 
2926  
C-H Stretch Alkane 
2830 
2160 S-H  Thiol  
2033 C-N Stretch Imine  
1713 
C=O Stretch Carbonyl 
1661 
1532 N-H bend Secondary amines 
1435 =C-H bend Alkenes 
1386 -C-O-C- Ether 
1309 -C=C- Aromatic  
1212 C–H bend Alkenes 
1094 
C–N stretch 
Aromatic and 
Aliphatic amine 998 
931, 667 =C–H bend Alkenes 
 
 
The 
1
H NMR spectrum (Figure 54) of compound O-APMA shows the oxadiazole group and 
the linker at the following position: 2.5 ppm (t, CO-CH2-CH2-CO, 4H), 6.63 ppm, 6.93 ppm, 
7.49 ppm and 8.21 ppm (m, aromatic protons, 4H) and APMA at: 1.74 ppm (m, NH-CH2-
CH2-CH2-NH, 2H), 1.86 ppm (s, CH3-C(CH2)-CO, 3H), 3.16 ppm (t, NH-CH2-CH2-CH2-NH, 
4H), 5.34 ppm, 5.69 ppm (s, CO -C(CH3) -CH2, 2H), 7.93 ppm (s, CO-NH-(CH2)3- NH-CO, 
2H). 
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Figure 54- 
1
H NMR spectra of O-APMA in DMSO carried out using 300MHz NMR at 25 
°C. 
The 
13
C-NMR spectrum (Figure 55) of O-APMA in DMSO shows the peaks of carbonyl 
groups at 162.28 ppm, 167.67 ppm and 172.78 ppm, peaks at 106.87 ppm, 113.45 ppm, 
119.29 ppm, 127.21 ppm, 139.66 ppm and 151.96 ppm are characteristic for aromatic 
carbons. The signals at 36.56 ppm and 156.58 ppm were attributed to carbons in oxadiazole 
ring. The rest of peaks are corresponding to aliphatic carbons along the compound skeleton.  
 
 
 
 
 
 
 
 
 
 
 
Figure 55- 
13
C NMR spectra of O-APMA in DMSO carried out using 300MHz NMR at 25 
°C. 
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2.4.2.8- Characterization of RAFT polymerization of HPMA with modified 
APMA 
The FTIR spectrum of poly(HPMA-co-HPMA-P) is shown in Figure 56. 
 
 
 
 
 
 
 
 
 
 
Figure 56- FTIR spectrum of poly(HPMA-co-HPMA-P). 
The peak assignment for the FTIR spectra of poly(HPMA-co-HPMA-P)  (Figure 56) showed 
the presence of the broad big band with two peaks band at 3351 cm
-1
 which indicated 
presence of hydroxyl group from HPMA O-H overlap with the N-H band, peak at 1639 cm
-1
  
due to C=O group. Other peaks bandwidth of the principle bands are shown in Table 13. 
Table 13- Summary of functional poly(HPMA-co-HPMA-P). 
Compound code Frequency, cm
–1
 Bond Functional group 
p
o
ly
(H
P
M
A
-c
o
-H
P
M
A
-P
) 3351 
O-H Stretch 
N-H Stretch 
Alcohol 
Secondary amines 
2968 
C-H Stretch Alkane 
2926 
1639 C=O Stretch Carbonyls (general) 
1615 –C=C– stretch Alkenes 
1528 N–H bend Secondary amines 
1134 C–N stretch Aliphatic amines 
1113, 581 C–H bend Alkenes 
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The 
1
H-NMR spectra of poly(HPMA-co-HPMA-P) (Figure 57) shows the following Peaks 
palmitoyl group at: 1.00 ppm (t, CH2-CH2-CH3, 3H), 1.27 ppm (m, CH3(CH2)12, 24H), 1.4 
ppm (m, CO-CH2-CH2-CH2, 2H), 1.9 ppm (t, CO-CH2-CH2, 2H) APMA at: 1.65 ppm (m, NH-
CH2-CH2-CH2-NH, 2H), 2 ppm (s, CH3-C(CH2)-CO, 3H), 3.1 ppm (t, NH-CH2-CH2-CH2-
NH, 4H), HPMA at: 1.8 ppm (d, NH-CH2-CH(CH3)OH, 1H), 1.13 ppm (d, CH3-CH(OH)-
CH2, 3H), 3.85 ppm (h, CH3-CH(OH)-CH2, 1H), OH group at 4.9 ppm, amine protons at 7.5 
ppm and the end group 5.4 ppm -5.7 ppm, (s, 2H). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 57- 
1
H NMR spectra of poly(HPMA-co-HPMA-P) in DMSO carried out using 
300MHz NMR at 25 °C. 
 
 
 
 
 
64 
 
The FTIR spectrum of poly(HPMA-co-HPMA-D) is shown in Figure 58. 
 
 
 
 
 
 
 
 
 
 
 
Figure 58- FTIR spectrum of poly(HPMA-co-HPMA-D). 
The FT-IR spectrum (Figure 58) indications the presence of a broad band of O-H overlap 
with the N-H band and present as a big band with two peaks at 3299 cm
-1
, sulphonyl group 
1652 cm
-1
, C=O group at 1614 cm
-1
, and C-C aromatic  1426 cm
-1
 -1367 cm
-1
  peaks.  
Table 14- Summary of functional poly(HPMA-co-HPMA-D). 
Compound code Frequency, cm
–1
 Bond Functional group 
p
o
ly
(H
P
M
A
-c
o
-H
P
M
A
-D
) 
3299 
O-H Stretch 
N-H Stretch 
Alcohol 
Secondary amines 
2973  
C-H Stretch Alkane 
2931 
1652 S=O Stretch Sulphonyl 
1614 C=O Stretch Carbonyl 
1548 –C=C– stretch Alkenes 
1456 N–H bend Secondary amines 
1426 
C–C stretch (in–ring)  Aromatics 
1367 
1330 =C–H bend Alkenes 
1298 S=O  Sulphonyl 
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1230 C–N stretch Aromatic amines 
1142 C–H bend Alkanes 
1116, 1087 C–N stretch Aliphatic amines 
1000, 609 =C–H bend Alkenes 
 
 
The 
1
H NMR spectrum (Figure 59) of poly(HPMA-co-HPMA-D) shows the dansyl group at 
the following position: 3 ppm (s, N-CH3, 6H), 7.25 ppm (d, naphthalene proton in position 6, 
1H), 7.65 ppm (q, naphthalene protons in position 3 and 8, 2H), 8.13 ppm (d, naphthalene 
protons in position 4, 1H), 8.3 ppm (d, naphthalene protons in position 7, 1H), 8.48 ppm (d, 
naphthalene proton in position 2, 1H) and APMA at: 1.6 ppm (m, NH-CH2-CH2-CH2-NH, 
2H), 1.9 ppm (s, CH3-C(CH2)-CO, 3H), 3.38 ppm (t, NH-CH2-CH2-CH2-NH, 4H), HPMA at: 
1.8 ppm (d, NH-CH2-CH(CH3)OH, 1H), 1.13 ppm (d, CH3-CH(OH)-CH2, 3H), 3.85 ppm (h, 
CH3-CH(OH)-CH2, 1H), OH group at 4.9 ppm, amine protons at 7.85 ppm and the end group 
5.4-5.7 ppm, (s, 2H). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 59- 
1
H NMR spectra of poly(HPMA-co-HPMA-D) in DMSO carried out using 
300MHz NMR at 25 °C. 
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The FTIR spectrum of poly(HPMA-co-HPMA-C) is shown in Figure 60. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 60- FTIR spectrum of poly(HPMA-co-HPMA-C). 
The FTIR spectrum indicate presence of a broad band of O-H overlap with the N-H band and 
present as a big band with two peaks at 3299 cm
-1
. The peak at 1614 cm
-1
 is assigned to C=C 
stretching while the peak at 1655 cm
-1
 due to C=O stretching. Other peaks bandwidth of the 
principle bands are shown in Table 15. 
Table 15- Summary of functional poly(HPMA-co-HPMA-C). 
Compound code Frequency, cm
–1
 Bond Functional group 
P
o
ly
(H
P
M
A
-c
o
-H
P
M
A
-C
) 3299 
O-H Stretch 
N-H Stretch 
Alcohol 
Secondary amines 
2973  
C-H Stretch Alkane 
2931 
1655 C=O Stretch Carbonyls (general) 
1614 –C=C– stretch Alkenes 
1548 N–H bend Secondary amines 
1426,1330 C–C bend Alkanes 
1314 C–O stretch Esters 
61
0.
01
65
0.
97
82
4.
49
91
3.
75
10
53
.2
5
10
87
.4
8
11
16
.4
5
11
42
.5
5
12
30
.3
3
13
30
.6
6
13
67
.6
4
14
26
.4
6
15
48
.6
6
16
14
.3
1
16
53
.0
132
99
.2
2
 60
 65
 70
 75
 80
 85
 90
 95
 100
%
T
 1000   1500   2000   2500   3000   3500   4000  
Wavenumbers (cm-1)
%
T
ra
n
sm
it
ta
n
ce
 
Wavenumbers (cm-1) 
67 
 
1230 C–N stretch Aliphatic amines 
1142, 1116 C-O Bend Carbonyl 
1087, 1053 C–O stretch Esters 
1015 C–N stretch Aliphatic amines 
913 C-O Bend Carbonyl 
824, 610 =C–H bend Alkenes 
 
The 
1
H NMR spectrum (Figure 61) poly(HPMA-co-HPMA-C) shows the cholesteryl group 
at the following position: 1 ppm ((CH3)2-CH-CH2, 6H), 0.67 ppm-2 ppm (m, cholesteryl 
protons, 38H), 2.37 ppm (m, CH2, 2H), 4.45 ppm (b, oxycyclohexyl, 1H), 6.2 ppm (b, 
alkenyl, 1H), and APMA at: 0.88 ppm (m, NH-CH2-CH2-CH2-NH, 2H), 1.98 ppm (s, CH3-
C(CH2)-CO, 3H), 3.24 ppm (t, NH-CH2-CH2-CH2-NH, 2H), HPMA at: 1.7 ppm (d, NH-CH2-
CH(CH3)OH, 1H), 1 ppm (d, CH3-CH(OH)-CH2, 3H), 3.85 ppm (h, CH3-CH(OH)-CH2, 1H), 
OH group at 4.1 ppm, amine protons at 7.35 ppm and the end group 5.4 ppm-5.7 ppm, (s, 
2H). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 61- 
1
H NMR spectra of poly(HPMA-co-HPMA-C) in DMSO carried out using 
300MHz NMR at 25 °C. 
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The FTIR spectrum of poly(HPMA-co-HPMA-O) is shown in Figure 62. 
 
 
 
 
 
 
 
 
 
 
 
Figure 62- FTIR spectrum of poly(HPMA-co-HPMA-O). 
The FT-IR spectrum (Figure 62) showed the presence of hydroxyl and amine group as on 
broad peak at 3298 cm
-1
, couple peaks at 1653 cm
-1
 and 1614 cm
-1
 and due to presence two 
types of C=O group. 
 
Table 16- Summary of functional poly(HPMA-co-HPMA-O). 
Compound code Frequency, cm
–1
 Bond Functional group 
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o
ly
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P
M
A
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o
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P
M
A
-O
) 
3298 
O-H Stretch 
N-H Stretch 
Alcohol 
Secondary amines 
2973  
C-H Stretch Alkane 
2932 
1839 S-H Thiol 
1715 C=N Stretch imine 
1653 
C=O Stretch Carbonyl 
1614 
1544 N-H bend Secondary amines 
1456 =C-H Alkene 
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1331 -C=C- Alkene 
1230 C–H bend Alkane 
1087, 1000 C–N Stretch Amine 
913-650 =C–H bend Alkene 
 
The 
1
H NMR spectrum (Figure 63) of poly(HPMA-co-HPMA-O) shows the oxadiazole 
group and the linker at the following position: 2.65 ppm (t, CO-CH2-CH2-CO, 4H), 6.7, 6.93, 
7.9 and 8.1 ppm (m, aromatic protons, 4H) and APMA at: 1.02 ppm (m, NH-CH2-CH2-CH2-
NH, 2H), 1.86 ppm (s, CH3-C(CH2)-CO, 3H), 3.16 ppm (t, NH-CH2-CH2-CH2-NH, 4H), 
HPMA at: 1.8 ppm (d, NH-CH2-CH(CH3)OH, 1H), 1.13 ppm (d, CH3-CH(OH)-CH2, 3H), 
3.85 ppm (h, CH3-CH(OH)-CH2, 1H), OH group at 4.9 ppm, amine protons at 7.5 ppm and 
the end group 5.4 ppm-5.7 ppm, (s, 2H). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 63- 
1
H NMR spectra of poly(HPMA-co-HPMA-O) in DMSO carried out using 
300MHz NMR at 25 °C. 
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2.4.2.9- Characterization of block copolymerization 
The FTIR spectrum of poly(HPMA-co-HPMA-O)-b-PEG is shown in Figure 64. 
 
 
 
 
 
 
 
 
 
 
Figure 64- FTIR spectrum of poly(HPMA-co-HPMA-O)-b-PEG. 
The poly(HPMA-co-HPMA-O)-b-PEG exhibits absorptions those of hydroxyl and amine 
group at 3298 cm
-1
. The increase of the transmission peak of hydroxyl and amine groups 
confirm the PEG incorporation into the (HPMA-co-HPMA-O) polymer.  
 
Table 17- Summary of functional poly(HPMA-co-HPMA-O)-b-PEG. 
Compound code Frequency, cm
–1
 Bond Functional group 
P
o
ly
(H
P
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A
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-H
P
M
A
-O
)-
b
-
P
E
G
 
3298 
O-H Stretch 
N-H Stretch 
Alcohol 
Secondary amines 
3089 =C-H Stretch Alkene 
2974, 2931 C-H Stretch Alkane 
1839 S-H Thiol 
1715 C=N Stretch imine 
1653, 1614 C=O Stretch Carbonyl 
1548 N-H bend Secondary amine 
1455 =C-H Alkene 
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1330 -C=C- Alkene 
1230 C–H bend Alkane 
1087, 1000 C–N Stretch Amine 
913-610 =C–H bend Alkene 
 
The 
1
H NMR spectrum (Figure 65) of poly(HPMA-co-HPMA-O)-b-PEG shows the 
oxadiazole group and the linker at the following position: 2.65 ppm (t, CO-CH2-CH2-CO, 
4H), 6.7 ppm, 6.93 ppm, 7.9 ppm and 8.1 ppm (m, aromatic protons, 4H) and APMA at: 1.02 
ppm (m, NH-CH2-CH2-CH2-NH, 2H), 1.86 ppm (s, CH3-C(CH2)-CO, 3H), 3.16 ppm (t, NH-
CH2-CH2-CH2-NH, 4H), HPMA at: 1.8 ppm (d, NH-CH2-CH(CH3)OH, 1H), 1.13 ppm (d, 
CH3-CH(OH)-CH2, 3H), 3.85 ppm (h, CH3-CH(OH)-CH2, 1H), OH group at 4.9 ppm, amine 
protons at 7.5 ppm and the end group 5.4-5.7 ppm, (s, 2H), PEG peaks at: 3.5 ppm (t, O-CH2-
CH2, 2H) and 4.19 ppm (t, O-CH2-CH2, 2H),  joint group 6 ppm (s, 2H). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 65 - 
1
H NMR spectra of poly(HPMA-co-HPMA-O)-b-PEG in DMSO carried out 
using 300MHz NMR at 25 °C. 
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The FTIR spectrum of poly(HPMA-co-HPMA-D)-b-PEG is shown in Figure 66. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 66- FTIR spectrum of poly(HPMA-co-HPMA-D)-b-PEG. 
 
The peak assignment for the FTIR spectra of poly(HPMA-co-HPMA-D)-b-PEG showed the 
presence of the broad band with two peaks 3299 cm
-1
. These peaks indicated OH and NH 
groups had occurred, block copolymerization with PEG was confirmed by the increase in the 
transmission of this peak.  
Table 18 - Summary of functional poly(HPMA-co-HPMA-D)-b-PEG. 
Compound code Frequency, cm
–1
 Bond Functional group 
P
o
ly
(H
P
M
A
-c
o
-H
P
M
A
-D
)-
b
-
P
E
G
 
3299 
O-H Stretch 
N-H Stretch 
Alcohol 
Secondary amines 
2974  
C-H Stretch Alkanes 
2931 
1653 S=O Stretch Sulphonyl 
1614 C=O Stretch Carbonyl 
1544 –C=C– stretch Alkenes 
1456 N–H bend Secondary amines 
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1426 
C–C stretch (in–ring)  Aromatics 
1367 
1330 =C–H bend Alkenes 
1298 S=O  Sulphonyl 
1230 C–N stretch Aromatic amines 
1142 C–H bend Alkanes 
1116-1087 C–N stretch Aliphatic amines 
1000-609 =C–H bend Alkenes 
 
The 
1
H NMR spectrum (Figure 67) of poly(HPMA-co-HPMA-D)-co-PEG shows the dansyl 
group at the following position: 3 ppm (s, N-CH3, 6H), 7.25 ppm (d, naphthalene proton in 
position 6, 1H), 7.65 ppm (q, naphthalene protons in position 3 and 8, 2H), 8.13 ppm (d, 
naphthalene protons in position 4, 1H), 8.3 ppm (d, naphthalene protons in position 7, 1H), 
8.48 ppm (d, naphthalene proton in position 2, 1H) and APMA at: 1.6 ppm (m, NH-CH2-
CH2-CH2-NH, 2H), 1.9 ppm (s, CH3-C(CH2)-CO, 3H), 3.38 ppm (t, NH-CH2-CH2-CH2-NH, 
4H), HPMA at: 1.8 ppm (d, NH-CH2-CH(CH3)OH, 1H), 1.13 ppm (d, CH3-CH(OH)-CH2, 
3H), 3.85 ppm (h, CH3-CH(OH)-CH2, 1H), OH group at 4.9 ppm, amine protons at 7.85 ppm 
and the end group 5.4-5.7 ppm, (s, 2H), PEG peaks at: 3.15 ppm (t, O-CH2-CH2, 2H) and 
4.19 ppm (t, O-CH2-CH2, 2H), joint group 5.7 ppm (s, 2H). 
 
 
 
 
 
 
 
 
 
Figure 67- 
1
H NMR spectra of poly(HPMA-co-HPMA-D)-b-PEG in DMSO carried out 
using 300MHz NMR at 25 °C. 
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2.5- Discussion 
Our TLC, FTIR and NMR analysis of the products show that we successfully grafted APMA 
amino groups with palmitoyl, dansyl, cholesteryl and oxadiazole moieties.  
Our choice of pendant group to add onto the APMA monomer was based on the literature. 
Our first pendant group was addition of a palmitoyl moiety. Yogesh et al, acylated low 
molecular weight chitosan (LMWC) at the amine group with palmitoyl chloride. Acylation of 
LMWC showed a dramatic increase in the drug loading from 13.8 ± 0.95% to 30.2 ± 1.9% in 
addition to 80±2.08% as maximum drug released in 10 h while only 52.3 ± 2.14% was 
released in 24 h for low molecular weight palmitoyl chitosan (LMWPC) (Yogesh et al., 
2012).  
Acylation is one of the chemical modification methods that is used to increase the 
hydrophobic character of polymers that is used in gene and drug delivery systems, benefiting 
from the amphiphilic structure, hydrophilic core and many hydrophobic tails to: (A) improve 
the organic solubility of some natural polymers like chitosan (Radrigues, 2005), (B) increase 
drug loading capacity of polymer and sustained drug release (Yogesh et al., 2012), and (C) 
can effectively decrease the dendrimer cytotoxicity(Wang et al., 2012). 
In this respect, Thompson and colleges reported the use of amphiphilic poly(allylamine) 
(PAA) consisting of randomly grafted palmitoyl moieties followed by quaternising with 
methyl iodide to study the capability of these self-assembled polymers to form nano-
complexes with insulin in pH 7.4 Tris buffer (Thompson et al., 2009). They reported that all 
the polymers had less cytotoxicity than PAA and showed high insulin complexation 
efficiency between 78% and 93% (Thompson et al., 2009). Further carried out research done 
by Katugampola and Winstead studied the substitution degree 42%, 44% and 81% of 
palmitoyl chloride chitosan on the rheological behaviour and thermal stability, they found 
increasing thermal stability and crystallinity of palmitoyl chitosan with increase in the 
substitution degree (Katugampola and Winstead, 2014). 
 
The FTIR spectra for P-APMA (Figure 29) shows the presence of three sharp intense peaks at 
3294 cm
-1
, 2916 cm
-1 
and
 
1637 cm
-1 
and were
 
assigned to the -NH, C-H and carbonyl groups 
respectively, which occurred in both APMA and palmitoyl moiety. The 
1
H and 
13
C NMR 
spectra confirm the chemical structure for P-APMA; the 
1
H NMR spectrum (Figure 30) 
indicates two significant peaks at 0.75 ppm and 1.27 ppm which belong to palmitoyl units 
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and three important bands at 5.36 ppm, 5.8 ppm and 6.12 ppm, 6.75 ppm which are 
characteristics of the APMA unit. The 
13
C NMR spectrum (Figure 31) displays the peaks at 
14.15 ppm and 18.67 ppm, corresponding to the methyl groups of palmitoyl and APMA 
respectively. Especially, the spectrum shows two peaks at 139.7 ppm and 119.9 ppm due to 
vinyl group. The spectrum also indicates two signals at 174 ppm and 168 ppm which belongs 
to carbonyl groups, all these peaks suggested the formation of the P-APMA. 
The second and third hydrophobic pendant groups we used were dansyl and cholesteryl 
respectively. Dansyl and cholesteryl moieties work as universal hydrophobic drug 
solubilizers when it’s substituted as a grafted group on polymers (Hoskins et al., 2012a).  
 
Fluorescent nanoparticles have been attracting much attention because of their: (a) high 
brightness, (b) improved photostability, and (c) tunable emission properties. Additionally, 
fluorescent nanoparticles are a powerful alternative tool for traditional molecular 
fluorophores in a wide range of applications such as labelling or sensing tools (Ouadahi et al., 
2012).  Dansyl moiety, which is used in the current work, has been commonly used as a 
fluorescent label in later biological characterisation due to the occurrence of the conjugated 
aromatic ring systems. More precise representation of nanoparticles in vivo fate can be 
obtained by using fluorescent labels. On the other hand, polymer cytotoxicity and physical 
properties can be changed due to occurrence of its (Hoskins et al., 2012a). 
 
In the FTIR spectrum of the D-APMA (Figure 33), showed the occurrence of broad band of 
N-H at around 3289 cm
-1
. Also peaks of sulphonyl group at 1712 cm
-1
, C=O group at 1655 
cm
-1
, and C-C aromatic  1530 cm
-1
 -1406 cm
-1
  were seen confirming the combination of the 
APMA with the dansyl group. The 
1
H NMR spectrum (Figure 34) shows peaks observed 
between 7.2 ppm and 8.38 ppm, these were due to the hydrogen atoms on the aromatic rings 
of naphthalene structures. Besides, the spectrum displays a single peak at 5.67 ppm which is 
indicative of the vinyl group and two peaks at 6.14 ppm and 7.27 ppm which arise from the 
hydrogen atoms of amine groups. The 
13
C NMR data (Figure 35) are consistent with the 
1
H 
NMR data confirming the combination of the APMA with dansyl group.  
 
Cholesterol and its derivatives are soluble-fat-molecules that occur in nature and are defined 
as amphiphilic or hydrophobic groups based on the chemical structure of the subunits that are 
present in the molecule (Zhou et al., 2009). Cholesterol has the ability to cross cellular 
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membranes making it an effective component to use in therapeutic delivery systems (Sevimli 
et al., 2012). Ashlynn et al, achieved high paclitaxel loading 14% and an encapsulation 
efficiency around 92% by using cationic micelles self-assembled from an amphiphilic 
copolymer poly{(N-methyldietheneamine sebacate)-co-[(cholesteryl oxocarbonylamido 
ethyl) methyl bis(ethylene)ammonium (PMDS) (Ashlynn et al., 2011). This type of micelles 
self-assembled had been conjected to poly (ethylene glycol) (PEG) with different cholesterol 
grafting degrees to improve the stability of micelle/DNA complexes in the blood for 
systemic in vivo gene delivery. Wanga et al, found that PMDS and PEG-PMDS without 
cholesterol could not form stable micelles but formed large particles (Wanga et al., 2007).  
 
The FTIR spectrum of C-APMA (Figure 37) indicates two peaks appeared at 3386 cm
-1
 and 
3272 cm
-1
 due to NH group. Further peaks at 1659 cm
-1
 and 1702 cm
-1
 are assigned to C=C 
stretching and C=O stretching respectively. The 
1
H NMR spectrum (Figure 38) shows the 
peaks at 0.67-2 ppm which are characteristics of the cholesteryl protons in the C-APMA. The 
spectrum also displays two singlet peaks at 5.3, 5.76 ppm, corresponding to the vinyl group, 
in addition to two singlet peaks at 6.67 ppm and 7.26 ppm due to the amine group in the 
APMA. The 
13
C-NMR spectrum (Figure 39) shows two significant peaks of carbonyl groups 
at 157 ppm and 168 ppm for cholesteryl and APMA respectively, peaks at 11.86, 18.70 and 
22.85 ppm due to the methyl groups in the cholesteryl and APMA, and the peaks at 22.54 and 
139.85 ppm corresponding to vinyl groups in the cholesteryl and APMA.  
 
Lastly, we tried to conjugate an oxadiazole moiety onto the APMA monomer. 1,3,4-
oxadiazole moiety is a hydrophobic heterocyclic compound due to its aromatic structure and 
also contains two nitrogen atoms and an oxygen atom in a five-membered ring attached to a 
thiol (SH) group. This group has the ability to make strong dative covalent attachment with 
colloidal gold surfaces for the HNPs (Barnett et al., 2013). Compounds containing 1,3,4-
oxadiazole cores have been used in wide rang as anticancer, antifungal, antibacterial and anti-
inflammatory (Oliveira et al.,2012). 
 
The reaction between APMA with 5-(4-chlorophenyl)-1,3,4-oxadiazole-2-thiol was not 
successful when we used the direct substation reaction. This can be interpreted that the 
chlorine atom is attached to a benzene ring, overlapping of the p-orbital of the chlorine atom 
with the π orbitals of the benzene ring, thus making the carbon-chlorine bond stronger, and it 
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is far less reactive than when in a haloalkane. So we created a new way to prepare this 
compound by building up this molecule throughout 4 steps. 
For the reaction of the aminobenzoylhydrazine with carbon disulphide the FTIR spectrum 
(Figure 41) indicates that the desired product 5-(4-Aminophenyl)-1,3,4-oxadiazole-2-thiol 
was formed, showing the characteristic primary amine group peak at 3446 cm
-1
 and 3349 cm
-
1
 and aromatic C=C at 1440 cm
-1
, 1503 cm
-1
 and 1514 cm
-1
. The
 1
H NMR spectrum (Figure 
42) indicates two significant peaks at 6.65 ppm and 7.5 ppm due to the aromatic protons. The 
13
C-NMR spectra (Figure 43) of D1 showed the presence of the aromatic group peaks and 
oxadiazole aliphatic carbons peaks. 
D2 was synthesized by using the most common activation method of carboxylic group, 
(Veronese and Morpurgo, 1999) by reacting D2 with NHS in the present of DCC as a catalyst 
to produce active form (D3) which is suitable for the next step which involves coupling with 
the primary amines of the APMA.  
The FTIR spectra for D2 (Figure 45) shows broad peaks of hydroxyl at 3330 cm
-1
  as 
carboxylic acids exist mainly as dimers due to the intermolecular hydrogen bonding, this led 
OH peak to be broad and medium intensity compared with non-dimeric form, (Lin-Vien et al, 
1991) in addition to two  peaks exhibited at 1707 cm
-1
 and 1645 cm
−1
 due to the absorbance 
of carboxylic acid and amide carbonyl groups respectively (Stuart, 2004). 
 
The result obtained from (Figure 46) for D1showed two sets of peaks were observed, the 
addition of succinic anhydride to the 5-(4-Aminophenyl)-1,3,4-oxadiazole-2-thiol (D1) 
produced extra peaks at 2.5 ppm (Figure 47), due to the aliphatic hydrogen’s of succinic 
moiety attached to the amine group. Four sets of doublets are observed between 6.6 ppm -
8.18 ppm these were due to aromatic protons with one neighbouring proton therefore forming 
a doublets peak. The presence of aliphatic carbons in addition to aromatic carbons at 
13
C 
NMR spectrum (Figure 48) strongly suggests the attachment of the succinic moiety to D1. 
 
FTIR spectra of D3 (Figure 49) exhibited characteristic peaks attributed to NH group and 
carbonyl groups respectively, as well as the absence of hydroxyl group of carboxylic acid 
(D2) which confirms the formation of amide bond. In the 
1
H NMR spectrum (Figure 50), the 
peaks 2.47 ppm and 2.76 ppm which are characteristics of the succinimide group. The 
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spectrum also displays four doublet peaks corresponding to the benzene group, in addition to 
two triplet peaks due to linker group in the D3.  
The presence of thiol group at 2033 cm
-1
, N-H and 3303 cm
-1
 as well as C=N at 1713 cm
-1
 on 
the FTIR of O-APMA  (Figure 53) suggested the attachment of the APMA moiety had been 
successful. Furthermore, peaks were also evident due to the C=C bonds within the APMA 
moiety. The evidence for the D3 and APMA conjugation was also obtained by 
1
H and 
13
C 
NMR. 
The free radical polymerization reaction mechanism consists of three steps: initiation, 
propagation and termination, the termination step could take either rout A or B as shown in 
Figure 68.  The 
1
H NMR spectrum (Figure 57, 69, 61, 73, 65 and 67) of HPMA copolymers 
show the presence of a couple of peaks in the region of olefinic protons at 5.4 ppm-5.7 ppm. 
These peaks arise from the hydrogen atoms of the olefin groups which give us evidence that 
the disproportionation reaction taken route A (Hatada et al., 1986). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 68- Disproportionation termination routes. 
Fourier transform infrared spectroscopy was used to characterize all the copolymer 
derivatives in order to identify the functional groups attributed to the feeder monomers. FTIR 
spectra show the copolymerization reaction between HPMA and APMA-R has been success. 
PEG block copolymerization reaction caused increase in the intensity peak of hydroxyl and 
amine groups in FTIR spectra, in addition to the presence of a new single bound at 5.7-6 ppm 
in NMR spectra which related to the CH2 joint group. All that confirms the PEG 
incorporation into the (HPMA-co-HPMA-O) and (HPMA-co-HPMA-D) polymers was 
successful. 
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2.6- Conclusion 
In summary, APMA modified monomers and HPMA-co-APMA-R-b-PEG copolymers were 
successfully prepared. The successful synthesis of the copolymers and modified monomers 
(structure and properties) was confirmed by 
1
H NMR, 
13
C NMR, FTIR, melting point and 
thin layer chromatography. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
 
 
 
 
 
 
 
 
 
 
Chapter Three 
 
 
Synthesis and characterisation of hybrid 
nanoparticles 
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3.1- Introduction 
Over the last two decades, magnetic nanoparticles (MNPs) have emerged as new front 
runners in the race for the treatment of cancer. Extensive studies have been carried out in 
order to incorporate diagnostic and therapeutic functions for this matter forming theranostic 
agents. Many magnetic nanoparticle systems in combination with gold, iron oxide, quantum 
dots, silver nanoparticles and carbon nanotubes have been investigated (Nekolla et al., 2016, 
Modugno et al., 2015, Boncel et al., 2017). Gold coated magnetic iron oxide nanoparticles 
(hybrid nanoparticles, HNPs) have been reported for their potential for image guided cancer 
therapy (Barnett et al., 2012, Hoskins et al., 2012b). The unique properties of these 
nanoparticles arise from their architecture. The iron oxide core displays extraordinary 
magnetic properties, while the gold surface offers enhanced biocompatibility, facilitates 
attachment with thiolated (-SH) molecules and has potential to act as a triggered heat source 
after laser irradiation. Changing the size, charge, shape and gold shell thickness have been 
used to tune and tailored the optical and magnetic properties of this particles (Barnett et al., 
2012, Saimon et al., 2016, Sailor and Park, 2012). 
 
A limitation associated with MNPs in sensing applications arises from the problems of low 
surface charge at neutral pH and large surface area to volume ratio, which leads the MNP 
aggregation whilst dispersed in solvents; in addition to low electrical conductivity and limited 
optical properties. However, these entire problems can be tackled by coating MNPs with a 
gold shell (Saimon et al., 2016). HNP synthesis involves two steps, iron oxide core synthesis 
and subsequent gold coating. Various chemical methods such as co-precipitation, micro-
emulsion and thermal decomposition have been used for the synthesis of the iron oxide core. 
Co-precipitation is the common method used in the fabrication of these nano particles. 
Several synthetic recipes have been reported by Cornwell and Schwertmann (Equation 1-5) 
(Teja and Koh, 2009, Mutasim, 2015).  
 
Gold deposited onto MNPs can be formed either directly or indirectly. The differences in the 
surface nature of MNPs and gold make directly coating more difficult. Many new techniques 
have been investigated to address this problem.  
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In a study by Zhang and colleagues, a novel method combining wet chemistry and laser 
irradiation. The gold layer was formed onto the MNPs cores (which were fabricated by wet 
chemistry) by laser irradiation of Au powder in liquid medium. Ban and colleagues, reported 
successful coating of 11 nm iron cores by 2.5 nm gold shell via partial replacement reaction 
in a polar aprotic solvent (Verma et al., 2014, Zhang et al., 2006, Ban et al., 2005).  
Another technique consists of using polymer layers or glue layers between the magnetic core 
and the outer golden shell. This technique is known as indirect gold coating. Polymer coating 
of MNPs has been successfully employed by using poly (N-vinylpyrrolidone) (PVP), poly (4-
vinylpyridine), poly (vinyl alcohol) (PVA), poly (ethylene glycol) (PEG), chitosan and 
poly(ethyleneimine) (PEI) (Saha et al., 2012). 
 
Jin and co-workers reported developing a new class of HNP by coating the iron oxide 
nanoparticles within phospholipid-polyethylene glycol terminated with carboxylic acid (PL-
PEG-COOH) followed by a layer of poly-L-histidine. The outer gold shell formed through 
the reduction of gold chloride onto the chelating agent with hydroxylamine (Figure 69). In 
comparison with the direct method, HNP particles tend to be more uniform and compact in 
size (Jin et al., 2010). 
 
 
 
FeSO4 + KOH + KNO 3 Fe3O4
90 C 
N2 gas
3 Fe
2+
 + NH3OH
+
 + 3 H2O Fe3O4 + NH4
+
 + 6 H
+
3 FeS2 + 5 O2 Fe3O4 + 3 S + 3 SO2
4 C6H5NO2 + 9 Fe + 4 H2O Fe3O4 + C6H5NH2
N2 gas
FeCl2
500 C
in air
85 C
FeSO4 + NaOH Fe(OH)2 Fe3O4 + 2 H2O + 2 H
N2 gas
100 C 
N2 gas (1) 
 
(2) 
 
(3) 
 
(4) 
 
(5) 
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Figure 69- Schematic of MNP-gold core-shell NPs 
In 2009 Goon and colleagues reported that coating of magnetite core with PEI before 
saturation of the surface with 2 nm gold seeds enhances the chemical resistance of the 
magnetite core in addition to enhancement in the HNPs stability against aggregation.  
Synthesis of HNPs must be fully characterised in terms of metal content, surface charge and 
particle size. In order to do this, a number of techniques are use. The principles of which are 
documented below. 
 
3.1.1- Inductively Coupled Plasma – Optical Emission Spectroscopy (ICP-
OES) 
Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES) is a useful analytical 
technique used for quantitative measurement of metal elements within a sample. ICP-OES 
technique has been used commercially available since 1983 in a huge range of applications 
(Warra and Jimoh, 2011). Basically, ICP-OES consist of two parts: Inductively coupled 
plasma ICP which is response to create plasma to convert the sample atoms to ions, then the 
ions will be separated and detected by the optical emission spectrometer OES part. A 
schematic diagram of ICP-OES can be seen in Figure 70 (Boss and Fredeen, 1997). 
ICP-OES has several advantages over other techniques, including low sample consumption, 
Low detection limit, high sensitivity and multi-element analysis technique (Warra and Jimoh, 
2011). Generally speaking, samples are introduced as fine aerosols into the ICP plasma by 
using argon as sample carrier gas.   Once the sample and argon are mixed an applied spark 
causes formation of argon ions which will lead to create argon discharge or plasma. (Boss 
and Fredeen, 1997)  
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Figure 70- Schematic diagram illustrate the essential features of ICP-OES. 
 
3.1.2- Transmission electron microscopy TEM 
Transmission electron microscopy (TEM) is a powerful technique used to study samples in 
nanoscale size. TEM is an ideal method can be used to study a wide range of materials such 
as metals and biological materials, also it can be utilised to characterize biophysical and 
morphological properties of antibody aggregates formation. In this technique, a beam of 
electrons with high energy is allowed to pass through a very thin layer of specimen which 
causing scattered by the internal structures (Hongbao et al., 2006, Joyce et al., 2015). 
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Figure 71- Schematic diagram illustrate the essential features of TEM. 
 
3.1.3- Photon correlation spectroscopy 
One of the most important techniques used to determined macromolecules and nanoparticles 
size and shape in solution is photon correlation spectroscopy (PCS) (Figure 72) and it is also 
known as Dynamic light scattering (DLS); this technique was developed by Robert Pecora in 
1964 (Pecora, 1985).  When a monochromatic light beam passes through a sample solution, 
Brownian motion of the solution particles causes fluctuations in scattered intensity, this 
occurs in a very short time (Novich and Ring, 1984). Particles in solutions have a random 
movement and speed level affected directly by their size, as large particles move more slowly 
in a liquid than smaller particles, speed of motion is used to measure the particle size (Figure 
73). 
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Figure 72- Schematic diagram illustrate the essential features of PCS. 
 
 
 
 
 
 
 
 
 
Figure 73- Particles size effect on their movement. 
 
3.1.4- Ultraviolet- visible spectroscopy 
UV-Vis Spectroscopy is the most common method used in qualitative and quantitative 
analysis as well as in characterisation of nanoparticles optical properties and electronic 
structure. It has become a useful tool to most scientists to study, metal or ligand binding, the 
stability of compounds and reaction kinetics (Mohamed et al., 2012, Alison and Bruce, 
2010). An ultraviolet and visible (UV-Vis) spectrophotometer is a device designed to 
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measure the transmittance or absorbance of a beam of light when it passes through an 
unknown sample. The spectral range is between 190 nm and 800 nm. (Brian, 2002) The 
instrument is made up of the components shown in Figure 74. 
  
 
 
 
 
 
 
Figure 74- Schematic diagram illustrate the essential features of UV-Vis spectrophotometer. 
 
Ultraviolet-visible spectroscopy absorption occurs due to π-electrons or non-bonding 
electrons (n-electrons) transitions resulting in a transition to an excited state. 
 
3.1.5- Aims and Objectives 
The aim of this chapter was fabrication of HNPs for incorporation into the intrinsic HPMA 
based polymer backbone (Chapter 4) which will act as laser initiated nano-heaters resulting in 
drug release as well as allowing for real time imaging using MRI. The particles will be 
fabricated and characterised using zeta potential measurement, photon correlation 
spectroscopy, inductively coupled plasma -optical emission spectroscopy (ICP-OES), 
transmission electron microscopy and ultraviolet- visible spectroscopy. 
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3.2- Materials and Methods 
3.2.1- Materials 
Item 
No 
Material Supplier 
1 Sodium borohydride, 99% Acros organics 
2 Hydroxyl amine, 50 wt. % in H2O Sigma-Aldrich Co. 
3 Potassium carbonate, ≥  99% Fisher Scientific, UK 
4 Poly(ethylenimine)  Mn 750,000 & 2000 Sigma-Aldrich Co. 
5 Sodium hydroxide, 99% Fisher Scientific, UK 
6 Potassium nitrate, 99% Sigma-Aldrich Co. 
7 Iron III sulfate heptahydrate, 99.5%  Acros organics 
8 Sulfuric acid, 99% Sigma-Aldrich Co. 
9 Gold III chloride hydrate, 99.99%  Sigma-Aldrich Co. 
10 Nitric acid, 70% Fisher Scientific, UK 
11 Hydrochloric acid, 37% Fisher Scientific, UK 
12 Gold standard for ICP Fluka analytical 
13 Iron standard for ICP  Fluka analytical 
 
3.2.2- Methods  
The synthesis of HNPs involves four key processes, iron oxide core synthesis, polymer 
coating of iron core, gold seeding and the subsequent gold coating. Synthesis of HNPs in this 
work was carried out as Goon and colleagues described (Goon et al., 2009). This method 
involves using a ‘‘glue layer’’ of PEI between the magnetic iron core and the outer gold shell 
which is called indirect gold coating. 
3.2.2.1- Synthesis of iron oxide nanoparticles 
Co-precipitation of iron in a basic aqueous solution, which was performed by Sugimoto et al, 
is one of the common methods used in the synthesis of iron oxide nanoparticles (Sugimoto et 
al., 1980). Briefly, 1.03 g of sodium hydroxide and 1.82 g of potassium nitrate were 
dissolved in 180 mL deionised water. Nitrogen gas was bubbled into the reaction solution, 
and then it was stirred magnetically at 90 °C for 1 h, while 3.89 g of Iron III sulfate 
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heptahydrate was dissolved in 20 mL sulfuric acid with sonication. The resultant solutions 
were mixed together. A magnetic stirrer and bar was used to stir the suspension.  After 24 h 
stirring at 90 °C under nitrogen, the resultant Fe3O4 were collected magnetically and then 
washed with deionised water several time. Afterwards, the resultant product was suspended 
in 25 mL water.  
 
3.2.2.2- Polymer coating of iron oxide nanoparticles 
Based on the electrostatic interaction method, negatively charged iron oxide was coated by 
the cationic PEI in this stage (Figure 75). In addition to prevent the magnetic core aggregate 
and maintain nanoparticle stability, PEI provides an active surface to attached gold nano-
seeds onto iron core. Poly(ethylenimine) MW 750,000 (100 mL, 5 mgmL
-1
 ) was probe 
sonicated with 5 mL of the previous suspension for 2 h using Soniprep 150 plus, MSE Co, 
MSS150.CX4.5. The coated iron core was separated magnetically from the solution and 
washed with water for several times before being suspended in 5 mL of water. 
 
 
 
 
 
 
 
Figure 75- Schematic diagram of iron oxide nanoparticles coating by PEI. 
 
3.2.2.3- Gold seeding  
Gold seeds ≈ 2 nm diameters were synthesized by adding 375 μL of 4 % HAuCl4 and 500 μL 
of 0.2 M K2CO3 to 100 mL icy cold water. The reaction was stirred at room temperature for 
10 min, followed by adding 5 x 1mL portions of 0.5 mgmL
-1
 of sodium borohydride solution 
slowly. The pale yellow solution instantly turned deep red upon mixing with the borohydride 
solution. After that, solution left to stir on ice bath for further 10 mins.  
 
Following this step, nanoparticles gold seeds attached to the Fe3O4-PEI (Figure 76), 90 mL of 
gold seeds suspension and 2 mL of Fe3O4-PEI solution were added to the flask under constant 
stirring at room temperature for 2 h, the HNPs were magnetically separated from the solution 
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and the active product was washed several times with water and then suspended in 5 mL of 
water. 
 
 
 
 
 
 
Figure 76- Schematic diagram of gold seeding process. 
 
During the final stage, gold chloride is reduced onto the NPs to form the external gold shell 
(Figure 77). Firstly, NPs particles were added to 20 mL PEI 2000 (1 mgmL
-1
) and stirred for 10 
min to stabilize gold seeds. Particles were washed with water and freshly prepared 110 mL of 
0.01 M sodium hydroxide was added, stirring the mixture at 60 °C. Followed by, adding 750 
μL of 0.2 M NH2OH solution and 500 μL of 1 % HAuCl4. After 10 min, 250 μL of NH2OH 
and 500 μL of 1 % HAuCl4 were added four times. The resultant were magnetically separated 
from the solution and washed several times with water and then diluted in 5 mL of water. 
 
 
 
 
 
 
Figure 77- Schematic diagram of gold coating process. 
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3.3- Hybrid nanoparticles Characterisation  
3.3.1- Inductively Coupled Plasma - Optical Emission Spectroscopy (ICP-
OES) 
A PerkinElmer (ICP-OES, Optima 7000V DV, PerkinElmer, Wokingham, UK) was used to 
determine iron and gold content of the HNPs. Prior to analysis; samples were digested using 
an acid digestion procedure (1:10 sample: acid). This digestion is carried out using a 
concentrated solution of hydrochloric acid: nitric acid (1:1) at 100 °C. Samples then diluted 
with deionised water (1:10) to be ready for analysis (Barentt et al., 2013a). 
The amount of iron and gold present in the samples were quantified by comparing to a 
standard calibration carried out previously with iron and gold standard solutions (0.05 
-10 μgmL-1), R2 = 0.999. 
3.3.2- Transmission electron microscopy TEM 
Gold nanoparticles were visualised using JEOL JEM-12 microscope (Jeol, Japan) using 
analysis software.  Sample aliquots of 2 μL were drop-cast onto formvar-coated mesh copper 
grids (200 mesh, Agar Scientific Co, UK). The grid then was allowed to air dry face up.  
 
3.3.3- Photon correlation spectroscopy 
Particle size, polydispersity index and zeta potential of each step were measured via photon 
correlation spectrometery (PCS, Zetasizer Nano-ZS, Malvern Instruments, UK). All 
measurements were performed in triplicate at 25 °C and the mean of three readings was 
determined. 
3.3.4- Ultraviolet- visible spectroscopy 
UV-visible spectra were acquired using UV-2600 UV-Vis (NIR) with an ISR-2600 Plus 
Integrated sphere, Shimadzu, Germany spectrophotometer. HNPs suspensions were placed in 
1 cm sample cells and their maximum absorbance was recorded at room temperature between 
350 nm-600 nm. 
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3.4- Results  
3.4.1- Inductively Coupled Plasma-Optical Emission Spectrometry  (ICP-
OES) 
 
Gold and iron content analysis of the NPs was carried out using ICP-OES. A standard 
solution with a mixture of the iron and gold (Fe and Au respectively) metals analysed was 
made up.  Calculation from the standard curves showed Fe:Au ratio in the HNPs was 5:1 
approximately. 
The following Figure 78 shows the comparison of the leaching results from HNPs sample 
detected by ICP-OES. 
 
 
 
 
 
 
 
Figure 78- A graph showing the concentrations of Fe and Au in HNPs detected by ICP-OES. 
3.4.2- Transmission electron microscopy imaging 
TEM is the one of the most powerful and popular techniques to characterize nanoparticles 
(Wang et al., 1999). In this technique, real images of NPs were taken. A typical TEM 
micrograph for Fe3O4 is shown in Figure 79A.  Fe3O4 nanoparticles images detailed out the 
shape and size, with a diameter of 0.1 µm approximately. Figure 79C represented Fe3O4-PEI 
nanoparticles, which were seeded with gold particles (2 nm), have a unique ‘bobbly’ surface. 
It was observed from the TEM images of the fully coated HNP nanoparticles (Figure 79D); 
particles seemed to have a star shape with around 0.05 µm diameter.  
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Figure 79-TEM images of (A) Fe3O4 nanoparticles, (B) Fe3O4-PEI nanoparticles, (C) Fe3O4-
PEI-Au seed-PEI and (D) HNPs. 
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3.4.3- Photon correlation spectroscopy 
As shown in Table 19, the zeta potential value of the Fe3O4 particles that are shielded with 
cationic PEI changed significantly comparing with the naked Fe3O4. The overall charge of 
Fe3O4-PEI was +33.7 mV due to the presence of charged primary amine groups in the PEI 
backbone while Fe3O4 was - 25.9 mV, this is attributed to the presence of sulphate moieties 
on the surface as previously reported (Mailänder and Landfester, 2009). The observed effect 
of gold atoms (negative charge) on Fe3O4-PEI NPs charge was quite clear in gold seeded and 
coated steps. The addition of gold showed a decrease in zeta potential of the optimized 
Fe3O4-PEI-Au seed-PEI and Fe3O4-PEI-Au coat NPs which found to be + 31.7 mV and + 19.7 
mV respectively. 
Particle size of the iron core particles (Table 19) was found to be 1.32 µm ± 0.02 µm. This 
suggests that strong magnetic properties of the iron oxide cores resulted in stronger 
interactions between the Fe3O4 particles forming larger aggregate clusters. Table 19 also 
shows a significant decrease in size when the Fe3O4 coated with PEI due to decrees the 
aggregation of the particles, while the Fe3O4-PEI-Auseed-PEI NPs, 0.67 µm ± 0.04 µm, are 
slightly bigger. Such an increase in size maybe caused by the addition of gold seeds on the 
surface of the Fe3O4-PEI. Because of the negative charge of the gold shell, it produces 
repulsion between the HNPs and prevents the aggregation, which leads these NPs to separate 
in small particles. 
In general, all the nanoparticles prepared herein experienced to a high polydispersity index 
(PDI), which is an indication size distribution (Table 19). Due to the particle aggregation in 
solution this is understandable. 
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Table 19- Size, polydispersity index and zeta potential analysis for 1 mgmL
-1
 aqueous 
polymer solutions n=3, ave (SD). 
Particle 
Hydrodynamic 
Radius µm± SD 
Polydispersity 
Index ± SD 
Zeta Potential 
mV ± SD 
Fe3O4 1.32± 0.02 0.42±0.06 - 25.9±1 
Fe3O4-PEI 0.57±0.05 0.38±0.09 + 33.7±5 
Fe3O4-PEI-Au seeds-PEI 0.67±0.04 0.38±0.03 + 31.7±2 
Fe3O4-PEI-Au coat 0.34±0.04 0.41±0.06 + 19.7±3 
 
3.4.4- UV/Visible spectroscopy  
 
UV-Vis measurements were curried out to provide further characterization of the 
nanoparticle properties based on the surface plasmon resonance (SPR). SPR is one of the 
most exciting and emerging surface-sensitive techniques for detecting noble metal, especially 
Au and Ag. In general when light is applied to the NPs, polarization of free electrons occurs 
induced by the exposed light. This results in a charge separation. The SPR persuades a strong 
absorption of the applied light, thus can be measured by using a UV–Vis spectrometer 
(Xiaohua and Mostafa, 2010).   
Based on the literature, Au-NPs show an absorption band between 500 nm and 550 nm. The 
NPs light absorption range is affected directly by their size and shape (John et al., 2013). 
Figure 80 shows a UV-visible spectrum of NPs in aqueous solution with and without gold 
functionalization. Fe3O4 and Fe3O4-PEI NPs showed a spectrum that is featureless, which 
indicates that no plasmon resonance occurs. The reason for this observation is due to these 
particles not consisting of any gold. Such a red-shift is characteristic for the gold seeded 
magnetic nanoparticles as a result of the addition of gold. The UV-Vis spectrum shows an 
absorption spectrum at 480 nm for the Fe3O4-PEI-Auseed-PEI NPs.  It can be seen clearly that 
the maximum absorption wavelength of Fe3O4-PEI-Aucoated was shifted to be 610 nm. This 
indicates that the full gold coating of the surface of particles was successfully achieved. 
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Figure 80- Shows the absorbance spectra of HNP particles. 
3.5- Discussion 
The characterisation results suggested that the hybrid iron oxide-gold nanoparticles were 
successfully synthesised. HNPs were prepared in this chapter using Goon et al synthesis 
method as fully described in section 3.2.2 and its subsections. For the characterisation of the 
hybrid iron oxide-gold nanoparticles, four different techniques approach were applied. 
Fe3O4 core nanoparticles were synthesized by a sequential reduction procedure described by 
Sugimoto et al., 1980. Particle size, zeta potential and morphology of the NPs were 
investigated by photon correlation spectrometer (Table 19) and transmission electron 
microscopy (Figure 79). For the NPs samples, the hydrodynamic z-average values measured 
with PCS was 1.32 µm ± 0.02 µm. Zeta potentials of the Fe3O4 before and after coating with 
PEI were -25.9 mV ±1 mV and +33.7 mV ±5 mV, respectively. Surface charge inversion 
observation is a suitable indication that layer-by-layer surface coating of iron core surfaces 
with PEI (cationic polymers) was successful. The sizes of the Fe3O4-PEI NPs showed 
different range as the naked Fe3O4 size. Fe3O4-PEI has PCS z-average size of 0.57 µm ±0.05 
µm. TEM images of the synthesised Fe3O4 NPs with and without PEI have clearly manifested 
the semi spherical shapes (Figure 79). 
As shown in Table 19, the zeta potential of the Fe3O4-PEI NPs that are seeded with 2 nm gold 
nanoparticles shows the decrease in positive zeta-potential whereas that of the full coated 
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gold shell shows further decrease in positive zeta-potential as a result of the presence of gold, 
which possess negative charge .  
The presence of gold NPs in the outer shell was confirmed by UV-Vis absorbance 
measurement which exhibits the NPs localised surface plasmon resonance (LSPR) 
behaviours. The absorption bands around 480 nm and 610 nm for the Fe3O4-PEI-Auseed-PEI 
and Fe3O4-PEI-Aucoated NPs respectively, are the plasmon resonance band which is a 
characteristic of gold. All the NPs prepared herein are uniform with a narrow polydispersity 
index (PDI). The formation of uniform NPs was further characterized using transmission 
electron microscopy. The TEM image (Figure 79) exhibits that the HNPs have heptagon 
morphology.  
A significant variation of the particle size by PCS and TEM methods is noted for the 
nanoparticles prepared here. The NPs size estimated by TEM analysis is smaller than PCS in 
each synthesis step. This phenomenon is possible due to the very small fraction of the sample 
represented in TEM image. Moreover, a number of factors have a great influence on the 
hydrodynamic diameter of the particles measured by dynamic light scattering such as 
polymer shells, hydration layer or other stabilisers, which lead the particles size to be seen 
larger in general (Heinz et al., 2014). 
In comparison with naked iron oxide, polymer coated iron oxide NPs tend to be smaller and 
more uniform; this result correlates well with the aim of using the polymer layer as stabiliser. 
Increase of the solution stability leads to decrease of particle agglomeration and size. Iron 
oxide NPs agglomerates and form large clusters due to the hydrophobic interactions between 
the NPs because of its large surface area-to-volume ratio and hydrophobic surfaces properties 
(Wei et al., 2008). A small increase in size was found in the gold seeding stage, and 
furthermore, zeta potential became less. This indicated that the gold seeds successfully bound 
to the coated NPs. Gold coating of the NPs reduced the hydrodynamic radius to 0.34 µm ± 
0.04  µm, this exhibited an increase in solution stability, and the significant decrease in zeta 
potential from + 31.7 mV ± 2 mV to + 19.7 mV± 3 mV confirmed this assumption (Table 
19). 
In general, previous studies have shown that the ratio of iron oxide in HNPs formulations was 
4-fold of gold (Malekigorji et al., 2017, Curtis et al., 2015). Our finding is consistent 
with previous studies in that the ratio of Au:Fe in formulation was approximately 1:5. The 
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electron micrograph (Figure 79) exhibited that the final HNPs particles have star shape. It has 
been reported that the surface-enhanced Raman scattering (SERS) activity of star-shaped 
structure nanoparticles was stronger than that of the spherical Au NPs which have similar size 
(Esenturk and Walker, 2009). Surface enhanced Raman of nano-stars molecules make them 
extremely useful for potential applications in the field of biosensors and molecular cancer 
imaging (Harmsen et al., 2015, Wang et al., 2010). 
These findings suggest that the morphological and physical properties of the HNPs after gold 
coating process showed good agreement with the biological and clinical standards. 
 
3.6- Conclusion  
The aim of this chapter is to produce gold-NPs and characterise them in order to incorporate 
into the intrinsic HPMA based polymer backbone to act as laser initiated nano-heaters. NPs 
were successfully prepared and investigated. The combination of TEM and PCS provided 
detailed information on the size of the NPs. Polymer layer between iron core and outer gold 
shell has been found to increase the solution stability by decreasing the particle 
agglomeration and size.   
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Chapter Four 
 
 
Drug loading and release kinetics from polymeric 
aggregates 
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4.1- Introduction 
Triggered release of contents from polymeric nanoparticles has been extensively studied to 
date. Sudden shrinking of thermo-responsive polymers above the critical temperature makes 
this type of polymeric micelle ideal carrier vehicles to deliver anticancer agents to tumour 
sites (Aaron et al., 2011, Priya et al., 2009). 
By grafting (palmitoyl, dansyl, cholesteryl and oxadiazole) hydrophobic pendant groups onto 
the primary amine in the APMA monomer and then polymerised with water soluble thermo-
responsive HPMA spontaneous self-assemblies can be formed in aqueous environment where 
hydrophobic drugs are encapsulated inside the hydrophobic core. 
There are plenty of methods that have been used to enhance the pharmacokinetic and 
pharmacodynamics properties for a wide range of drug molecules. Most of these applications 
have been focused on using solvent evaporation, nanoprecipitation, emulsification/solvent 
diffusion, dialysis and supercritical fluid technology (SCF) to prepare biodegradable 
nanoparticles (Nagavarma et al., 2012). Tobias et al, have compared three different methods 
Oil/Water emulsion, direct dialysis and co-solvent evaporation to loaded dexamethasone into 
poly(ethylene glycol)-block-poly-4-(vinylpyridine) micelles, they reported that co-solvent 
evaporation was a more effective loading method than others (Tobias et al., 2013). 
 
Although, some of these techniques have shown promising results, using organic solvents to 
dissolve hydrophobic drugs has major disadvantages such as residual solvent toxicity. So to 
avoid this limitation, ultrasonic promoted drug encapsulation inside micelles was developed 
and is one of the most effective techniques to create nanoparticles in aqueous environments 
(Chih et al., 2012, Dutta and Sahu, 2012). 
 
Studies showed the advantage of the structural change of thermo-sensitive polymers at the 
LCST (Lower Critical Solution Temperature) to release encapsulated drug compounds into 
the surrounding environment (Stephanie et al., 2012). Incorporation of hybrid nanoparticles 
(HNPs) into the intrinsic structure of the thermo-sensitive polymer provides a localised 
trigger point for heating  after laser irradiation which can lead to accelerated drug release 
(Roach et al., 2013).   
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4.1.1- Model Drugs 
In this study four types of hydrophobic drugs were used in order to study the efficiency of the 
HPMA-APMA copolymers derivatives to enhance drug solubility.  
Propofol or 2,6-diisopropylphenol (C12H18O, MW = 178.271) (Figure 81) is one of the most 
popular general intravenous anaesthetic agents, the chemical structure belongs to the 
alkylphenol family. Propofol has been used in a wide range of clinical situations since its 
introduction in 1985’s (Trapani et al., 2000 and Wang et al., 2015). Propofol is a powerful 
antioxidant (Murphy et al., 1992), and has anticancer activities (Azmat et al., 2013 and Rafat 
et al., 2015). The hydrophobic structure of propofol led to restrict the aqueous solubility to 
100 μgmL-1 at 25 ºC (Hoskins et al., 2016). Therefore, an emulsion of oil-in-water (10mgmL-
1
) is formulated for intravenous administration (Morgan et al., 2002). 
Such formulations should be very stable and have a very small droplet size, otherwise, the 
pulmonary capillaries it may embolism (Jihong et al., 2001). Some additives including 
antimicrobial agents should be added to this system to prevent sepsis (Baker and Naguib, 
2005). Furthermore, emulsion intravenous administration often association with pain on 
injection (Adam et al., 2004). 
 
 
 
 
 
 
Figure 81- Chemical structure of propofol. 
 
Griseofulvin (C17H17ClO6, MW = 353) (Figure 82) is an orally administered antibacterial and 
antifungal drug used in treatment of ringworm and dermatophyte infections.  Singh and 
colleagues reported the combination of griseofulvin with other anticancer drugs have a 
significant use in cancer chemotherapy (Singh et al., 2008). Griseofulvin is a white to creamy 
powder and has a hydrophobic structure. This results in poor solubility in aqueous solutions 
with around (200 μgmL-1 at 25 °C) (Townley, 1979, Royal Pharmaceutical Society of Great 
Britain, 2000). However, its poor solubility in aqueous solutions led to the absorption at 
gastrointestinal tract to be variable and patient dependant. There are many techniques which 
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are used to enhance griseofulvin solubility and bioavailability including reduction in particle 
size, polymeric formulation and co-administration with fatty meals (Sandy et al., 2016). 
 
 
 
 
 
 
 
 
 
 
Figure 82- Chemical structure of griseofulvin. 
 
Prednisolone (C21H28O5 MW = 360) (Figure 83) is man-made corticosteroid used in the 
treatment of inflammatory diseases such as, asthma, hepatitis, congenital adrenal hyperplasia 
and arthritis (Vogt et al., 2007). Prednisolone belongs to class II drugs according to the 
Biopharmaceutics Classification System (BCS), which indicated that it has high permeability 
and low solubility (215 μgmL-1 at 25 ºC) (Alkazzaz et al., 2015).  Over the years, several 
attempts (Win et al., 1976, Parvin et al., 2011, Neelam and Purshotam, 2007) have been 
made to improve prednisolone dissolution rate with different degrees of success. 
Prednisolone is administered as a suspension, (Katrina and Leisa, 2000) injection, (Roberto et 
al., 2013) ointment, (Lobenhoffer and Meyer, 2001) and as eye drops (André et al., 2014). 
 
 
 
 
 
 
 
 
 
 
Figure 83- Chemical structure of prednisolone. 
 
Paclitaxel (PTX) (C47H51NO14 MW = 853) (Figure 84), is a microtubule-stabilizing drug 
against depolymerisation used in wide application for the treatment of certain cancers 
including ovarian, breast, lung and pancreatic cancer (Beth, 2014, Wen and Manuel, 2013). 
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However, its potential application for cancer treatment has been hindered due to 
extremely low aqueous solubility of 0.3 μgmL-1 ± 0.02 μgmL-1. Several different approaches 
have been performed to overcome this problem such as using ethanol or poly(oxyethylated) 
castor oil (Cremaphor) to solubilize paclitaxel for intravenous administration. However, 
intravenous administration of (Crepaclitaxel; Taxol) emulsion caused many side effects such 
as infusion hypersensitivity reaction and often has to be pre-medication with steroids and 
antihistamines. Another pharmacological effect which has been observed with this 
formulation is the alteration in the toxicity profile and anticancer efficacy (Lee et al., 2003, 
Wen and Manuel, 2013). These side effects of formulation of paclitaxel efficacy suggest the 
need for new formulation to enhance aqueous solubility. This work will examine the ability 
of our novel copolymer formulation to address this problem. 
 
 
 
 
 
 
 
 
 
 
 
Figure 84- Chemical structure of paclitaxel. 
 
Drug formulation into polymeric micelles is a common form of technology used to improve 
solubility and hence efficacy. After formulation it is very important to characterise excipient 
efficiency based on drug loading and release. This characterisation is usually carried out 
using high performance liquid chromatography described below. 
 
4.1.2- High performance liquid chromatography (HPLC) 
Chromatography as discussed in Chapter 2, is a great separation technique which can be 
utilised to analyse complex mixtures of molecules based on distribution between stationary 
and mobile phases (Jared et al., 2015). 
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One of the most important types of chromatography is HPLC; become commonly used 
nowadays for separations and purifications in a wide range of areas including food industries, 
biotechnology, polymer, environment and pharmaceuticals (Hema et al., 2009). 
In a typically HPLC system (Figure 85) the eluent (mobile phase) is pumped by the solvent 
reservoirs at adjust flow rate, then the auto-sampler will inject a fixed amount of the sample 
into the flow, the eluent and the sample will pass through the column, which is packed with 
the stationary phase (usually silica), where the separation occurs under high pressure 
followed by the detector. The whole system is connected to a built-in computer interface 
control. 
Based on the molecule properties like size, polarity and charge, chromatographic separation 
can be subdivided into number modes include: reversed-phase (RP), size exclusion (SE), ion 
exchange (IE) (Chi-San, 1995, Haddad and Jackson, 1990).  
Reversed-phase (RP) is the most common over other HPLC modes, and nearly all substances 
can be separated by RP technique (Snyder et al., 2010). Separation mechanism based on the 
hydrophobic binding of the solute molecule in the mobile phase (polar) to the immobilised 
hydrophobic stationary phase such as inorganic polymers with large surface areas, silica gel 
and carbon (Rubinson and Rubinson, 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 85- Schematic diagram illustrate the essential features of HPLC. 
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4.1.3- Aims and Objectives 
Polymeric nanoparticles have been shown high efficiency in drug delivery applications. The 
aim of this chapter is to study drug loading and release properties of different copolymer 
derivatives using propofol, griseofulvin, prednisolone and paclitaxel as hydrophobic drug 
model molecules. Drug loading capacity and release was determined using HPLC instrument. 
Micelles average diameter and size distribution were determined using photon correlation 
spectroscopy. 
 
4.2- Materials and Methods 
4.2.1- Materials 
Item 
No 
Material Supplier 
1 Propofol, ≥ 97 % Sigma-Aldrich Co. 
2 Griseofulvin, 97 % Alfa Aesar 
3 Prednisolone, ≥ 99 % Sigma-Aldrich Co. 
4 Paclitaxel, 99.64 % Medchem express 
5 
HPMA-APMA-R and  (HPMA-APMA-R )-b-PEG 
copolymers 
Synthesised in Chapter Two 
6 HNPs Synthesised in Chapter Three 
7 0.45μm GDX PVDF filters Fisher Scientific, UK 
8 HPLC Grade methanol   Fisher Scientific, UK 
9 HPLC Grade acetonitrile  Fisher Scientific, UK 
10 Potassium dihydrogen phosphate, HPLC grade Sigma-Aldrich Co. 
11 Orthophosphoric acid, 85 %  Sigma-Aldrich Co. 
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4.2.2- Methods 
4.2.2.1- Copolymer Solubility Study 
Structural modifications of Poly (HPMA) included copolymerization ratio and type have 
different effects on the poly(HPMA) dissolution in water.  The effects of hydrophobic grafted 
groups (APMA-P, APMA-D, APMA-C and APMA-O) on the solubility of thermo-
responsive water-soluble poly(HPMA) were investigated. 
 
4.2.2.2- (HPMA-co-AMPA-O)-b-PEG-HNP Conjugation 
A 6 mg/mL 90% (HPMA 99%-co-AMPA-O 1%)-b-PEG 10% (10 mL) solution was prepared 
in deionised water followed by ultrasonication using a probe sonicator for 10 min before 
adding HNPs (60 μL). All the mixture was sonicated for a further 10 min. 
 
4.2.2.3- Drug Loading  
Serial concentrations (1 mgmL
-1
, 3 mgmL
-1
, and 6 mgmL
-1
) of polymer in deionised water 
were probe sonicated by (Soniprep 150 plus, MSN, UK) for 10 min. Followed by, adding 
hydrophobic drugs at 1:1, 1:5 and 1:10 initial polymer: drug weight ratio, 10 min further 
probe sonication was run for the polymer-drug solutions to get the maximum drug 
encapsulation. Samples were left to reach room temperature, then 0.45 μm syringe filters 
(with pre-filters) were used to remove the unencapsulated drugs. Exception: Paclitaxel 
solution was filtered by filter paper because the non-soluble drug particles blocked filter 
pores. 
For all the formulations, the loading capacity (LC) and encapsulation efficiency (EE) was 
calculated using equations 6 and 7 respectively. 
 
% LC = (drug determined by HPLC/ polymer concentration)  x 100% ……………………(6) 
% EE = (drug determined by HPLC/ original drug concentration)  x 100% …….……....…(7) 
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4.2.2.4- Solubility Study 
4.2.2.4.1- Determination of Propofol 
The quantity of propofol in the samples was determined by an isocratic reverse-phase HPLC 
(Perkin Elmer Flexar LC, Netherlands) using a Symmetry column (Pinnacle DB C18 5 µm x 
150 mm x 3.2 mm) at 25°C. The mobile phase consisted of methanol : water (80:20 v/v) with 
a flow rate of 1.0 mLmin
-1
. An UV-Vis detector was set at 229 nm. Propofol concentrations 
in the self-assemblies samples were obtained by comparing the resultant peak at 2.2 min with 
propofol standard calibration curve (R
2
= 0.998). 
 
4.2.2.4.2- Determination of Griseofulvin 
Griseofulvin levels contained in the polymeric micelles formulation were measured using 
(Perkin Elmer Flexar, US) HPLC. A reverse-phase Pinnacle DB C18 5 µm x 150 mm x 3.2 
mm HPLC column was used with flow rate of 1 mLmin
-1
 (45:55 v/v of acetonitrile: 45 mM 
potassium dihydrogen phosphate in water and adjusted to pH 3 with orthophosphoric acid) in 
an isocratic mode. Griseofulvin detection was achieved using an ultraviolet detector set at 
293 nm. The resultant peak at 2.8 min was analysed and compared to a standard calibration of 
griseofulvin dissolved in the same mobile phase R
2
 = 0.999 to quantify the drug contents in 
the samples. 
4.2.2.4.3- Determination of Prednisolone 
Prednisolone concentration in the self-assemblies was determined by comparing the resultant 
peak at 1.65 min with standard calibration containing the prednisolone dissolved in the 
mobile phase R
2
 = 0.999. A reverse-phase pinnacle DB C18 5 µm x 15 0 mm x 3.2 mm 
HPLC column from Restek Co. UK was used as stationary phase. The mobile phase consisted 
of 64:36 (v/v) water:acetonitrile, which flowed at a rate of 1 mLmin
-1
. UV detection was 
performed at 243 nm.  
4.2.2.4.4- Determination of Paclitaxel  
Quantification of paclitaxel was performed by reverse phase HPLC (pinnacle DB C18 5 µm x 
150 mm x 3.2 mm HPLC column from Restek Co. UK) with flow rate of 1 mLmin
-1
 of the 
mobile phase (55:45 v/v) water : acetonitrile. Paclitaxel peak was obtained at 6.2 min by 
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using UV/Vis detector at 227 nm. Paclitaxel quantification was achieved by reference to a 
calibration curve produced from dissolving paclitaxel in water : acetonitrile (55:45 v/v) R
2
 = 
0.999. 
4.2.2.5-Particle size and size distribution measurements 
Particle size and polydispersity index measurements were carried out for all the polymer-drug 
formulations which were prepared in section 4.2.2.2 and polymer alone in water with photon 
correlation spectrometery (Zetasizer Nano-ZS, Malvern Instruments, UK). All measurements 
were performed in triplicate at 25 °C and the mean of three readings was used determined.  
4.2.2.6- Transmission electron microscopy 
TEM imaging of the (HPMA-co-APMA-O)-b-PEG in the presence or absences of HNPs 
were viewed under the TEM. This was carried out as previously reported in section 3.3.2 
 
4.2.2.7- In vitro drug release 
Dynamic dialysis procedure has been used to determine the rates of drug release from 
polymers. Briefly, 2 mL of each sample was transferred into a dialysis tube (MW cut off = 
12000-14000 Da). Subsequently, the polymer containing dialysis tube was dialyzed against 
200 mL deionised water for 24 h with stirring at different temperatures. 1 mL of the external 
deionised water was periodically sucked up and replaced with 1 mL of fresh deionised water. 
The amount of the released drug was determined by using HPLC. Equation 8 describes the 
rate of release of the drug from optimum formula  
 
 
% Drug release = 
 
 
 
 
 
 
--------------------------------------------------------        × 100                  (8) 
The initial amount of drug in optimum 
formula 
Amount of drug released 
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4.3- Results 
4.3.1- Copolymer Solubility Study 
The results obtained illustrate the association behaviour of the hydrophobic groups attached 
to the polymer. As shown in Table 20, poly(HPMA) derivatives solubility tend to decrease as 
the extent of hydrophobic pendants increase. The individual copolymers solubility considers, 
for the cholesteryl copolymer we found that even a relatively low copolymerization ratio of 
APMA-C (1 %) is sufficient to make the polymer insoluble. 
 
Table 20- Effect of grafted hydrophobic groups onto copolymer solubility. 
Copolymerization 
Ratio % 
HPMA-co-APMA-P 
/Copolymer  Code 
HPMA-co-APMA-D 
/ Copolymer  Code 
HPMA-co-APMA-C 
/ Copolymer  Code 
HPMA-co-APMA-O 
/ Copolymer  Code 
0.25  P-0.25  D-0.25  C-0.25  O-0.25 
1  P-1          D-1    O-1 
2    D-2    O-2 
5        O-5 
10        O-10 
 
 
4.3.2- Solubility Study 
To consider the applicability of copolymer derivatives which were prepared in chapter three 
to be used as solubilising agents the loading capacity of the formulations was considered. 
4.3.2.1- Determination of Propofol Solubility in HPMA-co-APMA-R 
Figure 86 shows the maximum concentration of propofol solubilised by each copolymer 
formula. Comparing the solubilisation values is observed that O-1 presented relatively high 
solubilisation in comparison with the other formulations, the solubility of propofol in P-0.25, 
C-0.25 and D-2 ranged from 313-fold, 317-fold and 346-fold respectively, to being up to 
411-fold higher (O-1) as compared to the aqueous solubility. 
110 
 
0
5
10
15
20
25
30
35
40
45
C
o
n
ce
n
tr
a
ti
o
m
 o
f 
P
ro
p
o
fo
l 
so
lu
b
li
se
d
 
m
g
m
L
-1
 
 
 
 
Figure 86- Maximum concentration of propofol solubilised by each copolymer formula (6 
mgmL
-1
) at 1:1, 1:5 or 1:10 initial polymer:drug loading ratios (n=3, ave ± SD). 
Results of propofol loading on different APMA-R grafting ratio are presented in Figures  87 
and 88. Figure 87a compares drug loading of various APMA-P grafting ratio. The 
comparative loading study showed, the highest propofol loading was found for the 0.25 % 
palmitoyl formulation, where a high polymer concentration (6 mgmL
-1
) was used.  At 3 
mgmL
-1
, the data obtained indicated the amount of solubilised propofol 1:5 polymer:drug 
initial feed ratio was quite similar for both grafting ratios. The observed slight reduction at 
higher polymer concentration in the 1 % grafting ratio (10.6 mgmL
-1
) compared to 12.5 
mgmL
-1
at 0.25% formula. Additionally, the data obtained at higher polymer concentration for 
the 0.25% grafting ratio at 1:5 polymer:drug initial feed ratio formulations was higher than 
their corresponding at 1 %. In fact, the here presented method allows to achieve a propofol 
amount of 31.3 mgmL
-1
, demonstrating a 313-fold increase to the reported aqueous solubility 
of propofol, 0.1 mgmL
-1
 (Hoskins et al., 2012). 
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Figure 87- Drug loading of propofol onto a) HPMA-co-APMA-P and b) HPMA-co-APMA-
D at varied grafting ratio and different initial drug:polymer loading ratios (n=3, ave ± SD). 
Interestingly, increasing the APMA-D ratio in HPMA-co-APMA-D showed significant 
improvement in the propofol solubility. Results of propofol solubilised at each concentration 
(1 mgmL
-1
, 3 mgmL
-1 
and 6 mgmL
-1
) and drug:polymer ratio are presented in Figure 87b. Of 
the three polymer concentrations, 6 mg/ml showed equal or higher solubility of propofol as 
compared to other concentrations. At 2 % molar grafting was found to display the highest 
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propofol concentration at 1:10 polymer:drug ratio (34.66 mgmL
-1
). For 0.25 % and 1 % 
molar grafting, 1:10 polymer:drug initial feed ratio seem to have a sufficient drug-loading 
values, whereas other initial feed ratio have less drug entrapped into the copolymer structure. 
Similarly, 2 % molar grafting formula accepts almost double of the drug as compared with 
the 1:5 polymer:drug initial feed ratio.  
Solubilisation effect of C-0.25 at higher copolymer concentrations on propofol is stronger 
than that of at lower polymer concentration. This behaviour is a consequence of the 
increasing the scaffold micelles. Figure 88a shows the concentration of propofol solubilised 
at each concentration (1 mgmL
-1
, 3 mgmL
-1
and 6 mgmL
-1
) and drug:polymer ratio. The 
surfacing effect of C-0.25 at 6 mgmL
-1
and 1:10 polymer:drug initial feed ratio resulted in 
317-fold. 
The HPMA-co-APMA-O ratio optimization data are shown in figure 88b. These results 
showed that the solubility is significantly improved in the case of the copolymer with 
propofol ratio of 1:10. Changing the ratio to 1:1 and 1:5 produced less significant 
enhancement in solubility. Furthermore, with increasing the copolymerization ratio of 
APMA-O the solubility of propofol was also increase. However with further increase of the 
grafting ratio more than 1 % the efficiency of the system goes down. The loaded amounts 
onto O-1 at 6 mgmL
-1
and 1:10 polymer:drug initial feed ratio exceeded the reported aqueous 
solubility values as 41.1 and 0.1 mg/ml respectively, which mean propofol solubility 
increased 411-fold. 
To examine whether increased propofol solubility with the HPMA-co-APMA-R copolymer 
translated into an increase in other drugs solubility. The extent of griseofulvin and 
prednisolone solubility was measured for this purpose. 
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Figure 88- Drug loading of propofol onto a) HPMA-co-APMA-C and b) HPMA-co-APMA-
O at varied grafting ratio and different initial drug:polymer loading ratios (n=3, ave ± SD). 
4.3.2.2- Determination of Griseofulvin Solubility in HPMA-co-APMA-R 
The maximum enhancement in the dissolution data for griseofulvin is provided in (Figure 
89). These data show that copolymer formulas significantly enhanced the solubility of 
griseofulvin compared with the aqueous solubility. From the dissolution profiles it is seen 
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that palmitoyl pendant groups were the most high effective in solubilizing the griseofulvin 
compared to dansyl, cholesteryl and oxadiazole which exhibited the lowest drug 
encapsulation, representing a 103-fold, 51-fold, 60-fold and 54-fold improvement in 
efficiency over the reported aqueous solubility 0.2 mg/ml respectively, (Townley., 1979, 
Royal Pharmaceutical Society of Great Britain., 2000). 
 
 
 
 
 
 
 
 
 
Figure 89- Maximum concentration of griseofulvin solubilised by each copolymer formula 
(6 mgmL
-1
) at 1:1, 1:5 or 1:10 initial polymer:drug loading ratios (n=3, ave ± SD). 
Figure 90a shows the concentration of griseofulvin solubilised in HPMA-co-APMA-P at each 
concentration (1 mgmL
-1
, 3 mgmL
-1 
and 6 mgmL
-1
) and polymer:drug ratio. Higher 
griseofulvin loading was obtained for the 1:10 polymer:drug initial feed ratio at 6 mg/ml 
(20.75 mgmL
-1
) of P-0.25, than for the P-1 (9.2 mgmL
-1
). Current trends revealed 
well correlation between griseofulvin and propofol solubilisation. Furthermore, the amount of 
griseofulvin solubilized was significantly increased with increasing polymer concentration 
for both copolymers. P-0.25 exhibited more than 103-fold (20.75 mgmL
-1
) increase in 
dissolution in at high polymer concentration compared to 46-fold (9.2 mgmL
-1
) for P-1. It is 
obvious that sometimes increasing initial polymer:drug mass loading ratio, resulted in lower 
drug solubilisation. This could be due to remove highly griseofulvin accommodated self-
assembly during the filtration process. 
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Figure 90- Drug loading of griseofulvin onto a) HPMA-co-APMA-P  and b) HPMA-co-
APMA-D at varied grafting ratio and different initial drug:polymer loading ratios (n=3, ave ± 
SD). 
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Results of drug loading on different grafting molar ratio of APMA-D are presented in Figures 
90b. HPMA-co-APMA-D exhibited griseofulvin solubility increase profiles due to the 
amphiphilic properties. However, HPMA-co-APMA-D self-assemblies showed a much 
different trend to the cholesteryl copolymers. D-2 with more grafting ratio, more than D-0.25 
and D-1, improved solubility by greater extent, this was expected since it has higher 
hydrophobic portion. Rank order of solubility improvement is as follows, D-0.25 (50 fold), 
D-1 (93 fold) and then D-2 (120 fold).  
Griseofulvin was loaded at various polymer:drug ratios, and the loading efficiencies are 
shown in Figure 91a . Both 1:5 and 1:10 initial feed ratio at 1 mgmL
-1 
demonstrated similar 
loading efficiencies. A sharp increase in drug loading was observed at 1:10 initial feed ratio 
with increasing copolymer concentration to 3 mgmL
-1
, and further but moderate increase was 
found at 6 mgmL
-1
, while the level of drug loading  drop down to more than 2 mgmL
-1 
at 1:5 
initial feed ratio for both copolymer concentrations. With 1:10 initial feed ratio, there is some 
loading that is gradual for the 1 mgmL
-1
 whereas for higher copolymer concentrations, 
loading is almost double. 
Griseofulvin solubility study, using HPMA-co-APMA-O, showed that APMA-O 
demonstrated extended drug solubility in water at different grafting ratio. The O-1 showed 
increase in the aqueous solubility up to 54-fold compared to 42-fold, 46-fold and 41-fold of 
O-2, O-5 and O-10 respectively. Higher solubility increment can be noticed with increase in 
copolymer concentration. This result suggests that drug molecules preferably tend to 
solubilize in hydrophobic portion of the copolymer.  
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Figure 91- Drug loading of griseofulvin onto a) HPMA-co-APMA-C and b) HPMA-co-
APMA-O at varied grafting ratio and different initial drug:polymer loading ratios (n=3, ave ± 
SD). 
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4.3.2.3- Determination of Prednisolone Solubility in HPMA-co-APMA-R 
Figure 92 presents comparative maximum drug loading for HPMA-co-APMA-R. All 
formulas present herein had higher drug solubility compared to that in aqueous medium. In 
contrast to griseofulvin, prednisolone demonstrates more solubility in D-2 and O-1. In fact, 
D-2 induces more than 60-fold increase in the solubility of prednisolone while O-1 56-fold. 
Similar trends were observed to P-0.25 and C-0.25 with around 51-fold and 46-fold higher 
solubility.  
 
 
 
 
 
 
 
 
 
 
Figure 92- Maximum concentration of prednisolone solubilised by each copolymer formula 
(6 mgmL
-1
) at 1:1, 1:5 or 1:10 initial polymer:drug loading ratios (n=3, ave ± SD). 
The solubility of prednisolone dramatically increased, with 1:1 polymer:drug initial feed ratio 
in the 3 mg or 6 mg of P-1 solution, which is 46 times higher than that found for aqueous 
medium. However, increasing the initial feed ratio effect was not regular as it fluctuated. The 
rate of prednisolone loading onto P-1 was higher than P-0.25 at all initial feed ratio, but just 
lower than P-0.25 at 6 mgmL
-1
 (1:10 polymer:drug) (Figure 93a). 
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Figure 93- Drug loading of prednisolone onto a) HPMA-co-APMA-P and b) HPMA-co-
APMA-D at varied grafting ratio and different initial drug:polymer loading ratios (n=3, ave ± 
SD). 
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The highest drug loading was found for the both D-1 and D-2 formulations, where a high 
polymer concentration was used, and the initial polymer:drug feed was at a high ratio. 
However, changing polymer concentration of D-0.25 and polymer:drug feeding ratio 
did not exhibit significant change in prednisolone solubility (Figure 93b).  
 
Three of the copolymer concentrations with basic APMA-C moieties, 1 mgmL
-1
, 3 mgmL
-1 
and 6 mgmL
-1
, were unaffected significantly by increasing the polymer:drug initial feed ratio 
(Figure 94a). However, at 1:5 polymer:drug initial feed ratio, the solubility of prednisolone 
was increased slightly with a relative copolymer  increase. This perhaps was due to loaded 
the maximum drug concentration on copolymer causes expansion of the micelles size bigger 
than the filter pores, which lead to passed small particles that have the same amount of drug.  
 
At higher polymer concentrations both the O-1 and O-5 appeared to load the maximum 
concentration of prednisolone at 1:10 polymer:drug initial feed ratio. However at higher 
grafting ratio O-2 and O-10 respectively this was less. Results also showed that amount of 
drug solubilised by the O-0.25 invariable as copolymer concentration was increased. This 
could be to low hydrophobic moieties percentage in copolymer backbone (Figure 94b).   
 
Based on the previous drug loading results, C-0.25, P-0.25, D-2 and O-1 exhibited the highest 
improvement in drug aqueous solubility for the three hydrophobic drugs. In this respect, it is 
generally accepted that high improvement in drug aqueous solubility achieved with D-2 and 
O-1. This finding helps to reduce the range of polymers used in next step.  
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Figure 94- Drug loading of prednisolone onto a) HPMA-co-APMA-C and b) HPMA-co-
APMA-O at varied grafting ratio and different initial drug:polymer loading ratios (n=3, ave ± 
SD). 
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4.3.2.4- Determination of Propofol, Griseofulvin and Prednisolone Solubility 
in (O-1)-b-(PEG) and (D-2)-b-(PEG) 
In this step block copolymers have been prepared individually from D-2 or O-1 with PEG (as 
described in chapter 2) in two different ratios 90%:10% and 80%:20% respectively. The 
results of 80% : 20% copolymers formulas showed no remarkable differences in drug 
solubility and release from 90%:10% copolymers formulas (appendix, Figure 1-4). In this 
sense, the rest of this study was performed with ratio of D-2 or O-1: PEG  90%:10%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 95- Drug loading of propofol onto (O-1)-b-(PEG) and (D-2)-b-(PEG) at different 
initial drug:polymer loading ratios (n=3, ave ± SD). 
The second part of the drug loading study was performed to determine the effect of PEG 
addition on solubilising efficiency of D-2 and O-1. Solubilisation effect of (D-2)-b-(PEG) on 
propofol and prednisolone was less strong than that of D-2. This behaviour is a consequence 
of the hydrophilic properties of PEG which lead to reduce the ability of the amphiphilic 
copolymer. However, griseofulvin solubility did not effect. (D-2)-b-(PEG) exhibited 
improvement in drug aqueous solubility demonstrating 138-fold for propofol, 69-fold for 
griseofulvin and 37-fold for prednisolone respectively (Figures 95, 96 and 97). Block 
copolymer comprised of   0-1 has been found to be less affected by PEG addition than those 
containing relative D-2 amounts, indicating greater stability. Figure 95 presents drug loading 
onto (O-1)-b-(PEG). These profiles suggest that we get 359-fold for propofol, 53-fold for 
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griseofulvin and 48-fold for prednisolone respectively. As indicated above, the addition of 
PEG caused a decrease in the solubilising efficiency of D-2 and O-1, but they still have 
excellent effect on the solubility of hydrophobic drug models.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 96- Drug loading of griseofulvin onto (O-1)-b-(PEG) and (D-2)-b-(PEG) at different 
initial drug:polymer loading ratios (n=3, ave ± SD). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 97- Drug loading of prednisolone onto (O-1)-b-(PEG) and (D-2)-b-(PEG) at different 
initial drug:polymer loading ratios (n=3, ave ± SD). 
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4.3.2.4- Determination of Propofol, Griseofulvin and Prednisolone Solubility 
in (O-1)-b-(PEG)-HNPs 
HNPs were used in this study as laser initiated nano-heaters resulting in drug release as well 
as allowing for real time imaging using MRI. For this purpose, HNPs were being 
incorporated into the intrinsic (O-1)-b-(PEG) copolymer backbone. The effect of the HNPs 
addition on hydrophobic drugs solubility efficacy was determined. At 6 mgmL
-1
, (O-1)-b-
(PEG)-HNPs seem to have sufficient drug-loading values. Figure 98 illustrates that 
copolymer formula was capable of solubilising up to 28.9 mgmL
-1
, 13.5 mgmL
-1
and 10.5 
mgmL
-1 
of propofol, griseofulvin and prednisolone respectively using 1:10 initial 
polymer:drug feed ratio. For these drug candidates, propofol loading showed as much as 289-
fold increase in the solubility profile from the aqueous solubility of the drug, flowed by 
griseofulvin 68-fold then prednisolone 49-fold. However, propofol solubility was relatively 
lower compared to (O-1)-b-(PEG) while griseofulvin and prednisolone showed increased in 
solubility.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 98- Maximum concentration of propofol, griseofulvin and prednisolone solubilised by 
(O-1)-b-(PEG)-HNPs copolymer formula (6 mgmL
-1
) at 1:10 initial polymer:drug loading 
ratios (n=3, ave ± SD). 
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4.3.2.5- Determination of Paclitaxel Solubility in (O-1)-b-(PEG) and (O-1)-b-
(PEG)-HNPs 
Based on the previous results, a strategy of using (O-1)-b-(PEG) and (O-1)-b-(PEG)-HNPs to 
improve PTX solubility was adopted. The solubility tests of PTX with 6 mgmL
-1 
of both 
copolymers formulations, using 1:1 initial polymer:drug mass ratio were carried out. The 
results indicated that the (O-1)-b-(PEG) and (O-1)-b-(PEG)-HNPs  were capable of 
solubilising 0.936 mgmL
-1 
± 0.2 mgmL
-1
 and 0.841 mgmL
-1 
± 0.2 mgmL
-1
of PTX 
respectively (Figure 99). This was an incredible increase in the aqueous solubility (0.3 μgmL-
1
) by 3,120-fold and 2,803-fold respectively.  
 
 
 
 
 
 
 
 
 
Figure 99- Maximum concentration of paclitaxel solubilised by (O-1)-b-(PEG)-HNPs 
copolymer formula (6 mgmL
-1
) at 1:1 initial polymer:drug loading ratios (n=3, ave ± SD). 
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Table 21- Summery of polymer-drug formulation conditions and encapsulation properties 
(encapsulation efficiency (EE) and loading capacity (LC)), results shown as average, n=3. 
 
 
Copolymer 
% LC % EE 
Pro Gris Pred PTX Pro Gris Pred PTX 
P-0.25 521 345 217 --- 52 35 22 --- 
C-0.25 528 340 990 --- 53 34 99 --- 
D-2 577 200 433 --- 58 20 43 --- 
O-1 685 181 201 --- 69 18 12 --- 
(D-2)-b-
(PEG) 
231 231 135 --- 23 23 14 --- 
(O-1)-b-
(PEG) 
598 178 350 15 60 18 35 15 
(O-1)-b-
(PEG)-HNPS 
482 226 176 14 48 23 18 14 
 
Pro= propofol, Gris= griseofulvin, Pred= prednisolone, PTX= paclitaxel. 
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4.3.3-Particle size and size distribution 
Particle size distributions of optimal copolymer formulations are shown in Table 22. The data 
clearly show that size of self-assemblies of copolymers loaded with different model drugs can 
be varied. Change in particle size distribution was dependent on the drug molecule size and 
the amount of drug loaded. As expected for copolymer alone samples, particle size was in the 
range of nanometres and smaller than loaded samples. Particle size of P-0.25, C-0.25, D-2 
and O-1 without drug was found to be 0.14 µm ± 0.02 μm, 0.1 μm ± 0.01 μm, 0.2 μm ± 0.01 
μm & 0.1 μm ± 0.005 μm, with the poly dispersity index (PDI) of 0.7 ± 0.2, 0.7 ± 0.2, 0.5 ± 
0.06 and 0.6 ± 0.2 respectively (Table 22). 
The effect of drug loading on the resulting self-assemblies size distribution was quite clear 
with propofol and griseofulvin formulations. Increasing the drug loading caused increase in 
the mean diameter of the copolymer self- assemblies. The expansion of the O-1 self-assembly 
to accommodate larger quantities of propofol (41.1 mgmL
-1
) resulted in an increase in the 
copolymer size to 2.3 μm ± 0.05 μm compared to griseofulvin formulation with solubilisation 
of 10.87 mgmL
-1 
and a size of 0.2 ± 0.04 μm. In agreement with this hypothesis is the fact 
that even the molecule size for griseofulvin is doubled that of the propofol molecule, but the 
solubilizing amount of propofol 4-times bigger than griseofulvin. This illustrates the high 
drug solubilizing resulting in large particles size.  
The synergistic effect of prednisolone molecule size and loaded amount resulted in huge 
increasing D-2 self-assembly formula size to (5 μm ± 0.04 μm) compared to (0.2 μm ± 0.01 
μm) of griseofulvin formulation which have almost the same amount of solubilised drug, 
13.11 mgmL
-1 
and 12.02 mgmL
-1 
respectively. Similar behaviour was observed for the P-
0.25, C-0.25 and O-1 samples. Another cause of the synergistic effect was observed in 
the solubilisation of griseofulvin and prednisolone by (D-2)-b-(PEG) and (O-1)-b-(PEG). The 
(O-1)-b-(PEG) size was increased from 0.22 μm ± 0.04 μm to 0.31 μm ± 0.006 μm upon 
encapsulation of the paclitaxel while there was significant increased from  0.12 μm ± 0.005  
μm to 0.7 μm ± 0.08 μm in (O-1)-b-(PEG)-HNPs size. 
 
 
 
 
 
 
128 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(O
-1
)-b
-
(P
E
G
)-
H
N
P
S
 
(O
-1
)-b
-
(P
E
G
) 
(D
-2
)-b
-
(P
E
G
) 
O
-1
 
D
-2
 
C
-0
.2
5
 
P
-0
.2
5
 
C
o
p
o
ly
m
er 
0
.1
2
 
±
 0
.0
0
5
 
0
.2
2
 
±
 0
.0
4
 
0
.2
 
±
 0
.0
0
3
 
0
.1
 
±
 0
.0
0
5
 
0
.2
 
±
 0
.0
1
 
0
.1
 
±
 0
.0
1
 
0
.1
4
 
±
 0
.0
2
 
A
lo
n
e 
F
o
rm
u
la
tio
n
 S
ize (μ
m
) 
1
.3
 
±
 0
.0
4
 
1
.8
 
±
 0
.0
2
 
1
.5
 
±
 0
.1
 
2
.3
 
±
 0
.0
5
 
3
.3
 
±
 0
.0
9
 
0
.5
 
±
 0
.0
2
 
0
.9
 
±
 0
.0
9
 
P
ro
 
1
.2
 
±
 0
.1
 
0
.5
 
±
 0
.0
3
 
0
.2
 
±
 0
.0
4
 
0
.2
  
±
 0
.0
4
 
0
.2
 
±
 0
.0
1
 
0
.3
 
±
 0
.0
1
 
0
.2
 
±
 0
.0
0
7
 
G
ris 
1
.2
 
±
 0
.1
 
2
 
±
 0
.1
 
0
.9
 
±
 0
.1
 
0
.9
 
±
 0
.1
 
5
 
±
 0
.4
 
0
.6
 
±
 0
.0
0
8
 
1
.1
 
±
 0
.2
 
P
re
d
 
0
.7
 
±
 0
.0
8
 
0
.3
 
±
 0
.0
0
6
 
--- 
--- 
--- 
--- 
--- 
P
T
X
 
 
0
.4
 
±
 0
.0
9
 
  
0
.5
 
±
 0
.0
9
 
  
0
.4
 
±
 0
.0
1
 
  
0
.6
 
±
 0
.2
 
  
0
.5
 
±
 0
.0
6
 
  
0
.7
 
±
 0
.2
 
  
0
.7
 
±
 0
.2
 
 
A
lo
n
e 
F
o
rm
u
la
tio
n
 P
D
I 
 
0
.3
 
±
 0
.0
5
 
  
0
.3
 
±
 0
.0
5
 
  
0
.4
 
±
 0
.0
4
 
 
 
0
.1
 
±
 0
.0
6
 
  
0
.3
 
±
 0
.1
 
  
0
.4
 
±
 0
.0
0
8
 
  
0
.3
 
±
 0
.0
2
 
 
P
ro
 
 
0
.5
 
±
 0
.0
1
 
  
0
.4
 
±
 0
.0
3
 
  
0
.7
 
±
 0
.1
 
  
0
.6
 
±
 0
.2
 
  
0
.8
 
±
 0
.3
 
  
0
.2
 
±
 0
.0
0
9
 
  
0
.4
 
±
 0
.0
4
 
 
G
ris 
 
0
.8
 
±
 0
.2
 
  
0
.3
 
±
 0
.1
 
  
0
.8
 
±
 0
.0
5
 
  
0
.8
 
±
 0
.1
 
  
0
.7
 
±
 0
.1
 
 
 
0
.3
 
±
 0
.0
4
 
 
 
0
.8
 
±
 0
.0
3
 
 
P
re
d
 
 
0
.3
 
±
 0
.1
 
  
0
.3
 
±
 0
.0
3
 
 
--- 
--- 
--- 
--- 
--- 
P
T
X
 
T
a
b
le 2
2
- P
h
o
to
n
 co
rrelatio
n
 sp
ectro
m
etry
 size an
aly
sis o
f o
p
tim
al C
o
p
o
ly
m
ers fo
rm
u
latio
n
s at 6
 m
g
/m
l w
ith
 
in
itial p
o
ly
m
er:d
ru
g
 feed
 ratio
 o
f 1
0
:1
, (n
=
3
, av
e). 
P
ro
=
 p
ro
p
o
fo
l, G
ris=
 g
riseo
fu
lv
in
, P
red
=
 p
red
n
iso
lo
n
e, P
T
X
=
 p
aclitax
el 
129 
 
4.3.4- Characterisation of (O-1)-b-(PEG) in the absence and in the presence 
of HNPs Nanoaggregates 
 
Transmission electron micrograph is particularly useful to evaluate the morphology and the 
size of the aggregate copolymer micelles. Figure 100 displays transmission electron 
micrographs of aggregates obtained from (O-1)-b-(PEG) in the absence and in the presence 
of HNPs. None of the TEM images in this study required stain for visualization. In samples 
corresponding to copolymer alone the micrograph (Figure 100a) shows nearly spherical 
aggregates at 6 mg/ml, approximately 0.25 µm in size, that were visualized by TEM on a 
copper grid, size observed on the micrograph correlated well with the dynamic light 
scattering experiment value (Table 22).  
 
 
 
 
 
 
 
Figure 100-TEM micrographs of optimal formulations nano-aggregates of (O-1)-b-(PEG) 6 
mgmL
-1
 sample a) in the absence of HNPs, b) in the presence of HNPs. 
In the synthesis of (O-1)-b-(PEG)-HNPs nanoaggregates, (O-1)-b-(PEG) were conjugated 
directly onto the HNP via dative covalent linkage between gold surface and the thiol (-SH) 
moiety in the oxadiazole pendant group (Figure 21). The low concentration and steric 
hindrance effects of HNPs suggest that only one –SH group was capable to attach to one 
HNP (Christopher et al., 2013). (O-1)-b-(PEG)-HNPs copolymer forms ≈ 0.12 µm ± 0.005 
µm aggregates in aqueous suspension, as detected by PCS (Table 22). These nano-aggregates 
could be captured in electron micrographic images on copper grids and these sizes correlated 
well with the previous value. TEM image for 6 mg/ml solution of copolymer concentration 
b) a) 
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(Figure 100b) show that the (O-1)-b-(PEG)-HNPs are formed spherical micelles with a 
micelle radius ≈ 0.13 µm in agreement with light scattering results. Moreover, some large 
aggregates of different sizes were detected. 
 
 
Figure 101- Representation of the (O-1)-b-(PEG) conjugation to gold surface of HNPs via 
oxadiazole pendant group. 
Zeta potential was experimentally identified for the amphiphilic (O-1)-b-(PEG) self-
aggregated nanoparticles in water and found to be 9.9 ± 1, suggesting that the positively 
charged amine and carbonyl groups in the O-1 molecules were mainly distributed on the 
outer surface of the nanoparticles contributing to the hydrophilic potential. Subsequently the 
zeta potential shifted to 0.25 mV ± 0.2 mV after the HNPs were added (Figure 102b). The 
reduced surface charge is possibly due to the attachment of HNPs with thiol (-SH) group that 
presence in the oxadiazole structure which force APMA amine and carbonyl groups to be 
driven to an interior micellar structure away from the water.  
A decrease in hydrodynamic radius 121 nm ± 5 nm (Figure 102a) and TEM particle diameter 
≈ 130 nm was observed, hence indicating that attachment was successful. 
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Figure 102- Representation a) size and zeta potential of optimal formulations nano-
aggregates of (O-1)-b-(PEG) 6 mgmL
-1
 sample in the absence and in the presence of HNPs. 
 
4.3.5- In vitro drug release 
The temperature effects on the drug release behaviours of the optimal formulations of 
copolymers were investigated at four different temperatures 5 ºC, 30 ºC, 40 ºC and 50 ºC. 
This investigation is carried out in sink conditions over 24 h in triplicate with a magnetic 
stirrer.  Measurements of propofol release from highest drug loading formulations (Figures 
103-106) show that HPMA-co-APMA-R copolymers did not respond to change in 
surrounded temperature. Furthermore, altering the pH of the outer solution also failed to 
achieve any enhancement in the dissolution profiles of the propofol from HPMA-co-APMA-
R at different temperature. 
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Figure 103- In vitro release of propofol from P-0.25 formulation at different temperatures. 
 
 
 
 
 
 
 
 
Figure 104- In vitro release of propofol from D-2 formulation at different temperatures. 
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Figure 105- In vitro release of propofol from C-0.25 formulation at different temperatures. 
 
 
 
 
 
 
 
 
 
Figure 106- In vitro release of propofol from O-1formulation at different temperatures. 
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To set-up thermos-responsive copolymer for controlled drug release, approaches based on 
introducing an appropriate amount of poly ethylene glycol (PEG) block as a part of O-1 and 
D-2 amphiphilic copolymers. A significant enhancement in response to the change in 
temperature as the drug was released across the membrane was improved when the PEG was 
present for the three hydrophobic drugs models (Figure 107 and 108). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 107- In vitro release of propofol from (D-2)-b-(PEG) formulation at different 
temperatures. 
Propofol release profile from the (O-1)-b-(PEG) was slightly higher in response than that 
from the (D-2)-b-(PEG) especially at 50 ºC. The drug release from (D-2)-b-(PEG) at 40 °C 
was greater than 2/5 of the amount released at 50 °C, 30 °C and 5 ºC. However, no significant 
difference in drug release between these temperatures (Figure 107) was seen.  
The release profile of propofol from (O-1)-b-(PEG) at 40 °C and 50 °C was quite similar at 
the first 150 min. However, the pattern at 50 °C tends to display much slower release than 
that at 40 °C, over the followed period (Figure 108).  
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Figure 108- In vitro release of propofol from (O-1)-b-(PEG) formulation at different 
temperatures. 
When griseofulvin was incorporated in (D-2)-b-(PEG) copolymer, the effect of temperature 
was even more pronounced and the hydrophobic griseofulvin drug, which still released more 
efficiently than from (O-1)-b-(PEG). 
At 50 °C and 40 °C, the amount of the released griseofulvin was around 2-fold and 1-fold 
respectively, compared to the released at 5 ºC, whereas the increase was less, compared to the 
released at 30 °C (Figure 109). 
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Figure 109- In vitro release of griseofulvin from (D-2)-b-(PEG) formulation at different 
temperatures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 110- In vitro release of griseofulvin from (O-1)-b-(PEG) formulation at different 
temperatures. 
In 50 °C, around 50 % of prednisolone released from (D-2)-b-(PEG), after 15 min, while 
these amount of drug released after 30 min , 45 min and 330 min at 40 °C, 30 °C and 5 ºC 
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respectively, it appeared that no more prednisolone was released after around 90 min at both 
40 °C and 50 °C  while the drug was consistently released at 30 °C and 5 ºC until after 120m 
and 330 min respectively (Figure 111). The same pattern was observed in (O-1)-b-(PEG), and 
again the higher release occurred in higher temperature (Figure 112). The release from (O-1)-
b-(PEG) formulations was significantly faster than (D-2)-b-(PEG). 
The results demonstrated that increasing temperature significantly enhanced the release rate 
of hydrophobic drugs from both formulations. In general, griseofulvin and prednisolone 
release from (D-2)-b-(PEG) and (O-1)-b-(PEG) were faster than those containing propofol, 
which showed similar release profiles. The results also confirmed that PEGylated copolymer 
formulations possessed respond to change in environmental temperature compared to the 
unPEGylated formulations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 111- In vitro release of prednisolone from (D-2)-b-(PEG) formulation at different 
temperatures. 
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Figure 112- In vitro release of Prednisolone from (O-1)-b-(PEG) formulation at different 
temperatures. 
Propofol release from the (O-1)-b-(PEG)-HNPs during the 24 h experiments was clearly 
attenuated when compared to the (O-1)-b-(PEG) with every different temperature studied. 
Figure 113 illustrates that propofol was released from the polymer structure but it was still 
entrapped in the interior layers of the membrane, this is possibly because of the phenol 
tending to ionize in water and having a negative charge which causes a type of weak ionic 
bonding with the copolymer formula. Also, the release of propofol from (O-1)-b-(PEG)-
HNPs was found to be more efficient at 40 C than other temperatures (Figure 114). 
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Figure 113- Propofol entrapped in the interior layers of the membrane. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 114- In vitro release of propofol from (O-1)-b-(PEG)-HNPs formulation at different 
temperatures. 
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The in vitro release rate of griseofulvin from (O-1)-b-(PEG)-HNPs was evaluated, a fast drug 
release rate was observed in response to temperature increase. The higher release rate was 
observed at 50 °C while the release rate of griseofulvin at lower temperatures was found to be 
much lower. In contrast, (O-1)-b-(PEG)-HNPs exhibited a release of griseofulvin of about 
86% for 120 min at 50 °C and 40 °C. Whereas the griseofulvin release at 30 °C and 5 ºC 
show up to 74% and 62% cumulative release in 210 min and 300 min respectively. It is 
necessary to mention here, that the release rate of griseofulvin after HNPs added is a bit 
higher than that before it (Figure 115). 
 
 
 
 
 
 
Figure 115- In vitro release of griseofulvin from (O-1)-b-(PEG)-HNPs formulation at 
different temperatures. 
Prednisolone release profiles from (O-1)-b-(PEG)-HNPs, processed at different temperatures 
are presented in Figure 116. When the processing temperature increased, a significant 
increase in the prednisolone release rate was observed; around 94 % and 93 % of the drug 
was released at 50 °C and 40 °C after 120 min respectively from (O-1)-b-(PEG)-HNPs. 
Furthermore, prednisolone release rate was further accelerated with increasing temperature as 
a result of adding HNPs. 
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Figure 116- In vitro release of prednisolone from (O-1)-b-(PEG)-HNPs formulation at 
different temperatures. 
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4.4- Discussion  
Thermo-responsive polymers are a class of smart polymers that respond to change in 
temperature. This property makes this type of polymers useful materials in a wide range of 
applications especially, in the field of drug delivery systems. However, stimuli-responsive 
polymers such as pHPMA have been limited to carrying hydrophobic drugs due to their 
hydrophilic nature. To improve drug loading capacity, it can be modified or grafted with 
hydrophobic moieties to serve as a micellar core and enables incorporation of poorly water-
soluble drugs. The two most important factors for determining the stability, drug loading 
capacity and drug release profile of polymeric micelles are chemical nature and molecular 
weight of the hydrophobic moieties (Talelli et al., 2010). 
To enable a comparative study of HPMA stimuli-responsive copolymers in terms of 
improving hydrophobic drugs solubility in aqueous medium and regulate the release of drugs 
in response to an internal or external temperature change. Four different hydrophobic groups, 
including palmitoyl, dansyl, cholesteryl and oxadiazole groups grafted onto APMA 
monomers were ultimate be polymerised with water-soluble thermo-responsive HPMA. 
Modification ratios were altered in order to achieve the most relevant properties for our 
purpose. These hydrophobic groups were already reported as solubilisers for hydrophobic 
drugs (Trivedi et al., 2010, Mourya et al., 2011). In this context, poly(allylamine) (PAA) 
modified with different types of aromatic pendant groups have been reported to possess great 
solubilizing capacity for different hydrophobic drugs (Hoskins et al., 2012).  
In this investigation, HPMA copolymer derivatives were used as the hydrophobic 
solubilisers. It was observed that all the copolymer formulas have the ability to enhance drug 
solubility. The chemical structure of the candidate hydrophobic pendant group played an 
important role in determining the solubility of copolymer as the hydrophobic properties 
increased with increasing the copolymerisation ratio and hence lead to limited the grafting 
ratio for some formulations especially those that contain cholesteryl and palmitoyl 
moieties.  On the other hand, it is also an essential property that plays an important 
character in the solubility of the model drugs. Dansyl and oxadiazole formulations had 
showed great increase in propofol solubility compared with palmitoyl and cholesteryl 
formulations. The aromaticity of these moieties can explain this behaviour as propofol is a 
small aromatic molecule and tends to make strong π–π stacking interactions, which facilitates 
the drug solubility (Figure 86).  The same trend was apparent for prednisolone samples but 
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this time the difference was less than propofol.  Although similar to cholesteryl group and 
prednisolone, prednisolone has even less solubility in cholesteryl copolymer formulations; 
this can be attributed to steric hindrance that occurs between these two large size groups 
(Figure 89).  By contrast, palmitoyl proved to be the best solubilising moiety for griseofulvin 
(Figure 92). The relative steric hindrance experienced by other pendant groups whilst drug 
incorporation is occurring when a core expansion occurring with palmitoyl formulation. 
Typically, with increasing copolymerisation ratio, the grafted copolymers showed 
an increased ability to solubilise hydrophobic drugs. However, a further increase of                                       
hydrophobicity due to increased copolymerisation ratio and high drug loading leads to make 
them more easily aggregate to form large clusters. Particles that are larger than the filter pores 
cannot pass through the filter and that will reflect on drug loading efficacy. 
In general, drug loading shifted to higher values with increased initial polymer:drug mass 
loading ratios. However this was not true in some cases. As the amount of incorporated drug 
has been increased this could lead to high lipophilic character which makes the hydrophobic 
interaction between drug-drug molecules much higher than that between drug-copolymers 
(Mingming et al., 2010).  
Based on the observations, O-1 and D-2 seemed to be the best alternative formulations to 
enhance model hydrophobic drugs solubility. These two formulas have been utilized 
to prepare block copolymers with PEG to boost copolymer responsivity to temperature 
change.   It has been reported that PEGylation can results in an increase in controlled drug 
diffusion. Maeda and colleagues administered four-fold increase in IVM release velocity 
from silicone -rod formulation as a result of addition of poly (ethylene glycol) (PEG4000) in 
the matrix (Maeda et al., 2003). Block copolymers of poly (ethylene glycol) with poly 
(trimethylene carbonate) (PEG−PTMC) undergo controlled reverse thermal gelation at 
temperatures between 20 to 75 °C by changing polymer concentration, molecular weight and 
composition of the polymer (So et al., 2007). 
Data from HPLC analysis showed that (O-1)-b-(PEG) and (D-2)-b-(PEG) was capable of 
solubilising model drugs with the same efficiency of the non-PEGylated or sometime less 
(Figures 95-97). This was expected since the PEG block has hydrophilic properties which 
lead to reduce the ability of the amphiphilic copolymer to solubilised hydrophobic drugs.  
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HNPs have been used by our research group to formulate various types of drug delivery 
systems. Herein, we used HNPs as localised nano-heaters to accelerated drug release from 
our system in response to temperature change. The influence of HNPs on the drug loading 
efficiency of (O-1)-b-(PEG) formulation was characterized.  
(O-1)-b-(PEG)-HNPs amphiphiles appeared to increase the maximum concentration of 
griseofulvin and prednisolone solubilised. This might be due to (O-1)-b-(PEG)-HNPs 
adopting different conformations, which are less compact, that lead to accommodate larger 
amounts of drug molecules (Christopher et al., 2012). The loading concentrations for each 
drug were 13.57 mgmL
-1
 and 10.57 mgmL
-1
 (Figure 98). By contrast, the addition of HNPs 
appeared to decrease propofol loading slightly comparing with (O-1)-b-(PEG) (Figure 98). 
This was unexpected given the HNPs were in competition with the drug molecules for area 
on the copolymer structure. Loading capacities were 482 %, 226 % and 176 % and drug 
encapsulation efficiencies were 48 %, 23 % and 18 % for propofol, griseofulvin and 
prednisolone respectively (Table 21).  
The results of the solubility studies indicated that such models possessed high drug loading 
capacity and encapsulation efficiency (Table 21). Furthermore, these copolymer systems 
showed high capability to solubilise four different poorly soluble drugs that have different 
chemical structures, formula mass, water solubility and states. Accordingly, it is generally 
accepted that HPMA-co-APMA copolymer formulations can be used as a universal 
solubiliser for pharmaceutical applications. 
Propofol, griseofulvin and prednisolone were chosen by many researchers as module 
hydrophobic drugs in solubility improving methods because they are relatively inexpensive, 
poorly-soluble in water and have different problems associated with these formulations. 
Recently, Hoskins et al, reported that the use of sulfonated calix[4]resorcinarenes as drug 
solubilising agents improved propofol and griseofulvin  solubility in aqueous medium. The 
data showed that the increasing carbon-alkyl chains on the lower rim of 
calix[4]resorcinarenes compounds from 4 to 7 enhance solubility of both drugs up to 3 
mgmL
-1
 and 8 mgmL
-1
, respectively (Hoskins et al., 2017). Amphiphilic chitosan-
based polymers (Mw < 20 kDa) that self-assemble in aqueous media were used by Xioazhong 
et al, to enhance solubilisation and bioavailability of propofol and prednisolone. They 
reported the carbohydrate amphiphiles formed micellar clusters in aqueous environments, the 
optimal amphiphiles polymer formulations with propofol and prednisolone were at 5 mgmL
-1
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with 4.43 mgmL
-1
and 1 mgmL
-1
of drug being solubilised respectively (Xioazhong et al., 
2006). The results obtained in this work are exceeding the previous works; our formulations 
were capable of increasing the aqueous solubility of propofol up to 41.1 mgmL
-1
 (O-1), 
griseofulvin 20.75 mgmL
-1
 (P-0.25) and prednisolone 13.11 mgmL
-1
 (D-2). 
Paclitaxel (PTX) has been reported to be an effective anticancer agent used to treat a variety 
of tumours. However, its low solubility and permeability hampered PTX’s pharmacological 
advantage (Zhijun et al., 2015). Several techniques have been proposed to solve these 
problems, including polymer nanoparticles, solid lipid nano-spheres and nano-emulsions (Fu-
Heng et al., 2015). Tomohiro and colleagues loaded water-soluble and biocompatible 2-
methacryloyloxyethyl phosphorylcholine polymers with PTX. The maximum concentration 
of PTX reported in the polymer aqueous solution reached 5.0 mgmL
-1
 (Tomohiro et al., 
2003). Herein, the data showed (O-1)-b-(PEG) and (O-1)-b-(PEG)-HNPs formulations were 
capable of improving the PTX solubility in aqueous medium. Optimum solubilisation was 
achieved at 6 mgmL
-1
concentration and 1:1 polymer:drug feed ratio (Figure 99). (O-1)-b-
(PEG) improved drug aqueous solubility to 0.936 mgmL
-1
compared to 0.841 mgmL
-1
by (O-
1)-b-(PEG)-HNPs. 
Elevated temperature has been extensively utilised to accelerate drug release rate from 
different drug delivery systems (Shen and Burgess, 2012, Zolnik et al., 2006, Jie et al., 2016). 
Thermo-responsive polymers show a sharp change in properties in response to internal 
or external temperature changes; this feature makes them an ideal candidate for the loading 
and delivery of anticancer agents. Aniket and colleagues developed new magnetic-based 
core-shell particles (MBCSP) consisting of a thermo-responsive shell of poly (N-
isopropylacrylamide-acrylamide-allylamine) and a core of poly (lactic-co-glycolic acid) 
(PLGA) to target skin cancer cells. Aniket reported that (MBCSP) rapidly released loaded 
drugs in response to changes in temperature (Aniket et al., 2012). In this study, the in vitro 
release measurements of propofol from the highest drug loading formulations indicate that 
change in surrounding temperature had no effect on the release profile of the HPMA-co-
APMA-R copolymers (Figures 103-106). The addition of APMA-R moieties to HPMA in 
copolymerisation reaction can shift alteration of the transition temperature to a large extent or 
it can even disappear. This is due to alter the hydrophilic/hydrophobic balance (Arijit et al., 
2015) 
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Typically, by adding a hydrophilic block such as PEG to HPMA-co-APMA-R the problem 
can be tackled. (D-2)-b-(PEG) and (O-1)-b-(PEG) results strengthen this concept by 
obtaining controlled release in response to temperature changes, as drug release was 
significantly accelerated at elevated temperatures. In general, the drug release from the (D-2)-
b-(PEG) was attenuated when compared to the (O-1)-b-(PEG). Also, the release rates of the 
griseofulvin and prednisolone were faster than propofol on the same conditions of release, as 
can be seen in Figures 107-112. During the release experiments, the hydrophobic drug 
models were released more efficiently from the copolymer formulations at high temperature.  
Magnetic nanoparticles (MNPs) are getting very important and attraction in biomedical 
applications due to their ability to act as localised nano-heaters which offers combined 
therapies involves killing cancer cells by hyperthermia and drug that release from a thermo-
responsive polymer in response to temperature changes (Aniket et al., 2012). In this respect, 
the potential of HNPs to act as thermal triggers for drug release is evaluated in vitro and the 
rate of drug release in response to thermal increase investigated as well. The results showed 
that HNPs addition had accelerated griseofulvin and prednisolone released. By contrast, 
propofol release attenuated as compared  to (O-1)-b-(PEG), this could be due to propofol 
behaviour in aqueous medium as propofol belong to phenolic drugs family and has  pKa = 11 
(weak acid) (Eriksson et al., 1997). Phenols can lose a hydrogen ion to give the phenoxide 
anion (Figure 117). Since the HNPs are positively charged, force of attraction between 
these oppositely charged ions will lead to delay propofol release.  
 
 
 
 
 
 
 
Figure 117- The ionisation of phenols. 
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4.5- Conclusion  
The purpose of this work was to investigate the potential of HPMA-co-APMA-R copolymers 
derivatives for effective delivery of model hydrophobic drugs. The prepared systems were 
characterized for particle size, PDI, zeta potential, drug loading capacities and drug release. 
The loaded amounts of the hydrophobic drugs used herein were considerably high upon using 
the HPMA copolymers. The drug release of HPMA-co-APMA-R copolymers in aqueous 
solution showed no response to change in surrounding temperature, but the addition of PEG 
enhanced the thermo-responsive behaviour. Furthermore, drug release was further 
accelerated with increasing temperature as a result of adding HNPs. The resulting block 
copolymer (O-1)-b-(PEG) with/without HNPs formed micellar structures in water. 
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5.1- Introduction 
Any drug development process must proceed through some steps including drug discovery, 
preclinical development and clinical studies. The fundamental element of preclinical and 
clinical studies is investigation of the effects of the molecularly targeted agents on the 
specific molecular targets. In order to reveal potential hazards and 
recommended starting dose for the use in humans, several of toxicological and 
pharmacological studies have to be performed before a clinical trial begins (Anthöfer, 2015). 
Typically, there are two types of testing which should be performed in the preclinical stage 
including in vitro and in vivo studies.  It is desirable to use in vitro studies instead of in 
vivo studies due to these being more cost effective both in monetary terms and in ethical 
terms (James, 2008). In vitro studies which are based on using cell and tissue cultures that 
grow outside the body in a laboratory environment are regularly utilized to check the toxicity 
and efficacy of potential drug or chemical molecules (Sonali et al., 2015). However, in vivo 
testing is required to adequately characterise the in vitro data (James, 2008). 
In the present study, pancreatic cancer cells (BxPC-3) were used as a modal cancer in order 
to investigate the ability of our copolymer formulations to improve cancer chemotherapy.  
Based on literature, pancreatic cancer is classified as one of the aggressive human 
malignancies with an increase in incident worldwide.  An analysis predicts pancreatic cancer 
to be the second leading causes of cancer-related death in the United States by 2030 (Rahib et 
al., 2014).  Therefore, more effort should be made to face this disease actively.    
 
5.1.1- Bioavailability Investigation  
 
Although the in vivo studies are vital in determination of biomaterial-tissue biocompatibility, 
many in vitro assays including cytotoxicity assays and drug uptake analysis should be used 
first. 
5.1.1.1- Cytotoxicity evaluation 
The assessment of cell viability in vitro is an important factor in verifying the cytotoxic effect 
of the therapy. Both the MTT and Trypan blue assays have been used previously to assess the 
viability of cells.  
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5.1.1.1.1- MTT Assay  
 
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium 
reduction assay has been a popular research method. The MTT assay has been widely used by 
researchers in thousands of published articles as evidence (Terry et al., 2013). It is a 
quantitative colorimetric assay proposed by Mosmann to quantitate cell survival and 
proliferation for mammalian cells. The MTT assay has been shown to be inexpensive, simple 
and a reliable test to screen the cytotoxicity of a drug. The assay is used to assess 
cytotoxicity, proliferation or activation via measuring the signal generated from living cells, 
which is dependent on the degree of activation of the cells (Mosmann, 1983, Kumaravel and 
Begum, 2015).  The MTT assay methodology is based on the reduction of the tetrazolium salt 
through the mitochondrial dehydrogenase of viable cells to form a purple formazan crystal. 
The quantity of formazan is measured by dissolving the formazan crystal in dimethyl 
sulfoxide (DMSO), following recording the absorbance at 570 nm by using a microplate 
reading spectrophotometer. The number of living cells extant in culture is proportionate to the 
amount of formazan produced. The exact reduction mechanism of MTT is still not well-
understood. It has been proposed that MTT involves reaction with NADH or accepted 
electrons from other reducing molecules (Figure 118) (Terry et al., 2013). 
 
 
 
 
 
Figure 118- Mechanism of MTT reduction into formazan. 
5.1.1.1.2- Trypan blue exclusion assay  
The trypan blue (TB) assay is a widespread method for assessing cytotoxicity in experimental 
examination; it also provides cell number and viability information.  The idea behind this 
method is based on uptake of TB by dead cells cytoplasm (stain dead cells blue) due to loss 
of membrane selectivity while it cannot produce colour in live cells which have an intact cell 
membrane. As a result, dead cells will appear darker than the viable cells. Therefore, the 
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fraction of unstained (live) and stained (dead) cells can be measured and calculated either by 
a haemocytometer, microscope or cell counting instruments (Freitas et al., 2014). In this 
work, TB assay is carried out by treating cells in the exponential growth phase to a 
formulation for a period of time. Cell death can be visualized by staining with trypan blue in 
50/50 ratio and the number of viable cells is counted. 
5.1.1.2- Intracellular drug uptake  
Understanding the interactions of drug formulations with cells and how these interactions 
impact their cellular uptake is vital to discovering the biomedical applications of these 
formulations, especially for drug delivery.  
In medicine, abundant drugs are facing problems to cross a strong barrier called the cell 
membrane. Typically the cell membrane is described as phospholipid bi-layers, regulating the 
exchange of materials between the cell and outside environment. Moreover, cell surface 
charge plays an important role on drug penetration. Molecules that have negative charge do 
not enter the cell wall at all as both sides of the bilayer phospholipid membrane surface 
are also negatively charged. By contrast, positively charged materials can penetrate deep into 
cell membranes (Sabina et al., 2013). 
Various techniques have been reported to enhance the ability of drug molecules to penetrate 
cell membranes such as encapsulating them in a polymeric material (chemical technique), use 
of biological carriers commonly viruses to deliver drugs to targeted tissues (biological 
technique), a physical force (physical technique), microinjection, ultrasound etc. (Judith et 
al., 1995, Robert et al., 2013, Flanagan et al., 1999, Mikhail et al., 2015). 
In this work, intracellular drug uptake experiment was used for determination of intracellular 
drug concentrations through the combination of chemical and physical techniques via using 
polymer, HNPs and heat to improve drug uptake and release. 
 
5.1.2- Aims and Objectives 
The aims of this chapter were to determine the cytotoxic activity of the following: paclitaxel 
alone; (O-1)-b-(PEG); (O-1)-b-(PEG)-HNPs; (O-1)-b-(PEG)-PTX and (O-1)-b-(PEG)-HNPs-
PTX on BxPC-3. Cytotoxic activity was determined using the MTT assay. Intracellular drug 
uptake will be determined. The effect of heat on cell viability will also be undertaken to 
determine the temperature change effect.  
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5.2.1- Materials  
Item 
No 
Material Supplier 
1 Paclitaxel Medchem express 
2 Hybrid nanoparticles (HNPs) Synthesised in Chapter Three 
3 (O-1)-b-(PEG) Synthesised in Chapter Two 
4 (O-1)-b-(PEG)-HNPs Synthesised in Chapter Four 
5 BxPC-3 cell line  LGC Standards Co., UK 
6 PRMI culture medium Life technologies Co., UK 
7 Trypsin-EDTA 0.05 % Life technologies Co., UK 
8 Foetal bovine serum Fisher Scientific, UK 
9 Phosphate buffered saline Fisher Scientific, UK 
10 Penicillin streptomycin Life technologies Co., UK 
11 
3-[4,5-dimethylthiazol-2-yl]-2,5- 
diphenyltetrazolium bromide (MTT) 
Sigma-Aldrich Co. 
12 Highly purified water Millex Q system (UK) 
13 HPLC Grade acetonitrile Fisher Scientific, UK 
14 DMSO Fisher Scientific, UK DMSO Fisher Scientific, UK 
 
5.2.2- Methods 
5.2.2.1- Cell culture preparation 
In this study, a BxPC-3 cell line was used as the pancreatic cancer cell model to study the 
toxicity of (O-1)-b-(PEG) with/without HNPs. The BxPC-3 cell line was cultured in RPMI-
1640 media containing 1 % penicillin streptomycin and 10 % foetal bovine serum (FBS), at 
37 ˚C in a 5% CO2 atmosphere.  
To determine the effect of paclitaxel, (O-1)-b-(PEG), (O-1)-b-(PEG)-HNPs, (O-1)-b-(PEG)-
paclitaxel and (O-1)-b-(PEG)-HNPs-paclitaxel on BxPC-3 cell, eleven different 
concentrations of these substances were prepared. Briefly, a 20 mgmL
-1
 stock solution was 
prepared by dissolving 200 mg of each substance in 10 mL sterile water (except paclitaxel 
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was dissolved in 50:50 of sterile water:DMSO). Serial dilution solutions were made from 
these stock solutions (1x10
-1
 - 1x10
-9
 mgmL
-1
) using media as the diluent (Table 23).  
 
Table 23- Preparation of Excipient Solutions for MTT assay. 
 
Drug concentration 
(mgmL
-1
) 
Volume of 20 mgmL
-1
 drug 
stock solution (μL) 
Total volume of media (ml) 
0.1 22.5 4.5 
0.05 11.5 4.5 
0.025 5.6 4.5 
0.01 2.25 4.5 
0.005 1.125 4.5 
* 0.001 90 4.5 
* 0.0001 9 4.5 
* 0.00001 1 4.5 
** 0.000001 450 4.5 
** 0.0000001 45 4.5 
** 0.00000001 4.5 4.5 
* Sample was made from 0.05 mgmL
-1 
concentration as a stock solution. 
** Sample was made from 0.00001 mgmL
-1 
concentration as a stock solution. 
 
5.2.2.2- Cytotoxicity evaluation 
Cytotoxicity of the copolymer formulations was investigated by using the MTT assay; the 
tests were carried out in BxPC-3 cells line.  
 
5.2.2.2.1- MTT assay procedure 
Firstly, 100 μLwell-1 of BxPC3 cells suspension in RPMI-1640 medium was seeded at 
densities of around 15,000 cells per well in 96-well plate and allowed to adhere for 24 h 
inside an ESCO CO2 Incubator at 5% CO2 at 37 °C. After this time, the media was replaced 
with 100 μL of freshly prepared culture medium containing various treatment samples as 
prepared above in a format shown in Figure 119.  
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Figure 119- Illustration the 96-well plate assembly for the MTT assay. 
The 96-well plates were further incubated for 24 h before the media was removed and 
replaced with a 175 μL solution of 10 % MTT in media and then incubated for 4 h in the cell 
incubator. After removing the MTT solution from the wells, 100 μL of DMSO was added to 
dissolve the purple formazan crystals trapped in cells. The light absorbance of the resultant 
purple colour was determined at 570 nm by using a microplate reader (Tecan, infinite 200 
pro, GmbH 5082, Australia). All assays were performed in triplicate. Cell viabilities were 
averaged and normalized to the untreated cells, which worked as negative controls cultured in 
the cell medium without sample added. Percentage cell viability and IC50 was calculated 
according to Equation 8. 
 
% Cell viability =                                                                                          ×100        (8) 
Absorbance of drug- Absorbance of PBS 
Absorbance of control - Absorbance of PBS 
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5.2.2.3- Determine intracellular drug concentrations in cellular uptake 
For cell uptake experiments, BxPC-3 pancreatic cancer cells were seeded at a density of 
(50,000 cells/well) in 6-well plates and cultured in RPMI-1640 media containing 1 % 
penicillin streptomycin and 10 % foetal bovine serum (FBS). Next, the media was replaced 
with 3 mL of a 0.05 mgmL
-1 
solution of PTX, polymer alone, polymer-HNPs, polymer-PTX 
or polymer-HNPs-PTX in RPMI-1640 media and incubated for 1 h, 4 h and 24 h at 37 °C in a 
humidified atmosphere of 95% air and 5% CO2 (Figure 120). At each time point, the culture 
media was removed; cells were washed three times with PBS to remove the trace amounts of 
the substances, followed by the addition of 185 μL trypsin. Plates were then placed in an 
incubator until the cells began to detach before 0.815 mL of the media was added. Trypan 
blue assay was then used to determine the density of viable cells per mL. To count viable 
cells, A mixture of 75 μL of cell suspension and 75 μL of trypan blue solution was prepared 
in an Eppendorf tube, a prorate amount of this mixture was pipetted into an automated cell 
counter (Invitrogen Countess®, UK). Percentage cell viability was calculated according to 
the Equation 9. 
 
 
 
The appropriate volume containing 100,000 cells was transferred to Eppendorf tubes and 
completed to 1 mL with deionised water, and then centrifuged at 500 rpm for 5 min in a 
Hermule Z-323 centrifuge. The supernatant was removed and cells were re-suspended in 
acetonitrile : water (45:55).  
The concentration of PTX was quantified using reverse phase high performance liquid 
chromatography (HPLC) (pinnacle DB C18 5 µm x 150 mm x 3.2 mm HPLC column from 
Restek Co. UK) with flow rate of 1 mLmin
-1
 of the mobile phase (55:45 v/v) water: 
acetonitrile, which was discussed in Chapter Four (Section 4.2.2.4.4). The drug accumulated 
in each cell was calculated by dividing each resulted calculated concentration by 100,000 
(cells number). All assays were performed in triplicate.  
 
 
% Cell viability =                                                                                          ×100        (9) 
Number of viable cells in sample 
Number of control cell  
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Figure 120- Illustration the 6-well plate assembly for the drug uptake study. 
5.2.2.4- In vitro thermo-responsive cytotoxicity assay 
Heating by exposure to laser irradiation in terms of accelerating the release of PTX from the 
thermo-responsive polymer-HNPs formulations is the suggested method in a clinical 
application. The heat-triggered release behaviours by external heating were studied herein via 
repeating the MTT procedure which was mentioned above, a small change was made in the 
previous assay including the following: after the 96-well plates were treated with samples as 
prepared above in a format shown in Figure 119 they were pre-incubated for 4 h at 37°C in a 
humidified atmosphere of 95% air and 5% CO2. After this time, 96-well plates were removed 
and placed into a pre-warmed incubator type Memmert IN-30 and heated at 44 °C for half an 
hour, the 44 °C incubator, has a thermal variant that can mimic the heat generated by the SPR 
of laser irradiated HNP gold coatings, after an incubation time 96-well plates were returned 
back into the 37 °C, 50 % CO2 incubator.  The IC50 was determined for all the plates and the 
heat activated IC50 results were compared to the non-activated plates in order to investigate 
the effect of temperature on cell cytotoxicity. 
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5.3- Results 
5.3.1- MTT Assay 
In order to know whether (O-1)-b-(PEG) with/without HNPs were capable of increasing the 
cytotoxic effect of paclitaxel on pancreatic cancer cell lines, the MTT cytotoxicity test was 
carried out to determine their effect on the cell viability of BxPC-3 at eleven different  
concentrations (Figures 121 and 122).  In general, results showed that all five substances have 
antiproliferative potential against the tested cell lines.  When compared to paclitaxel alone, 
(O-1)-b-(PEG)-HNPs-PTX and (O-1)-b-(PEG)-PTX, they were highly efficient in reducing 
the cell viability of cancer cell lines.  
For polymer alone and polymer-HNPs formulations, no significant effects in viability 
were observed after 24 h up to 0.1 μgmL-1 but the cell viability reduced significantly between 
the concentration of 1 μgmL-1 and 100 μgmL-1. The half-inhibitory concentration IC50 was 
obtained around 47 μgmL-1 for the polymer alone formulation and 50 μgmL-1 for polymer-
HNP formulation (Figure 121 and 122).  
The cytotoxic effect of PTX on BxPC-3 cell line in the eleven different concentrations was 
examined. When the BxPC-3 cell line was exposed to PTX, a steady increase in cytotoxicity 
was experienced with increasing PTX concentration at the same incubation time. It appeared 
that the PTX had a much lower IC50 values than the polymer alone and polymer-HNPs 
formulations. The observed IC50 for pure PTX was found out to be (1 μgmL
-1
). However, the 
same drug when loaded into (O-1)-b-PEG demonstrated a significant decreased in IC50 value 
from 1 μgmL-1 to around 0.55 μgmL-1. Data indicated that polymer formulation can improve 
the therapeutic effect of the PTX compared with the free PTX. Furthermore, it showed that 
the cytotoxicity of polymer-PTX on BxPC-3 is roughly 2 times higher than free PTX; this 
can be attributed to the higher uptake rate of the drug on BxPC-3 cells. 
Moreover, the (O-1)-b-(PEG)-HNPs-PTX exhibited significant cytotoxicity in vitro against a 
model pancreatic cell line. The half-maximal inhibitory concentration (IC50) of the (O-1)-b-
(PEG)-HNPs-PTX was higher than (O-1)-b-(PEG)-PTX and free PTX. The IC50 of hybrid 
formulation conjugated with polymer and loaded with PTX was around 10-fold and 20-fold 
less than that of the (O-1)-b-(PEG)-PTX and free drugs, respectively. 
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Figure 121- BxPC-3 cell viability (%) as determined by MTT assay after 24 h exposure to 
varied concentrations of PTX and polymer formulations (n=3, ave ± SD). 
 
 
Figure 122- IC50 (μg/ml) of PTX and polymer formulas as determined by MTT assay, after 
24 h (n=3, ave ± SD). 
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5.3.2-Determine intracellular drug concentrations in cellular uptake 
In order to get a more complete picture of the effect of polymer formula and HNPs it was 
crucial to determine the absorption rate and the amount of drug taken up. In Figure 123 the 
results of the drug uptake experiment are shown in which the course of PTX alone, (O-1)-b-
(PEG)-PTX  and (O-1)-b-(PEG)-HNPs-PTX formulations was followed over a period of 1 h, 
4 h and 24 h.  
(O-1)-b-(PEG)-HNPs-PTX formula showed a highest increasing initial uptake into BxPC-3 
cells at each time point, followed by (O-1)-b-(PEG)-PTX formula then PTX alone. For naked 
PTX, drug uptake on BxPC-3 cells was non-detectable by HPLC after 1 h of incubation, this 
amount increased to 3458 pg and 5240 pg after 4 h and 24 h incubation with the same 
incubation concentrations of PTX respectively. By contrast, both (O-1)-b-(PEG)-PTX and 
(O-1)-b-(PEG)-HNPs-PTX formulas showed increased of drug accumulated from the first 
incubation hour to reach 3458 pg and 3564 pg in each cell, respectively. At 4 h of incubation, 
the uptake of both (O-1)-b-(PEG)-PTX and (O-1)-b-(PEG)-HNPs-PTX formulas has been 
expressed as almost double that for free drug. The readings for the 24 h showed increased 
PTX uptake to reach 5969 pg for (O-1)-b-(PEG)-PTX, while there are more increased with 
(O-1)-b-(PEG)-PTX to hit 7008 pg per cell. Overall, it seems that PTX uptake pattern on 
BxPC-3 cells is more time dependant (Figure 123).  
 
 
 
 
 
 
 
Figure 123- Cellular uptake study on BxPC-3 cell line after 1 h, 4 h and 24 h exposure with 
PTX, (O-1)-b-(PEG)-PTX and (O-1)-b-(PEG)-HNPs-PTX  (n=3, ave ± SD). 
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5.3.3-In vitro thermos-responsive cytotoxicity assay 
In order to investigate the effect of temperature on cell cytotoxicity, the IC50 was determined 
for the heat activated plates and compared to the non-activated plates.   
In general, heat treatment did not result in a significant impact on cytotoxicity of polymer 
alone. The viability of BxPC-3 cells treated with polymer alone formulations at 37 ºC and 44 
ºC showed the same cytotoxicity pattern (Figure 124). By contrast, increasing the temperature 
from 37 ºC to 44 ºC decreased the viability of the BxPC-3 cells treated with (O-1)-b-PEG-
HNPs significantly, which suggests that introduction of HNPs onto the polymer backbone 
increased the cytotoxicity effect of the (O-1)-b-PEG at 44 ºC  (Figure 124). The half-maximal 
inhibitory concentration IC50 of heat treatment formulation was around 2 times less than that 
of the non-heat treatment formulation (Figure 125). 
 
 
 
 
 
 
 
 
 
Figure 124- In vitro thermos-responsive cytotoxicity test on BxPC-3 cell line as determined 
by MTT assay after exposure to varied concentrations of PTX and polymer formulations 
(n=3, ave ± SD). 
(O-1)-b-PEG-PTX was then tested after incubation at 44 ºC for 30 min followed by 24 h 
incubation. This resulted in a significant decrease in the viability of the BxPC-3 cells (Figure 
124) and IC50. These results indicate that our thermo-responsive polymer responded to heat 
treatment and released PTX faster. Incubation of BxPC-3 with (O-1)-b-PEG-PTX for half an 
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hour at 44 ºC reduced the IC50 to 0.1 μgmL
-1
compared to 0.55 μgmL-1 for non-heat treatment 
formulation. In other words, the IC50 of (O-1)-b-PEG-PTX formulation decreased more than 
five times when exposured to high temperate. 
Further reduction in cell viability and IC50 was achieved upon treatment of BxPC-3 with (O-
1)-b-PEG-HNPs-PTX in comparison with (O-1)-b-PEG-PTX. Cell viability of BxPC-3 
treated with (O-1)-b-PEG-HNPs-PTX decreased significantly upon incubating at 40 ºC (30 
min), which might be due to the higher amount of PTX being released from the particles at 
this temperature as a result of introducing HNPs which act as localised nano-heaters (Figure 
124). The IC50 value of (O-1)-b-PEG-HNPs-PTX on BxPC-3 at heat treatment trial was 
0.04μg/ml (Figure 125).  
 
Figure 125- IC50 (μgmL
-1
) of heat-treated PTX and polymer formulations as determined by 
MTT assay, after 24 h (n=3, ave ± SD). 
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5.4-Discussion  
In other studies PTX was loaded to different carriers such as carbon nano-shell (Hui et al., 
2017), polymeric NPs (Lipeng et al., 2017), liposomes (Yunjie et al., 2015), cyclic oligomers 
such as Calix[4]arene (Mo et al., 2016), however, few attempts focused on formulating a 
combination treatment based on using PTX and thermos-responsive polymers conjected to 
Au-NPs. 
In this study, Chapter two and Chapter three have developed a thermo-responsive targeted 
drug delivery system able to improve drug solubility and control the release of drugs in 
response to change in temperature. In chapter four, PTX was loaded to (O-1)-b-PEG 
with/without HNPs. PTX loading was confirmed by HPLC. The results indicated that the 
(O-1)-b-(PEG) and (O-1)-b-(PEG)-HNPs were capable of solubilising 0.936 mgmL
-1
 ± 0.1 
mgmL
-1 
and 0.841 mgmL
-1 
± 0.2 mgmL
-1 
of PTX respectively. 
Since promising drug loading and in vitro release, the thermo-responsive polymers 
conjected to Au-NPs system has been translated to in vitro study to evaluate biological 
activities, focusing on cytotoxicity properties, cellular uptake and evaluating the effect of 
temperature on polymer-drug formulations cytotoxicity. 
Possessing high cytotoxicity and specific delivery are the most important characteristics of 
any anti-cancer drug or formulation. The cytotoxicity of PTX and polymer formulations 
was examined on BxPC-3 cells by the MTT assay.  
In this study the fabricated copolymer had little cytotoxic impact on the BxPC-3 cell line, 
over the concentration range tested (100 μgmL-1 – 1.0 × 10-5 μgmL-1). Addition of HNPs to 
the polymer backbone exhibits an improved cell cytotoxicity profile compared to polymer 
alone especially, between the concentration 0.01 μgmL-1 and 10 μgmL-1. IC50 values for 
copolymer alone and copolymer-HNPs achieved by the MTT assay after 24 h, were around 
47 μgmL-1 and 50 μgmL-1 respectively (Figure 121). That implies HNPs addition to 
copolymer does not appear to have any impact on IC50 values comparing to copolymer alone 
(Figure 122). 
The cytotoxicity results of the PTX formulation on the BxPC-3 cell line revealed significant 
reduction of cell viability after 24 h (compared with the free drug copolymer formulations), 
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where the cytotoxic effect of PTX formulation was about 47-fold and 50-fold  greater than 
the cytotoxicity of copolymer alone and copolymer-HNPs, respectively (Figure 121 and 122). 
(O-1)-b-PEG-PTX formulation showed higher cytotoxicity on cancer BxPC-3 cells compared 
to naked drug (Figure 121 and 122). These results confirm the high efficacy of the copolymer 
formulation which could be associated with the higher uptake rate, leading to enhanced 
accumulation of the drug in cancer cells.  
The effect of (O-1)-b-PEG-HNPs-PTX displayed similar trend to that of (O-1)-b-PEG-PTX 
but the IC50 value on BxPC-3 cells was 0.05 μgmL
-1
, and its inhibitory effect on normal cells 
(BxPC-3) was extremely stronger.  
Based on previous study, PEG-b-PHPMA derivatives demonstrated some combined pros, 
such as high drug loading efficiency, extracellular stability and biocompatibility, in addition 
to triggered intracellular drug release, which are considered to be a promising system 
for anticancer drug development (Rongran et al., 2012). The cytotoxic effects of these DOX-
loaded core-cross-linked PEG-b-PHPMA-lipoic acid micelles on HeLa and HepG2 cells were 
characterised. IC50 values achieved by the MTT assays after 48 h, were around 6.7 and 12.8 
DOX equiv/mL, respectively. For blank micelles, no significant reduction in viability was 
observed after 48 h up to 1.0 mgmL
-1
. 
In another study, Christopher and colleagues conjugated HNPs to poly(allylamine) (PAA) 
polymer grafted with hydrophobic oxadiazole (Ox) pendant group. They also reported that 
the treatment of BxPC-3 cell lines with the novel polymer formulations results in increased 
drug uptake and decreased IC50 values compared with free drug. The IC50 value for PAA-
OX5 and PAA-OX5-HNPs were 60 μgmL-1 and 55 μgmL-1 respectively, while for PAA-
OX5-6TG and PAA-OX5-HNPs-6TG were 15 μgmL-1 and 0.95 μgmL-1 respectively 
(Christopher et al., 2013). 
Our findings indicate that the IC50 of (O-1)-b-PEG alone and (O-1)-b-PEG-HNPs were 47 
μgmL-1 and 50 μgmL-1 respectively, which is consistent with the previous report. By contrast, 
the (O-1)-b-PEG-PTX and (O-1)-b-PEG-HNPs-PTX appeared to be the more effective 
formulations when compared with previous studies. IC50 of (O-1)-b-PEG-PTX was 0.55 
μgmL-1, (O-1)-b-PEG- HNPs-PTX was 0.05 μgmL-1,   this was around 3-fold and 19-fold 
decrease compared to the PAA-OX5-6TG and PAA-OX5-HNPs-6TG respectively.  
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Enhanced cellular uptake and boosting the penetration efficacy of anti-cancer agents inside 
tumours is vitally important to successful anti-cancer therapy.  Various courier formulations 
have been attempted for this purpose including polymers, dendrimers and gold nanoparticles 
etc. (Liu et al., 2015, Akiya et al., 2016, Jianfeng et al., 2016). It has been found, that the 
polymeric micelles can enhance aqueous formulations of hydrophobic drugs, improve the 
cellular uptake and prolong in vivo circulation time and passive tumor targeting by the 
enhanced permeability and retention (EPR) effect (Yang et al., 2015).  Jin and colleagues 
loaded N-octyl-O-sulfate chitosan micelles with anticancer PTX for treating multidrug-
resistant (MDR) cancer. They reported that the polymer micelles loaded PTX had 
demonstrated high cellular uptake around 2-fold more than PTX, and the lowest efflux rate of 
PTX, thus leading to optimal cytotoxicity on both the human hepatocellular liver carcinoma 
(HepG2) and the MDR HepG2 (HepG2-P) cells (Jin et al., 2014). 
On the other hand, there have been several studies evaluating gold-nanoparticle (AuNPs) 
uptake in in vitro systems. Heo and colleague have designed and prepared a theranostic agent 
based on AuNPs surface-functionalized with anti-cancer paclitaxel drug and biotin receptors. 
They examined the intracellular uptakes of the functionalized AuNPs by three cancer cell 
lines, HeLa human breast, A549 human lung carcinoma and MG63 human osteosarcoma, it 
was found that biotin conjugated AuNPs surface-functionalized PEG, biotin and rhodamine B 
linked b-CD effectively induce intracellular uptake into the cancer cells (Heo et al., 2012). 
Results of other gold-nanoparticles functionalized with a thiolated poly(ethylene glycol) 
(PEG) monolayer capped with a carboxylate group conjected to oxaliplatin have shown 
unusual ability to penetrate the nucleus in the lung cancer cells (Brown et al., 2010). 
In the quantitative analysis of the cellular uptake of the PTX, (O-1)-b-PEG-HNPs-PTX 
showed the highest cellular uptake into the BxPC-3 cells; non- HNPs conjugated 
formulations, (O-1)-b-PEG-PTX, showed a bit lower cellular uptake at 1h and 4h and much 
lower at 24 h; while the naked PTX formula showed the lowest cellular uptake at all the time 
points (Figure 123). These results confirmed (O-1)-b-PEG formulations with/without HNPs 
significantly facilitated the uptake of PTX in the BxPC-3 cells. This enhancement could be 
due to improved bioavailability via increase in the drug solubility and protecting them from 
inactivation in the biological milieu which leads to extend circulation time, hence micelles 
could accumulate in the tumours to a greater extent, with higher uptake via the enhanced 
permeability and retention (EPR) effect provides a basis for the selective 
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accumulation.  Furthermore, the positive charged of the (O-1)-b-PEG-PTX and (O-1)-b-PEG-
HNPs-PTX formulations makes these molecules  readily cross cell membranes since the cell 
membrane is lipophilic and negatively charged (Jhaveri and Torchilin, 2014, Nori and 
Kopecek, 2015). The results of cellular uptake were in agreement with cytotoxic effect 
results, which confirmed the higher cytotoxic effect of hybrid formulations comparing with 
free drug, especially. 
Controlling the drug release from thermo-responsive polymers using temperature as a 
stimulus makes it a more attractive strategy, by exploiting exogenous variation in the local 
temperature, typical for tumour tissues. Drug release can be induced by tumour tissues as it 
has been shown to have slightly higher temperatures comparing to healthier tissues. Also, an 
additional temperature can be used to accelerate drug release by external source (Shirakura et 
al., 2014, Coelho et al., 2010).  Poly(N-isopropylacrylamide-co-N, N-dimethylacrylamide)-b-
poly(d,l-lactide-co-glycolide) [P(NIPAAm-co-DMAAm)-b-poly(d,l-lactide-co-glycolide) 
(PLGA)] with different compositions and lengths of PLGA block was synthesised by Liu and 
colleagues. This thermo-responsive polymer used to synthesis micelles containing 
doxorubicin (DOX). They reported that the DOX-loaded micelles possessed high stability in 
PBS containing serum at 37 °C, increasing the temperature above the normal body 
temperature (39.5 °C) caused deform the micelles, thus triggering DOX release (Liu et al., 
2005). 
In another interesting piece of research, Thermo-responsive core–shell magnetic 
nanoparticles consisting of γ- Fe2O3 iron oxide magnetic nanoparticles (MNP) coated with 
the thermo-responsive polymer poly(n-isopropylacrylamide) (PNIPAM) have been 
formulated to encapsulate doxorubicin (DOX) anticancer agent.  In vitro release experiments 
revealed that DOX release at temperatures above and below the LCST of PNIPAM (34 °C) 
had a weak dependence on swelling behaviour. Moreover, the in vitro simultaneous 
hyperthermia and drug release of therapeutically relevant quantities of DOX was achieved, 
14.7% of loaded DOX was released over the period of 47 min 
at hyperthermia temperatures. The particles showed Fickian diffusion release kinetics, 41% 
was the maximum drug release observed at 42 °C after 101 h.  In vitro experiments also 
showed that 14.7% of the total drug content was released after 47 min 
at hyperthermia temperatures (Purushotham et al., 2009). 
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In this work, the polymeric micelles, which released their drug content at 44 °C displayed a 
much higher cytotoxicity compared to micelles at 37 °C. This result establishes that 
temperature is, in fact, an effective tool for controlled release of drug and hence, the efficacy 
of micelles. Moreover, in vitro thermo-responsive cytotoxicity results from BxPC-3 cell lines 
showed that the viability of treated cells with (O-1)-b-PEG-PTX and hybrid formulations 
mostly decreased by increasing the temperature to 44 °C while the naked PTX showed 
temperature independent responses.  
Heat treatment of the samples increased (O-1)-b-PEG-PTX and (O-1)-b-PEG-HNPs-PTX 
inhibitory activities 5-fold and 1-fold respectively comparing with untreated samples. 
Increase in the temperature induced dehydration and increased hydrophobicity of the (O-1)-b-
PEG and (O-1)-b-PEG-HNPs, which led to release of PTX for subsequent diffusion to 
tumour cells. 
5.5-Conclusion  
PTX, (O-1)-b-(PEG), (O-1)-b-(PEG)-HNPs, (O-1)-b-(PEG)-PTX and (O-1)-b-(PEG)-HNPs-
PTX were tested for in-vitro cytotoxicity on BxPC-3 cells. In-vitro MTT assay results 
established the ability of (O-1)-b-(PEG)-PTX and (O-1)-b-(PEG)-HNPs-PTX novel 
formulations to accumulate and kill pancreatic cancer cells more effectively, compared to the 
free PTX. In vitro drug uptake study also indicated that the copolymer and its hybrid 
formulations internalise and accumulate inside pancreatic cancer cells significantly higher 
than that observed for the free drug administration. The effect of higher temperature has been 
studied and the results showed that the toxicity of PTX-copolymer formulations was 
increased by few folding after heating to 44 °C. 
Finally, this study confirmed that combining PTX and HNPs/copolymeric NPs at very low 
doses possess a synergic cytotoxic effect on BxPC-3 cells. Although this result was observed 
in triplicate, further investigation is required in order to fully understand if this finding is 
reliable. 
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Chapter Six 
General Conclusions and Future Work 
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6.1- General conclusion 
In this study, a novel thermo-responsive copolymer system has been prepared, which has the 
potential to act both as a drug delivery system and to enhance the solubility of some poor 
water-soluble drug via grafted hydrophobic groups onto the primary amine group of APMA 
monomers using palmitoyl, dansyl, cholesteryl and 5-(4-aminophenyl)-1,3,4- oxadiazole to 
incorporate into the HPMA copolymer at varied molar ratio. Block copolymer was prepared 
from these derivatives via copolymerize with poly ethylene glycol (PEG) to improve the 
thermo-responsive behaviour of the polymer. 
The hydrophobic groups of palmitoyl, dansyl, cholesteryl and 5-(4-aminophenyl)-1,3,4- 
oxadiazole were successfully grafted onto the primary amine group of APMA monomers. 
Three grafted groups, palmitoyl, dansyl and cholesteryl, are substituted onto the primary 
amine group of APMA in one step. However, due to the strong bonding of chlorine-carbon in 
oxadiazole structure, this forced as to create a new way to prepare this compound by building 
up this molecule throughout 4 steps. These monomers were polymerised with water soluble 
thermo-responsive HPMA. Optimal substitution onto the backbone of both hydrophobic and 
hydrophilic groups onto the primary amines of the polymer was determined. The chemical 
structures of new amphiphilic copolymers based on PHPMA as hydrophilic thermo-
responsive part and palmitoyl, dansyl cholesteryl and oxadiazole as hydrophobic grafted 
groups was investigated using various techniques including NMR, FTIR and melting point.  
The hydrophobic effect of grafted moieties played a significant role in determining the 
solubility of copolymers as shown in Table 20. The introduction of hydrophobic pendent 
moieties into the poly(HPMA) structure caused reduction in the aqueous solubility based on 
grafting ratio and grafted group structure. When the feeding ratio of APMA-P, APMA-D or 
APMA-C were increased from 0.25 % to 10 % the solubility of poly(HPMA) derivatives 
decreased dramatically, thereby indicating that the modified APMA moieties significantly 
improved the hydrophobic properties of the final amphiphilic copolymers. However, even at 
high APMA-O grafting ratios, those copolymers still possessed high aqueous solubility due 
to the amphiphilic nature of APMA-O. 
Hybrid nanoparticles (HNPs) were successfully synthesised. The prepared hybrid 
nanoparticles were characterised by different techniques. The inductively coupled plasma-
optical emission spectroscopy (ICP-OES) analysis showed that the ratio of iron: gold within 
169 
 
the formulation was around 5: 1. The transmission electron microscopy (TEM) grids of HNPs 
were analysed to observe the particle morphology and size parameters. HNPs particles 
seemed to have a star shape with around 50 nm diameter. Photon correlation spectroscopy, 
zeta potential and UV/Visible spectroscopy measurement results taken together suggest that 
the coating process of particles with poly(ethylenimine) (PEI), subsequently gold seeding 
then gold coating were successes. 
Four types of hydrophobic drugs, propofol, griseofulvin, prednisolone and paclitaxel, were 
used in order to study the efficiency of the HPMA-APMA copolymer derivatives to enhance 
drug solubility. The results of the solubility studies indicated that such models possessed high 
drug loading capacity and encapsulation efficiency. Furthermore, these copolymer systems 
exhibited high capability to solubilise insoluble drug candidates that having different 
chemical structures, formula mass, water solubility and states. Hence, it is generally accepted 
that HPMA-co-APMA copolymer formulations can be used as a universal solubiliser for 
pharmaceutical applications. The maximum amount of solubilised propofol ranged from 31.3 
to 41.1 mgmL
-1
, griseofulvin from 10.21 to 20.75 mgmL
-1
 and prednisolone from 8.91 to 
13.11 mgmL
-1
. Drug release from HPMA-co-APMA-R copolymers in aqueous solution 
revealed no response to change in temperature. This could be attributed to change in the 
LCST of pHPMA as a result of grafted with the APMA-R groups. 
To tackle this problem, an approach based on introducing an appropriate amount of poly 
ethylene glycol (PEG) block as a part of O-1 and D-2 amphiphilic copolymers was taken. O-1 
and D-2 appeared to be the best alternative formulations to enhance candidate hydrophobic 
drug solubility. These two formulas have been utilized to prepare block copolymers with 
PEG to boost copolymer responsivity to temperature change. HPLC results revealed that (O-
1)-b-(PEG) and (D-2)-b-(PEG) have the same drug loading efficiency as the non-PEGylated 
or sometime less. This could be attributed to the hydrophilic properties of PEG, which 
eventually lead to reduce the ability of the amphiphilic copolymer to solubilise hydrophobic 
drugs. On the other hand, it was shown that the O-1 and D-2 block copolymerisation with a 
PEG block enhances release of the contents remarkably at a higher temperature. As it is 
explained in results and discussion of chapter 4, this point attributed to maintenance of the 
hydrophilic/hydrophobic balance. Addition of the HNPs showed further acceleration in drug 
release with increasing temperature.  
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Paclitaxel (PTX) anticancer drug was encapsulated onto the (O-1)-b-(PEG) with/without 
HNPs. Drug loading, stability and drug release studies were carried out. Paclitaxel-polymer 
formulations have shown excellent drug solubilisation capacities. At 6 mg/ml the (O-1)-b-
(PEG) polymer achieved paclitaxel solubility more than 2000-fold greater than its aqueous 
solubility.  
In vitro cytotoxicity assays using (O-1)-b-(PEG)-PTX and (O-1)-b-(PEG)-HNPs-PTX novel 
formulations revealed that when BxPC-3 cells were exposed to the formulations, enhanced 
therapeutic efficacy was observed compared to the free PTX. 
Quantitative comparison of the uptake of PTX indicated that the copolymer and its hybrid 
formulations internalise and accumulate inside pancreatic cancer cells considerably greater 
than that observed for the free drug administration. These results were in agreement with the 
cytotoxicity assay results, confirming a higher cytotoxic effect of the copolymer formulations 
comparing with free PTX, especially the copolymer-HNPs formulation. Furthermore, the 
effect of increased temperature exhibits a larger impact on the toxicity of copolymer 
formulations than on free drug because of the increased PTX release. These effects are 
evident in a decrease in the IC50 of BxPC-3 cells.  
To sum up, this work has produced novel thermo-responsive copolymers based on 
amphiphilic poly(HPMA)-co-APMA derivatives. The results suggest that these derivatives 
are capable of solubilising poorly soluble hydrophobic drugs such as propofol, griseofulvin, 
prednisolone and paclitaxel efficiently. Successful control release of loaded drugs has been 
achieved by incorporation of appropriate amount of PEG block as a part of O-1 and D-2 
amphiphilic copolymers. Our in vitro data suggested that copolymer-PTX micelles had 
stronger cytotoxicity than free drug. Furthermore, the introduction of HNPs into the polymer 
backbone increased PTX cytotoxicity at 37 °C and 44 °C. These results taken together 
suggest that we are successful to reach the main goals of this research. 
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6.2- Future work 
The aim of the thesis was preparation of an amphiphilic graft polymer composed of a poly(N-
(2-hydroxypropyl) methacrylamide) pHPMA backbone in order to produce thermo-
responsive drug carriers for pancreatic cancer therapy. The results look promising, but more 
experiments are required to prove the utility of this system, such as studying the formulation 
stability in order to determine their potential as pharmaceutical excipients, study the ability of 
this system to solubilise another poor-soluble drug and carry out further in vitro release via 
laser irradiation instead of hot plate or oven.  
Further experiments should investigate the effect of pH on the copolymer structure and drug 
release profile. Many studies have confirmed the pH-responsivity behaviour of pHPMA 
derivatives (Choi et al., 1999, Jäger et al., 2015, Holley et al., 2013). It would be beneficial 
also to investigate the ability of these copolymers to be glucose-responsive insulin release 
systems as HPMA copolymers had showed this feature before (Ishihara et al., 1984).  
Outstanding opportunities exist in combining temperature, pH and bio-responsive control 
strategies to create systems with multi-state transitions. 
The thermo-responsive copolymer system used in the research was well optimised for the 
BxPC-3 cells. It is still unknown if the new thermo-responsive system is working on other 
cells/cell lines or not. Therefore, further investigations using a wider variety of cells/cell lines 
and assays are required. Also we investigated the biological effect of one copolymer 
derivative in conjugation with HNPs. In further investigation it’s necessary to the study the 
biological effect of the rest of the copolymer derivatives 
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1.0- Determination of Propofol Solubility in (D-2)-b-(PEG) and (O-1)-b-
(PEG) 
 
   
 
 
 
 
 
Figure 1- Drug loading of propofol onto (80% D-2)-b-(20% PEG) at different initial 
drug:polymer loading ratios (n=3, ave ± SD). 
 
    
 
 
 
 
Figure 2- Drug loading of propofol onto (80% O-1)-b-(20% PEG) at different initial 
drug:polymer loading ratios (n=3, ave ± SD). 
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2.0- In vitro release of propofol from (D-2)-b-(PEG) and (O-1)-b-(PEG) 
 
 
 
 
 
 
 
 
Figure 3- In vitro release of propofol from (80% D-2)-b-(20% PEG) formulation at different 
temperatures. 
  
 
 
 
 
 
 
 
 
 
 
Figure 4- In vitro release of propofol from (80% O-1)-b-(20% PEG) formulation at different 
temperatures. 
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